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Development and evaluation of point-of-care diagnostic technologies for providers and 
consumers 
Samiksha Nayak 
Point-of-care (POC) diagnostic technologies aim to expand access to traditional 
laboratory-based testing to near-patient settings. These settings can range from emergency or 
intensive care-units (ICUs) in the United States, to remote health posts in sub Saharan Africa. 
Differences in budget and infrastructure play a role in characterizing the wide array of possible 
“near patient” settings and must be taken into consideration in the engineering design process. In 
this dissertation we use translational engineering to develop practical and accessible microfluidic 
POC immunoassays for diverse settings, that include both provider and consumer facing 
applications.  
First, we examined Lyme Disease in the U.S., where existing diagnostic technologies 
face the challenge of rapid and accurate serodiagnosis in the face of largely non-specific clinical 
symptoms. We developed a multiplexed rapid test that could replicate enzyme-linked 
immunosorbent assay (ELISA) performance for Lyme Disease diagnosis. After screening 
candidate biomarkers, we evaluated performance of the multiplexed microfluidic test against 
ELISA using clinical serum samples and illustrated the potential to streamline current clinical 
algorithms requiring two immunoassays (ELISA and Western Blot) into one standalone test 
suitable for physician’s offices or urgent care clinics in the U.S. We also showed exploratory 
work towards a similar multiplexed test design for another bacterial spirochete infection, 
Leptospirosis.  
  
Next, we built on previous work towards a POC HIV-syphilis antenatal screening tool, to 
develop a smartphone-integrated, microfluidic assay for healthcare workers to use in low 
resource settings. The low-cost ($34), re-usable device (“smartphone dongle”) costs $34 to 
produce and provides results in 15 minutes. In this work, we focus on assay development efforts 
undertaken towards development of a fully integrated POC product suitable for deployment in 
the field, with practical considerations for the use of fingerstick blood, stability, scale-up and 
transport. We also streamlined the number of manual steps for end-user operation, through the 
use of lyophilized secondary antibodies, preloaded reagents on cassette, and an automatic result 
readout. While laboratory demonstration with clinical samples is important for initial 
characterization of POC devices, field evaluation reveals diagnostic performance under real-
world conditions. We tested the device in the hands of minimally trained healthcare workers in 
Rwanda and saw comparable performance to other immunoassays run under field conditions. We 
also performed a follow-up pilot field study in Rwanda to evaluate the feasibility of the 
smartphone dongle platform for self-testing by patients/consumers in a low-resource setting, one 
of the most challenging use-cases for POC devices.   
Finally, we sought to integrate intellectual frameworks from behavioral research and 
user-experience (UX) design in creating a new framework for evaluation of consumer-facing 
microfluidic devices, specifically towards HIV home-testing in the U.S. While overall rates of 
HIV are decreasing in the U.S., the population of gay, bisexual and other men who have sex with 
men (MSM) are disproportionately affected. Self-testing products for sexually transmitted 
infection (STI) testing could address unmet needs for these target populations in both increasing 
access and frequency of testing, as well as integrating use with sexual partners for early 
diagnosis or even prevention. We worked with a cohort of MSMs at high risk for HIV/STI 
  
transmission in New York City, and performed for the first time, a structured assessment of 
completely naïve users interacting with a smartphone interfaced microfluidic diagnostic device 
(“SMARTtest”). We integrated UX design value model of device usability, credibility, 
accessibility and acceptability into our evaluation framework, which influence user’s 
information, knowledge, motivation and behavioral skills towards engaging with a prevention 
method (“IMB” model). Thus far, such frameworks have rarely been applied to other consumer 
health monitoring devices, including microfluidic POC devices. As the microfluidic field 
moves towards more field demonstrations of devices, more untrained and minimally trained 
users will have access to such tools. It is important to understand how they use devices, what the 
device failure points are and what the most relevant design features are to spur user adoption and 
meaningful usage.  
Underlying our work in creating accessible and practical POC immunoassay tools for 
infectious disease detection, is the illustration of the translational development roadmap from 
proof-of-concept assay development to field studies and user-based evaluations for intended end-
use settings that range from U.S. based primary care clinics, rural health centers in low-resource 
settings as well as self-testing environments in both. Incorporating an understanding of the target 
use-case setting is critical in translating technologies for clinical use, whether in the 
infrastructure and services that are available, or end-user needs and constraints such as clinical 
workflow patterns, level of technical expertise and perceptions of usefulness and value. We show 
how user/use-case focused application of downstream translational engineering and testing 
informs upstream design choices and accelerates development of POC devices for real-world 
use. The sum of this work aims to illustrate tenets of translational engineering design and testing 
  
to advance insight into building POC products that are poised for greater adoption by target end 
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The goal of this thesis is to illustrate the translational “pipeline” of point-of-care (POC) 
immunoassay diagnostic development, from proof-of-concept assay development efforts in the 
lab, to testing with clinical specimens and integration of hardware and software elements for 
evaluation in the field. We illustrate practical considerations in POC development towards end-
user operation, scale up, manufacturing, and product shelf life for health settings both in the U.S. 
and in developing countries.  Finally, we explore structured evaluations with users themselves to 
evaluate potential for consumer-facing device deployment. The overall objective is to develop 
microfluidic diagnostic devices that are better poised for adoption by target end-users in diverse 
settings. 
 
The field of POC diagnostics offers the exciting possibility of providing rapid diagnostic results 
in non-laboratory settings.  The goal of POC diagnostics is to provide results with a fast 
turnaround time to enable decision making and potentially start of treatment within one clinical 
visit. With the rise of connected consumer devices, entire sectors of the economy (including 
retail, transportation, housing, and freelancing services) have been unmistakably transformed.  
The potential reach of POC diagnostics into all sectors of healthcare – and increasingly into daily 





routines of individual patients and consumers – demand that technical advances take into context 
this broader transformation.   
 
For healthcare providers, the landscape for medicine is poised for a dramatic shift.  In any 
decentralized setting, a connected POC diagnostic device could be available to aid the diagnosis 
of disease and selection of treatments.  With therapeutics becoming increasingly tailored to 
individuals’ precise genetics and biomarkers, the value chain of healthcare delivery could move 
up to accurate and accessible POC diagnostics as opposed to therapeutics.      
 
For consumers and patients, the impact could be even more dramatic.  With the rise of connected 
consumer electronic devices, patients and consumers are adjusting in how they interact with POC 
medical technologies alongside mobile devices, and more broadly, in how they manage and seize 
control of their own health.  Opportunities for home or self-testing can shift the burden of lost 
work hours and productivity in the appointment-based clinical care model. While patients with 
greater socio-economic agency can offset these burdens, daily-wage earners, particularly those in 
lower and middle-income countries could feel the benefits of increased access to care through 
POC tools. In due course, POC diagnostic and monitoring devices are expected to become 
ubiquitous, whether in an at-home setting, in a doctor’s office or hospital, or in low- and middle-
income countries. 
 
In today’s connected age, this progress is being made within the context of a broader and more 
diverse POC ecosystem than before (Fig. 1). Some of these components, such as assay chemistry 
and microfluidics, cover traditional ground for researchers in POC diagnostics, and are shown in 





this work in developing new assays for diverse disease applications.  Other components, ranging 
from data analytics to regulation, reflect broader forces which are influencing how POC 
technologies are being designed and developed.  
 
For POC diagnostic devices to be accessible to end users, the disparate steps of a multi-step 
diagnostic assay – including fluid handling, sample processing, signal amplification, washings, 
and detection – must be seamlessly integrated.  In this regard, microfluidics serves as an  
Figure 1. The POC ecosystem in a connected age. 
integrating force. In this work, we have used microfluidic and microscale engineering techniques 
as part of a larger trend in producing integrated devices which are self-contained, automated, 
easy-to-use, and rapid [1-4].  






1.1 Current landscape  
1.1.1 Upstream Development 
Traditionally, microfluidic POC developers have focused on individual upstream components 
such as assay chemistry, fluidic handling methods and instrumentation or sensor development 
(Fig. 2). Recent assay chemistry developments have been made in engineering antibodies with 
high affinity and specificity[5], antibody-mimetic proteins such as designed ankyrin repeat 
proteins (DARPins) which are thermally stable[6], non-immunoglobulin (non-Ig) scaffolds[7], 
and antigen-specific, single-domain antibodies[8-11].  Other assay chemistry developments  
include the use and modification of aptamers (short, single-stranded oligonucleotides with high 
specificity) as affinity reagents[12], enhancements to labeling molecules/nanoparticles for signal 
detection (e.g. multicolored silver nanoparticles for tunable absorbance spectra and multiplexed 
detection[13], europium (Eu) (III) chelated nanoparticles for bacterial detection in a lateral flow 
format[14]). With fluid handling methods, researchers have developed novel strategies in 
fabrication and fluidic actuation mechanisms, such as micromilling Lego blocks for highy 
reproducible, modular microfluidic components[15], optically-driven photodeformable polymers 
that could be manipulated to exert control over a variety of fluids[16], which could represent a 
new tool in microfluidic design (feasibility of actuating one component without affecting others 
in a high density chip still needs to be demonstrated), no-power valves based on magnetic 
adhesives for mixing reagents[17], electrostatic mixing method of reagent droplets on a chip[18] 
etc. Researchers have also made efforts in developing label-free sensing platforms for detecting 
multiple targets from clinical specimens (e.g. microcantilever-based detection based on their 





potential for label-free and sensitive detection[19]). Work has been done to integrate 
microfluidics with plasmonic sensors, which are a label-free detection method by monitoring 
interactions among electromagnetic waves and free electrons in metals (including surface 
plasmon resonance and surface-enhanced Raman scattering [20])[21]).  Other instrumentation 
efforts have been made for lateral flow assays such as electronic readers [22, 23] compact 
smartphone-based fluorescence detectors[24] etc.    
Figure 2. Translational framework for microfluidic POC diagnostic development 
 
 
1.1.2 Downstream Development  
A few groups have examined downstream considerations towards stability, an important aspect 
of producing POC assays suitable for field deployment. Some notable examples include the 
demonstration of long term dry storage of ELISA reagents horseradish peroxidase (HRP) 
conjugated antibody label and colorimetric substrate diaminobenzidine (DAB) at 45C for over 3 
months. This was achieved by leveraging formulations commonly used in the pharmaceutical 
industry for preservation of biomolecules, through the use of sugars like trehalose, bovine serum 
albumin (BSA) and ferrous irons[25]. Reconstituted HRP-antibody and DAB substrates were 





used in 2D paper network format to detect malarial biomarker Plasmodium falciparum histidine 
rich protein 2 (PfHRP2) in a sandwich immunoassay. While this format of colorimetric ELISA 
could be detected by eye, all quantification was still performed with flatbed scanner and image 
anlsysis software. Additionally, the test was demonstrated with antigen-spiked simulated samples 
(vs. whole blood or on chip plasma separation), and did not contain fluidic delivery and metering 
integration. Other efforts include the incorporation of freeze-dried reagents in a paper-based 
sensor for the detection of the Zika virus RNA genome, paired with a battery-powered electronic 
reader (manufacturing cost of $250)[26].   Sample preparation steps are not yet included, and the 
overall assay time is several hours. Integration of disparate assay steps for a complete sample-to-
result process remains a barrier to translational efforts by many POC microfluidic developers   
 
In one of the few studies highlighting integration, developers created a smartphone based video 
microscope and showed quantification of blood-borne filarial parasites could be performed under 
2 min, and required only a glass capillary and lancet as peripheral equipment[27].  A custom 
algorithm tracked the motion of the microfilaria by quantifying the displacement of red blood 
cells, and the results were tested in the field in  Cameroon, showing good correlation gold 
standard thick smear microscopy[27]. Key components of this technology that differentiate from 
other mobile-phone microscopy efforts is the automated quantitative algorithm and software 
interface allowing for one-touch completion of the assay. While diagnostic performance was not 
explicitly evaluated in a structured format for local doctors and technicians handling the assay 
compared to the study team, including local healthcare workers in testing efforts illustrates the 
potential of this platform for use by minimally trained health care workers. 
 





1.1.3  Commercial Efforts 
Table 1 illustrates examples of commercial efforts with fingerprick blood based 
technologies[28].  Abbott’s i-STAT device has been one of the more successful POC products, 
with deployment in almost a third of U.S. hospitals after two decades of service[28, 29]. Most of 
these products however, are still under development and evaluation. 
 
Recent epidemics of infectious diseases such as Ebola and Zika have highlighted the importance 
of rapid testing that can be field-deployable or used in emergency field-laboratories. A number 
of commercial efforts were undertaken to develop cartridge-based, sample-to-answer real-time 
RT-PCR systems for detection of the EBOVL gene of Ebola.  The Xpert Ebola system (from the 
company Cepheid) adapted the company’s previous work on tuberculosis to integrate sample 
preparation, virus inactivation, nucleic acid amplification, and detection[30].  In Sierra Leone, 
the Xpert Ebola assay showed high sensitivity and specificity for both venipuncture whole blood 
and oral swab clinical samples compared to laboratory RT-PCR[30].  In another system, the 
FilmArray Ebola system (from the company Biofire Defense) used a pouch with lyophilized 
reagents that were rehydrated, followed by sample dilution and injection into the reconstituted 
reagent pouch[31]; the pouch was inserted into the FilmArray instrument with results available 
after 1 hour[31, 32]. 
  





Table 1.   Selected commercial efforts with finger prick blood testing technologies (Taken from 
[28]) 
Company/location Technology Sample size/tests Status 
Abbott Electrochemical detection 
26 tests: chemistries, electrolytes, 
hematology, blood gasses, 
coagulation, cardiac markers, and a 
pregnancy test; 2–3 drops from a 
capillary, venous, or plasma sample, 
depending on the test; results in 
minutes 





antibodies, read with 
miniaturized fluorescent 
microscope 
2 drops of blood: 10 allergens in 20 
min 
abioSCOPE (reader) and abioGuide 




spectroscopy where the 
emission spectrum is 
dynamically controlled 
Microvolumes of blood: multiple 
biomarkers for liver, kidney, heart 
status in real time 
Beta-Bioled in development 
Cepheid (now part of 
Danaher) 
PCR on a cartridge 
3–4 drops of capillary blood: 
quantitative and qualitative assays for 
HIV, hepatitis C and Ebola 
Quantitative assays for HIV viral load 
and hepatitis C under development; 
qualitative assay for HIV has CE 
marking and WHO pre-qualification; 
qualitative assay for Ebola has CE 
marking and US and WHO emergency 
authorization 
Cor Vibrational spectroscopy 
Drop of blood taken from the arm: 
HDL, LDL, total cholesterol, fasting 
glucose, triglycerides, fibrinogen 
Cor Wellness System in development 
DMI 
Fluorescence and light 
scattering from multi-
plexed nanostrips 




10 ml of capillary or venous blood: 
hemoglobin and hematocrit in 30 s 
AnemiPoint: Undergoing evaluation 
Genalyte 
Photonic detectors 
lithographically printed on 
silicon chips 
One drop of venous or capillary blood: 
128 tests, starting with rheumatology 




technology adapted from 
computer disc drive 
technology 
Single drop of blood: modular with 
biomarkers in cancer, autoimmunity, 
heart diseases in minutes 
In development for laboratory use or 




Finger prick (capillary) or venous 
blood: 20 standard CBC parameters 
Hemoscreen, CE mark in EU, going 





Finger prick: troponin in 5 min Minicare I-20: CE marking 




sensing with magnetic 
nanoparticles 
Small volumes of serum: multiple 
biomarkers in minutes 
Under development 
HDL, high-density lipoprotein; LDL, low-density lipoprotein; WHO, World Health Organization; CBC, complete blood count. 





Comparison of FilmArray with RT-PCR were also performed for whole blood and urine 
samples[31].  Finally, the Idylla Ebola Virus Triage Test (from the company Biocartis NV) used 
a RT-PCR instrument and console, and provided results in 100 min from EDTA venipuncture 
whole blood samples[33].  The reagent cartridges did not require cold chain storage[33], and 
clinical results from the field are pending.  All three systems were given Emergency Use 
Authorization status by the regulatory authorities, and use was still confined to facilities with 
moderate to high complexity[34].  There exist challenges to implementation in more 
decentralized field settings, where even greater public health impact could be achieved.  Field 
use requires uninterrupted electricity, temperature control, and moderately trained personnel to 
conduct sample preparation[34].  In addition, without subsidies, cost of instruments and 
cartridges are also prohibitive for lower-resource settings (for example, the manufacturer list 
price for Filmarray reader is $39,500, with $129 per test kit)[35]. 
 
1.1.4 Use-Cases 
While it is widely acknowledged that POC testing is completed at or near the patient, this 
definition spans a large range of possible POC settings, each of which imposes a different set of 
specific design constraints on POC devices.  Previously, different levels of healthcare delivery 
have been described.  For example, one popular public-health model describes different “levels” 
(Level 1 being community outreach, Level 2 being primary health, and Level 3 being district 
level lab)[36].  Another model describing POC diagnostics for infectious diseases in low- and 
middle-income countries presents five different scenarios, from home to hospital[37].  Although 
these distinctions are useful in certain areas of POC diagnostics (i.e. global health), in our view, 
another description is needed to distinguish the key features across all POC settings.  





Specifically, a distinction should be made to uncouple infrastructure and budget.  For example, a 
“clinic” which is a non-profit entity in developing countries could be as geographically remote as 
a “clinic” in a military setting, but their cost constraints for the POC device are very different.  In 
another example, a device in the “field” for global health is as similarly removed from lab testing 
facilities as a monitoring device used at home in the U.S., but their cost constraints are again 
very different.  For developers of POC diagnostic devices, infrastructure and cost are two 
important and independent sets of constraints. 
 
Hence, we propose a general description of POC use cases in a 2 x 2 matrix, which separates 
budget (low and moderate) from infrastructure (clinic and home) (Fig. 3).  Design of POC 
devices can be targeted towards four distinct use cases. 
 
Use Case 1 (Clinic level, moderate budget) is the least-constrained category, allowing for higher 
material costs and greater access to accessory equipment and trained personnel. Examples 
include hospitals, emergency rooms, urgent care clinics, operating rooms, intensive care units, 
private pharmacies, and military base clinics.  At the other end of the spectrum, Use Case 4 (In 
the field, constrained budget) is the most constrained for a developer of POC device, operating at 
a low budget and minimal to no infrastructure. Examples include global health applications in 
low-resource settings, remote clinics, and self-testing at low cost and with minimal accessory 
resources.  Use Cases 2 and 3 are intermediate scenarios.  Use Case 2 (In the field, moderate 
budget) is constrained by its portability in the field but maintains a moderate budget, 
encompassing consumer devices for self-testing and healthcare monitoring, military personnel in 
the field, space travel, ambulance, and industrial and agricultural field testing.  Use Case 3 





(Clinic level, constrained budget) has the amenities of a basic clinical setting but is constrained 
by its budget.  Examples include non-profit health centers and some primary care clinics.   
 
.   
 
Figure 3.  POC use cases, uncoupling cost from infrastructure.   Differences in budget and infrastructure 
level play a role in categorizing four distinct use cases for POC devices.  
  







In recent years, there have been a number of advances in individual microfluidic components and 
academic demonstrations of POC technologies[38, 39], but less progress on integration and 
translation to “real-world” use[40].  
 
Paper based, lateral flow assays (sometimes called “dipstick” assays) on the other hand, have 
been very successful in deployment and adoption due to features like low cost, low to no-power 
usage, long-term stability, interpretation by minimally trained users (usually discrimination of 
visual bands or dots by eye), usability with a wide range of specimens, and minimal cold chain 
requirements for shipping/storage[41]- in sum, a consideration for usage in many POC settings 
(particularly for Use Case 4 resource-constrained, field usage). The World Health Organization 
lists 28 lateral flow rapid tests as “prequalified” in vitro diagnostic products for HIV and malaria 
(from companies such as SD Bioline, Chembio, Alere, Trinity Biotech, bioMerieux, OraSure, 
ABON Biopharm, ARKRAY Healthcare, Access Bio, Premier Medical etc[42]. Drawbacks of 
lateral flow assays however, are challenges with multiplexing and complex fluid handling 
integration as well as subjective interpretation of test lines (which can be affected by lighting 
conditions, amount of time passed and faintness of lines with biologically weak positive 
samples).  
 
Novel microfluidic technologies can address these challenges as well as provide enhanced 
clinical solutions for other diagnostic use-cases. A lot of recent work in the microfluidic POC 
field have shown proof-concept demonstrations towards achievement of clinically relevant 





sensitivity and specificity using simulated samples (and in some cases, clinical samples 
evaluated in laboratory conditions).  Few however, have connected systems integration and 
consideration of downstream design and evaluation elements to push these advances closer to 
clinical or field use.   
 
For systems integration for POC diagnostic devices, it will be critical to recognize that different 
POC settings (which include emergency room, ambulance, physician’s office, pharmacy, home, 
or in the field) hold vastly different constraints and requirements (see Use Cases in 1.1.4). By 
incorporating these design and user-experience criteria towards microfluidic POC development 
and evaluation, we aim to create a framework for tools that are poised for greater adoption and 
subsequently greater impact. 
 
Our objective is to consider downstream translational engineering to iterate on upstream design 
choices and accelerate development of POC devices for real-world use. Fig. 4 illustrates stages 
of development, including traditional focus areas for microfluidic researchers. We highlight 
areas of focus in this thesis that are guided by a holistic consideration for the use-case setting and 
target end-user in design and testing. For example, a key guidance parameter of assay 
development was to achieve clinically relevant diagnostic performance but also to minimize end-
user operation for minimally trained or untrained workers, which had implications for sample 
type/processing, reagent delivery and fluid handling. We also undertook efforts to consider 
stability and preliminary methods to scale up production in a controlled manner.   
 
 







Figure 4. Translational design and evaluation focus areas of this thesis 
Additionally, microfluidic devices must be integrated with hardware and software to ensure an 
appropriate user experience and highlight value for adoption. In this thesis, we considered user 
experience for systems integration with hardware and software to minimize the need for 
peripheral equipment and allow users to run a complex assay in a simplified format with low 
training burden. An understanding of the use-case setting also provides additional design 
considerations for hardware such as portability, ruggedness, cost, reliance on electricity etc. 
Implementing downstream evaluations in the field provided us with information on the 
diagnostic performance our devices have under real-world conditions, as well as feedback from 
users on feasibility of device use and acceptability for adoption. These evaluations are necessary 
to iterate on upstream design choices that can improve diagnostic performance, address friction 









1.3 Overview of thesis 
Our goal was to design and evaluate microfluidic POC diagnostic assays and platforms for 
specific use-cases. In doing so, we form a greater understanding of the practical engineering 
design criteria and considerations that could allow for new POC technologies to have greater 
clinical or consumer impact. We demonstrated these considerations within the full development 
spectrum, starting from a proof-of-concept demonstration of new assays (Chapter 2) to a more 
translational integration of components, leveraging the power of smartphones as platform 
devices (Chapter 3). We also explore the impact of these devices in the hands of different target 
end-users in the field, both from a provider and patient context (Chapter 3 and 4). Finally, we 
sought to perform for the first time a structured assessment of completely naïve users interacting 
with a smartphone interfaced microfluidic diagnostic device towards self- or home-testing 
(Chapter 4). 
 
The contents of this dissertation are organized in the following manner: 
Chapter 1: Introduction 
 
Chapter 2: Creating rapid, accurate and multiplexed serodiagnostic tests for bacterial 
spirochete infections.  We sought to develop rapid tests with increased specificity and 
sensitivity for bacterial illnesses that largely present with non-specific symptoms in humans. We 
focused primarily on the development of a rapid multiplexed test for Lyme Disease (2.1-2.4), a 
tick-borne illness with incidence rates that have doubled in the last decade in the United States.  
We aimed to replace the current two-tier serodiagnostic test format (ELISA followed by Western 





blot) with a single rapid test suitable for a doctor’s office or urgent care setting (Use Case 1). We 
sought to replicate ELISA performance in a microfluidic rapid test format as well as screen 
candidate antigens for potential disease staging. We also explored development of a rapid test for 
Leptospirosis (2.5-2.7), another bacterial spirochete infection with diverse and non-specific 
symptoms where current standard microscopic-agglutination tests (MAT) are underused due to 
laborious and expensive procedures.  
 
Chapter 3: Developing a microfluidic, smartphone integrated HIV-syphilis immunoassay 
and demonstrating use at the point-of-care. We sought to build on previous work in 
introducing a dual rapid test for HIV and syphilis for low resource settings by creating an 
integrated diagnostic system that can be used in the field (Use Case 4). Our aims were to use 
whole blood as a sample input, consider scale-up in fabrication, characterize stability and 
optimize pre-packaging of reagents to develop a “plug and play” system. Designing for this use-
case also entailed significant consideration towards cost, portability and automation. We sought 
to leverage the power and ubiquity of smartphones as a platform device to build a robust, 
integrated system with minimal user-operation steps to conduct a triplex immunoassay (HIV, 
treponemal syphilis, and non-treponemal syphilis). We characterized test performance of the 
device in the hands of minimally trained healthcare workers in Kigali, Rwanda (3.1-3.4). From 
this, we expanded assay and device development efforts in a followup pilot study with naïve 
users in Kigali, Rwanda to assess feasibility of smartphone-integrated diagnostic platform for 
home-testing in a developing country (3.4-3.8). 
 





Chapter 4:  Assessing the potential of a smartphone accessory for HIV home-testing. Self-
testing has been proposed as the next step in HIV prevention, particularly with high risk groups, 
where uptake of traditional testing and counseling services remains low. We sought to expand 
access to HIV and other STI testing outside of the clinic by exploring the use of our smartphone 
accessory and accompanying application (app) for home or self-testing in the U.S. (Use Case 2). 
We applied the Fisher  & Fisher Information-Motivation-Behavioral Skills (IMB) model as well 
as elements of user-experience (UX) design towards a structured evaluation of microfluidic POC 
technology. We sought to assess value of our product beyond an assessment of clinical 
sensitivity and specificity, by understanding how untrained users use our device, what the device 
failure points are and the most relevant design features to spur user adoption and meaningful 
usage. We also sought to explore user motivations and behaviors through the smartphone app 
with the goal of gathering large-scale testing data to improve linkage to care and health 
outcomes. We conducted an initial study with completely naïve users:  a sample of the men who 
have sex with men (MSM) population in New York City who qualified as a “high risk” cohort 
based on self-reported sexual behaviors.  
 
Chapter 5: Conclusions   
 
1.4 My role in each chapter and relevant publications 
Developing integrated diagnostic devices requires significant interdisciplinary and collaborative 
effort from team members with diverse backgrounds and expertise. The contributions from team 
members, collaborators and partners in the public and private sector were critical to the studies 





described in this thesis. Here, I would like to clarify my role in each study.  For Chapter 2, I led 
the multiplexed assay design, characterization and testing with clinical samples. For Chapter 3, 
my role was leading assay development efforts to improve the HIV/syphilis assay for field usage 
and helping conduct evaluation of the device in the hands of local healthcare workers in Rwanda 
for the first field trial. For the subsequent pilot study in Rwanda evaluating feasibility of the 
device for self-testing in a resource limited setting, I led study/field trial design and 
implementation and also guided assay and device development. For Chapter 4, I guided app and 
device development, designed evaluation tools and helped conduct user-testing visits in New 
York City.  
 
Manuscripts related to these sections are listed below: 
Chapter 2:  Nayak, S.*, Sridhara, A.*, Melo, R., Richer, L., Chee, N. H., Kim, J., ... & Gomes-
Solecki, M. (2016). Microfluidics-based point-of-care test for serodiagnosis of Lyme 
Disease. Scientific reports (*denotes equal contribution) 
 
Chapter 3: Laksanasopin, T.*, Guo, T. W.*, Nayak, S., Sridhara, A. A., Xie, S., Olowookere, O. 
O., ... & Chin, C. D. (2015). A smartphone dongle for diagnosis of infectious diseases at the 
point of care. Science translational medicine  (* denotes equal contribution) 
 
Chapter 4: Nayak, S., Guo T.W., Lopez-Rios, J., Lentz, C., Dolezal, C., Hughes, J., Frasca, T., 
Carballo-Diéguez, A., Balán, I., & Sia, SK. Structured evaluation of user experience with 
microfluidic-based point-of-care diagnostic device towards HIV home-testing  (Manuscript in 
preparation). 






Note:  This Overview (Chapter 1) and Conclusions (Chapter 5) contain elements of a previously 
written review:   
 
Nayak, S.*, Blumenfeld, N. R.*, Laksanasopin, T., & Sia, S. K. (2016). Point-of-care 
diagnostics: Recent developments in a connected age. Analytical chemistry (* denotes equal 
contribution) 















Creating rapid, multiplexed tests for 
bacterial spirochete infections  
 
 
In this chapter, we examine two bacterial spirochete infections of public health interest, Lyme 
and Leptospirosis, where rapid multiplexed tests could provide significant clinical value. This 






Lyme disease (LD) is widely distributed throughout temperate zones of the Northern Hemisphere 
[43] but lacks a reliable point-of-care (POC) diagnostic test.  Its prevalence is high and 
increasing. Newly diagnosed cases have doubled in the United States over the last decade [44]. 
The number of probable cases of Lyme disease in the U. S. has been revised upwards by 10 fold 






by the Centers for Disease Control and Prevention (CDC ) to account for widespread under-
reporting [45]: this number is now estimated at ˜300 000 cases per year [46].  
 
Lyme disease is a progressive disease with a wide array of largely non-specific clinical 
manifestations gradually developing from early to late stage. Late disseminated infection is 
associated with permanent damage to the nervous and musculoskeletal systems [47]. Erythema 
migrans (EM) is the clinical marker of early infection (stage 1) in up to 80% of patients with 
classic Lyme disease [48]. Of the patients presenting with stage 1 LD, ˜35% present with 
atypical rashes that are often misdiagnosed [49], thereby putting a large group of patients at risk 
for developing late Lyme, antibiotic-refractory arthritis and/or post-treatment Lyme disease 
syndrome. In addition to Borrelia burgdorferi sensu stricto, the CDC recently reported the 
discovery of a new spirochete species (Borrelia mayonii) that causes LD in people in the upper 
Midwest [50]. The newly discovered Lyme causing B. mayonii is associated with additional 
symptoms not previously described for LD (nausea and vomiting) and with diffuse rashes rather 
than the classic Bull’s Eye of EM which further complicates clinical diagnosis of the disease 
[50]. About 15% of patients treated with the recommended 2-4 week course of antibiotics will 
have lingering symptoms of fatigue, pain or joint and muscle aches that can last more than 6 
months. Between the population of patients that present at the clinic with atypical rashes [49] and 
patients that are correctly diagnosed but go on to develop symptoms of late LD, a physician in an 
endemic area can be faced up with ~50% of patients at risk of developing late disease.  
 






Prompt diagnosis and treatment is critical to prevent disease progression. Unlike most bacterial 
diseases that can be defined microbiologically by direct observation, LD is currently defined 
indirectly through serologic assays given that Lyme-causing Borrelia grows slowly (up to 6 
weeks) in culture [51]. Current laboratory based serologic assays employ the C6 ELISA or a 
two-tier test comprised of whole-cell or recombinant antigen ELISA followed by IgG Western 
blot containing a number of B. burgdorferi antigens such as VlsE, p100, p66, p58, p45, p41, p39, 
p30/31, p28 and p18. The sensitivity of these assays varies between 35-56% for Early Stage I, 
73-77% for Early Stage II and 96-100% for Late Stage III LD [52-56]. However, only 10 to 50% 
of patients with culture confirmed very early localized Lyme disease (EM rash < 7 days) 
presented a detectable antibody response using the sero-analysis technology tested [57, 58].  
 
A recent study found that the C6 ELISA can substitute for immunoblots in the two-tiered testing 
protocol for LD without a loss of sensitivity or specificity [59]. Thus, a rapid serodiagnostic 
assay which can reproduce the performance of the C6 ELISA would fill a significant void. Here, 
we describe how we used microfluidics technology to develop a quantitative multiplexed rapid 
lab-on-a-chip point of care (POC) assay for the serodiagnosis of human Lyme disease towards 
U.S. based urgent care or physicians’ office settings (Use Case 1). We evaluate the diagnostic 
potential of various candidate antigens for a multiplexed serodiagnostic test (Table 2). 
Development of an assay or biomarkers that allow physicians to diagnose LD at the point of care 
enables prompt and proper treatment of patients.  
 
 







2.2.1 Lyme Disease characterized human serum panel 
Blinded de-identified surplus serum samples from patients with signs and symptoms of Lyme 
disease enrolled in previous studies conducted by the Lyme Disease Center at Stony Brook 
University, reference Lyme disease panels from CDC, and reference healthy individuals from a 
commercial source were used. Informed consent was obtained from all patients enrolled in the 
studies that originated the samples. Use of these samples was approved under FWA00021769 by 
IntegReview, Inc. Ethical Review Board IRB #2. The involvement of human subjects in the 
proposed studies falls under Exemption 4 as outlined under HHS regulations (45 CFR Part 46) and 
is not considered “clinical research” as defined by NIH. The methods were carried out in 
accordance with the relevant guidelines.  
Three different archived serum panels were used for testing and evaluation: 
1) Stony Brook Lyme Disease panel, n=20 samples. Twenty samples from patients presenting at 
the clinic with signs and symptoms of Lyme disease, some of which were culture confirmed. 
These samples were used to do preliminary studies and improvement of testing parameters. 
2) CDC LD panel, n=40 samples. Thirty-five samples in this panel were collected from patients 
diagnosed with Lyme disease by experienced physicians in endemic areas (Northeast and 
upper-Midwest). Five of the samples included in the panel were obtained from healthy 
individuals from the same areas. An extensive set of information, ranging from detailed 
clinical symptoms at presentation to serologic data from ELISA and Western Blot for these 
patients has been characterized. In addition, B. burgdorferi was cultured from 88% of the 
early Lyme cases and the remaining patients met a rigorous case definition for early 






disseminated or late Lyme disease and had a seropositive ELISA result.  This panel as well 
as all information on its clinical characterization was kindly provided by Dr. Martin Schriefer 
from the NCID/CDC. 
3) Cross-Reactive Human Sera Panel, n=25 samples. Sera from healthy patients from a non-
endemic area (Golden West Bio, Tennessee) was used to do specificity studies. 
 
2.2.2 Peptides (Lyme) 
The following peptides were used: pepBBK07 (kindly provided by Dr. Utpal Pal, U. of 
Maryland) and PepVF (synthesized at GenScript, Piscataway, NJ). PepVF design was modified 
from a peptide based in the core sequence from the full length 25-residue IR6 from B. 
burgdorferi B31 [60] by adding a 13 amino-acid sequence from FlaB. Crude extract of PepVF 
was synthetized by GenScript. 
 
2.2.3 Protein Purification  
OspA (outer surface lipoprotein A), OspB (outer surface lipoprotein B), OspC-K (outer surface 
lipoprotein C type K) and OspC-B (outer surface lipoprotein C type B) were purified in Dr. 
Gomes-Solecki’s laboratory as follows. Recombinant E. coli clones were grown in Tryptone 
Broth Yeast (TBY) medium supplemented with 50 μg/ml Kanamycin (Kn) at 37°C, shaking at 
225 rpm, until it reached an OD600 of 0.8. The expression of 6xHis tagged recombinant proteins 
was induced by adding 1 mM IPTG (isopropyl-β-d-thiogalactopyranoside) to the cells followed 
by incubation at 37oC for 3h. The cells were harvested by centrifugation at 4000 x g for 10 min 
at 4oC. The proteins were purified by affinity chromatography using the Ni-NTA Purification 






System (Invitrogen) following the manufacturer instructions. Protein concentration was 
determined by the Bradford protein assay (Bio-Rad, Hercules, CA, USA), and was stored at -
80oC. Pure recombinant proteins  (crude extract) were analyzed on a 10% denaturing 
polyacrylamide gel and electrotransferred to a polyvinyldene difluoride membrane (PVDF, 
Millipore, Billerica, MA) for analysis with antigen-specific- polyclonal mouse antibody. Purified 
recombinant proteins from B. burgdorferi such as flaB (flagellin B, p41), p100 (membrane 
lipoprotein p100/p93), BmpA (laminin binding protein A, p39), DbpA (decorin binding protein 
A), DbpB (decorin binding protein B) were purchased from ProSpec (Rehovot, Israel); VlsE 
(Variable Major Protein like sequence E, surface exposed lipoprotein) was purchased from My 
BioSource (San Diego, CA). 
 
2.2.4 Serological immune responses using ELISA 
Serum was tested for the presence of IgG against purified recombinant proteins and peptides by 
indirect ELISA, performed at Dr. Maria Gomes-Solecki’s laboratory. Antigens were coated on 
flat-bottom ELISA plates at 2μg/ml (Nunc MaxiSorp™, ThermoFisher) and indirect ELISA was 
performed using human serum (1:100). Goat anti-human (Lyme) or goat-anti-mouse 
(Leptospirosis) IgG (1:50,000) horseradish peroxidase-conjugated antibody (Jackson 
Immunoresearch, USA) was used as secondary antibody. Four healthy samples from the CDC 
panel were used (3 standard deviation above the mean) to determine the cutoff of the assay in 
Method 1; one healthy sample was positive against all recombinant B. burgdorferi proteins and 
was excluded from this study. Method 2 cutoff was determined by ROC curve analysis and 
choosing a point that maximized sensitivity and specificity. 







2.2.5 Point-of-care immunoassay  
Injection molded plastic microfluidic cassettes were functionalized by direct adsorption of 
antigen candidates (purified recombinant proteins and peptides of B. burgdorferi) at the 
following concentrations: 100 μg mL−1 pepVF, 20 μg mL−1 rOspC-K, 30 μg mL−1 rOspC-B, 1 μg 
mL−1 rVlsE, 200 μg mL−1 rP41, 60 μg mL−1 rP100, 30 μg mL−1 rDbpB, 100 μg mL−1 rBmpA, 
and 20 μg mL−1 rDbpA. Avidin-biotin conjugation was used for pepBBK07 functionalization: 50 
μg mL−1 streptavidin followed by 60 μg mL−1 pepBBK07. Functionalized cassettes included an 
internal negative control zone, spotted with no antigen, an internal positive control zone, spotted 
with 20 μg mL−1 rabbit anti-goat IgG antibody (Life Technologies) and multiplexed combination 
of three target antigen zones. All zones were treated for 1 hour with 1% BSA-0.05% Tween-20 
in PBS for blocking and stabilizing. Further details on cassette preparation can be found in 
previous studies[61-64]. To run the assay, polyethylene tubing (inner diameter: 0.86 mm, Zeus) 
was pre-loaded with all reagents and connected to the cassette inlet for delivery, in a method 
previously described [61, 62, 65]; initial wash of 2 μL of 0.05% Tween-20 in PBS, 30 μL of 
serum/plasma sample (10X dilution in 1% BSA), four 2 μL 0.05% Tween-PBS washes, 14.5 μL 
secondary gold-conjugated anti-hIgG (1.06ug/mL) and anti-hIgM (0.54 ug/ml) antibodies 
(OPKO Diagnostics) in 3% BSA-0.2% Tween-20 in PBS, followed by two 2 μL 0.05% Tween-
PBS washes and four 2 μL water washes, each separated by air spaces (Fig. 3A). As in previous 
work, these steps take about 10 minutes to flow (which includes all the binding steps of the 
immunoassay)[63]. Silver nitrate and reducing agents (OPKO Diagnostics) were subsequently 
drawn through the cassette. An initial intensity reading (I0) was taken immediately after silver 






entered the channel, and another intensity reading (I) was taken after 4.5 minutes of silver 
development. All experiments were read on a bench-top analyzer (OPKO Diagnostics) (Fig. 3A). 
Optical density was calculated as: 
OD = - log [I/ I0] 
 
2.2.6 Statistical analysis 
Assay performance of test was reported in term of sensitivity and specificity compared to 
reference test. Given the number of true positives (TP), true negatives (TN), false positives (FP), 











FP +TN  
 
For Lyme panel analysis, reference tests were culture confirmation and clinical diagnosis. In one 
method, receiver operating characteristic (ROC) analysis was performed to determine cutoff 
values and assess sensitivity and specificity. In another method, cutoff values were established at 
3STDEV above the average of four negative control samples. 95% Confidence Intervals (95% 
CI) were calculated.  Calculations were performed using Graphpad Prism. For markers 
containing multiple antigens (e.g. the three antigens multiplexed Lyme tests), we used a 1:1:1 
ratio of weighting constants to add up the signals, and then used ROC analysis to compare area-
under-the-curve (AUCs) with a new cutoff, similar to evaluation of different permutations of 
biomarkers as demonstrated in other works evaluating pooled set of markers [66, 67].  







Table 2.  Descriptions of Lyme antigens screened 
 
  
Family Antigen Name Description 
Membrane 
Proteins 
OspA Outer surface lipoprotein A 
Protein in borrelial outer surface membrane; 
expressed mainly by B.burgdorferi in ticks [68] 
OspB Outer surface lipoprotein B 
Protein in borrelial outer surface membrane; 
expressed mainly by B.burgdorferi in ticks [68] 
OspC-K Outer surface lipoprotein C, type K 
Protein in borrelial outer surface membrane; 
expressed by B.burgdorferi during transmission 
of spirochetes from ticks to mammals as well 
as in the vertebrate host [68] 
OspC-B Outer surface lipoprotein C, type B 
Protein in borrelial outer surface membrane; 
produced during early infection [69]  
BmpA Basic membrane protein A (p39) 
Borrelial outer membrane protein that binds to 
laminin in host's extracellular matrix;  
implicated as playing a role in some symptoms 
of Lyme disease [70]  
DpbA Decorin binding protein A 
Adhesin protein of B. burgdorferi that binds to 
decorin (a proteoglycan on surface of human 
cells); implicated in mediating tissue 
adherence of B. burgdorferi [71]  
DbpB Decorin binding protein B 
Adhesin protein of B. burgdorferi that binds to 
decorin (a proteoglycan on surface of human 
cells); implicated in mediating tissue 
adherence of B. burgdorferi [71] 
VlsE Variable major protein-like sequence E 
Surface exposed lipoprotein; belongs to a 
family of immunodominant variable major 
surface lipoproteins or VMPs that were 
involved in multiphasic antigenic variation in 
related Borrelia species [72]  
Peptides 
PepVF Peptide VF 
Synthetic peptide isolated from a conserved 
region of VlsE 
p100 Membrane lipoprotein p100 (p93) Immunodominant polypeptide 
BBK07 Lipoprotein BBK07  




flaB (p41) Flagellin B, p41 Protein found in borrelial flagella 






2.3 Results  
 
2.3.1 Lyme Disease point-of-care device 
The POC device, which we call mChip-Ld, consists of a signal detection device and a 
disposable, injection molded plastic cassette on which all the biochemical steps of the 
immunoassay are carried out (Fig. 5). Lyme-specific antibodies in a patient blood sample bind to 
antigens immobilized on the surface of the microfluidic cassette. Subsequent automated reagent 
delivery of all washes, secondary antibodies and silver amplification reagents results in silver ion 
reduction on gold nanoparticles attached to cassette surface. The detection mechanism, as 
previously described[61], consists of paired light-emitting diodes (LEDs) and photodetectors 
aligned directly with the microfluidic test zones (Fig. 5A). When inserted into the analyzer, each 
microfluidic test zone of the cassette is sandwiched between a red LED aligned above with a 
1mm pinhole and red-sensitive photodiode aligned directly below each test zone. Silver 
development on the cassette results in a proportional decrease in the light sensed by the 
photodiode and can be quantified by optical density values (Fig. 5B). Assay time to result is 
approximately 15 minutes. 
 
 







Figure 5. Overview of the mChip-Ld Device. (A) The plastic microfluidic cassette is inserted into a benchtop 
analyzer (Claros1 Analyzer, OPKO) which is used to power fluid flow, control temperature setpoints and detect 
signals. Sera/plasma samples as well as all washes, gold-labeled secondary antibodies and silver amplification 
reagents are pre-loaded and delivered automatically in sequence, passing over the five detection zones of the 
microfluidic channel. Pressure driven flow is achieved through attachment of a vacuum (simple syringe or 
benchtop analyzer) to the microfluidic cassette outlet. (B) Schematic of the biochemical and optical set up. 
Lyme antigens are adsorbed to the surface of the plastic microfluidic cassette. Sequential binding of the sample 
antibodies, gold-labeled detection antibodies and silver amplification reagents results in a visible signal that can 
be quantified as the optical density of the detection zone. Light emitted from a LED above the detection zone is 
collected by a photodiode. The presence of silver development, which absorbs incident light, reduces light 
sensed by the photodiode. 
 
2.3.2 Testing candidate antigens on ELISA 
In order to develop multiplexed panel designs for the POC test, we first screened candidate 
antigens using conventional ELISA.  We examined 12 candidate recombinant antigens: rP100, 
rBmpA, rP41 (FlaB), rDbpA, rDbpB, rOspA, rOspB, rOspC-K, rOspC-B, rVlsE, pepBBK07, 
and PepVF (Fig. 6, Table 3). We used a panel of Lyme positive samples (n=35) characterized by 
the CDC and healthy samples taken from non-endemic areas (n=25). Two cutoff methods were 
evaluated in the screening of candidate markers on ELISA. In Method 1, four healthy samples 
from the same area of collection as the Lyme positive samples were tested. Cutoff for each 
antigen was determined as 3 standard deviations above the mean signal of these four samples, 
thus prioritizing a high specificity test. In Method 2, receiver-operator curve (ROC) analysis was 
used to select a cutoff maximizing sensitivity and specificity looking at area under the curve 






(AUC), prioritizing a high sensitivity test. The full table of results is shown in Table 3. For the 
intended application of designing a high sensitivity test for screening decisions, Method 2 was 




Figure 6. ELISA screening of candidate antigens for Lyme diagnosis. Signal to cutoff plots showing 
specificity and sensitivity of candidate antigens using IgG ELISA compared to reference testing with clinical 
evaluation and cultures. (A) 25 sera samples from healthy individuals in a non-endemic area and (B) 35 sera 
samples clinically characterized as positive by the CDC for Lyme Disease and were used to test specificity and 
sensitivity of candidate antigens of rP100, rBmpA, rOspA, rP41 (FlaB), rDbpA, rDbpB, rOspB, rOspC-K, 
rOspC-B, pepBBK07, rVlsE and PepVF. 









Table 3.  Performance of two ELISA cutoffs for diagnosing Lyme disease (at any stage) 
 
ELISA Performance with Cutoff Method 1 (High Specificity): Early + Late Lyme 
  Sensitivity (%) CI (95%) Specificity (%) CI (95%) Cutoff AUC 
rP100 42.9 26.32 - 60.65 100.0 88.78 - 100.0 0.250 0.971 
rBmpA 31.4 16.85 - 49.29 95.0 75.13 - 99.87 0.296 0.936 
rOspA 22.9 10.42 - 40.14 95.0 75.13 - 99.87 0.128 0.784 
rP41 68.6 50.71 - 83.15 95.0 75.13 - 99.87 0.310 0.967 
rDpbA 42.9 26.32 - 60.65 100.0 83.16 - 100.0 0.190 1.000 
rDbpB 34.3 19.13 - 52.21 100.0 83.16 - 100.0 0.194 0.981 
rOspB 20.0 8.44 - 36.94 100.0 83.16 - 100.0 0.154 0.714 
rOspC-K 34.3 19.13 - 52.21 93.6 78.58 - 99.21 0.408 0.976 
rOspC-B 54.3 36.65 - 71.17 100.0 88.43 - 100.0 0.444 0.996 
pepBBK07 28.6 14.64 - 46.30 100.0 83.16 - 100.0 0.319 0.989 
rVlsE 82.9 66.35 - 93.44 100.0 83.16 - 100.0 0.303 0.993 
PepVF 77.1 59.86 - 89.58 95.0 75.13 - 99.87 0.124 0.961 
ELISA Performance with Cutoff Method 2 (High Sensitivity): Early + Late Lyme 
  Sensitivity (%) CI (95%) Specificity (%) CI (95%) Cutoff AUC 
rP100 97.1 85.08 - 99.93 75.0 50.90 - 91.34 0.090 0.971 
rBmpA 94.3 80.84 - 99.30 80.0 56.34 - 94.27 0.128 0.936 
rOspA 71.4 53.70 - 85.36 70.0 45.72 - 88.11 0.070 0.784 
rP41 100.0 90.00 - 100.0 95.0 75.13 - 99.87 0.157 0.967 
rDpbA 100.0 90.00 - 100.0 100.0 83.16 - 100.0 0.064 1.000 
rDbpB 100.0 90.00 - 100.0 95.0 75.13 - 99.87 0.060 0.981 
rOspB 74.3 56.74 - 87.51 70.0 45.72 - 88.11 0.071 0.714 
rOspC-K 94.3 80.84 - 99.30 95.0 75.13 - 99.87 0.106 0.976 
rOspC-B 100.0 90.00 - 100.0 95.0 75.13 - 99.87 0.188 0.996 
pepBBK07 100.0 90.00 - 100.0 95.0 75.13 - 99.87 0.103 0.989 
rVlsE 100.0 90.00 - 100.0 95.0 75.13 - 99.87 0.158 0.993 
PepVF 100.0 90.00 - 100.0 85.0 62.11 - 96.79 0.057 0.961 
Abbreviations: CI, confidence interval; AUC, area under the curve.












ELISA: Early Lyme 
  Sensitivity (%) CI (95%) Specificity (%) CI (95%) AUC 
rP100 96 79.65 - 99.90 75 50.90 - 91.34 0.904 
rBmpA 92 73.97 - 99.02 80 56.34 - 94.27 0.928 
rOspA 68 46.50 - 85.05 70 45.72 - 88.11 0.755 
rP41 100 86.28 - 100.0 95 75.13 - 99.87 0.964 
rDpbA 100 86.28 - 100.0 100 83.16 - 100.0 1.000 
rDbpB 100 86.28 - 100.0 95 75.13 - 99.87 0.984 
rOspB 68 46.50 - 85.05 70 45.72 - 88.11 0.685 
rOspC-K 96 79.65 - 99.90 95 75.13 - 99.87 0.983 
rOspC-B 100 86.28 - 100.0 90 68.30 - 98.77 0.998 
pepBBK07 100 86.28 - 100.0 95 75.13 - 99.87 0.988 
rVlsE 100 86.28 - 100.0 95 75.13 - 99.87 0.990 




Abbreviations: CI, confidence interval; AUC, area under the curve
ELISA: Late Lyme 
  Sensitivity (%) CI (95%) Specificity (%) CI (95%) AUC 
rP100 100 69.15 - 100.0 65 40.78 - 84.61 0.960 
rBmpA 100 69.15 - 100.0 75 50.90 - 91.34 0.955 
rOspA 80 44.39 - 97.48 65 40.78 - 84.61 0.855 
rP41 100 71.51 - 100.0 90 68.30 - 98.77 0.973 
rDpbA 100 69.15 - 100.0 95 75.13 - 99.87 1.000 
rDbpB 100 69.15 - 100.0 90 68.30 - 98.77 0.975 
rOspB 90 55.50 - 99.75 65 40.78 - 84.61 0.785 
rOspC-K 90 55.50 - 99.75 90 68.30 - 98.77 0.960 
rOspC-B 100 69.15 - 100.0 95 75.13 - 99.87 0.990 
pepBBK07 100 69.15 - 100.0 90 68.30 - 98.77 0.990 
rVlsE 100 69.15 - 100.0 90 68.30 - 98.77 1.000 
PepVF 100 69.15 - 100.0 80 56.34 - 94.27 0.965 






When testing the full panel of Lyme samples by ELISA, covering both Early and Late Stage 
Lyme, rP41, rDbpA, rDbpB, rOspC-B, rVlsE, pepBBK07 and PepVF showed the highest 
sensitivities (100% sensitivity) and specificities (> 90%) (Fig. 6, Table 3). The following 
proteins were highly sensitive as diagnostic candidates using Early Lyme test samples (>95% 
sensitivity): rP100, rP41, rDbpA, rDbpB, rOspC-K, rOspC-B, rVlsE, pepBBK07 and PepVF 
(Table 4A). Using Late Lyme samples we identified the following antigens (100% sensitivity): 
rP100, rBmpA, rP41, rDbpA, rDbpB, rOspC-B, rVlsE, pepBBK07 and PepVF (Table 4B). The 
least cross-reactive antigens (> 90% specificity) tested against serum samples from healthy 
individuals were: rP41, rDbpA, rDbpB, rOspC-K, rOspC-B, rVlsE and pepBBK07 (Fig. 2A). 
rOspA with sensitivity of 71.4% (95% CI: 54-85%), specificity of 70.0% (95% CI: 46-88%) and 
AUC of 0.784, as well as rOspB with sensitivity of 74.3% (95% CI: 57-87%) specificity of 70% 
(95% CI: 46-88%) and AUC of 0.714 showed the poorest performance compared to other 
antigens and were eliminated as candidates for POC testing (Table 3). By deconstructing 
diagnostic performance with the full sample panel into Early Lyme (Table 4A) and Late Lyme 
(Table 4B), we also illustrate the potential of candidate antigens for disease staging as well as 
diagnosis. 
 
2.3.3 Screening candidate antigens on the microfluidic platform 
To characterize sensitivity and specificity of these antigens for application in Lyme diagnosis 
using the rapid microfluidics format, we performed a preliminary screening test.  Due to the 
large number of antigens being screened (ten), we did not optimize this screening test as much as 
some previous studies on the mChip system[61-64].  For example, we did not optimize the 






conjugation chemistry beyond physiosorption, concentration of coating protein, and blocking 
conditions.  Instead, we looked for the markers that produced the best relative performance 
within the mChip-Ld data set.  Twenty patient samples were used to evaluate various 
permutations of multiplexed markers with surface conditions suitable for a panel (i.e. balancing 
conditions for optimal signal-to-noise ratios for most markers on a panel, not necessarily the 
highest signal-to-noise ratios that can be recorded on the mChip-Ld platform for an individual 
marker).    
 
Next we screened the immunoassay potential of individual candidate antigens (rP100, rP41/FlaB, 
rDbpA, rOspC-K, rOspC-B, rVlsE, pepBBK07 and PepVF) on the mChip-Ld POC platform 
against the same Lyme positive and healthy sample panels used in ELISA screening experiments 
(Fig. 7, Table 5). rOspC-K and PepVF proteins were highly sensitive (>80% sensitivity) as 
diagnostic candidates using Early Lyme test samples (Table 6A). Using Late Lyme samples, we 
identified the following antigens (>70% sensitivity): rP100, pepBBK07, rVlsE, rOspC-B and 
PepVF, with the latter two markers having >90% sensitivity (Table 6B).  The least cross-reactive 
antigens (> 80% specificity) tested against serum samples from healthy individuals were: rVlsE, 
rOspC-K and PepVF (Fig. 7A). A breakdown of Early and Late Lyme classification by candidate 
antigen on the POC platform shows that OspC-K skews towards ‘positive” disease classification 
for Early Lyme and ‘negative’ for Late Lyme, suggesting potential for discrimination between 
disease stages (Table 6).  
  











Figure 7. Preliminary screening of candidate antigens with mChip-Ld. Signal to cutoff plots showing 
specificity and sensitivity of candidate antigens on the mChip-Ld platform. Recombinant antigens rP100, 
rP41 (FlaB), rDbpA, pepBBK07, rOspC-K, rOspC-B, rVlsE and PepVF were chosen  for testing from the 
ELISA screening study.  (A) 25 sera samples from healthy individuals in a non-endemic area and (B) 35 
sera samples clinically characterized as positive by the CDC for Lyme Disease were used to test 
specificity and sensitivity of candidate antigens.  





















POC: Early + Late Lyme 
  Sensitivity (%) CI (95%) Specificity (%) CI (95%) AUC 
rP100 68.6 50.71 - 83.15 70.0 45.72 - 88.11 0.699 
rP41 62.9 44.92 - 78.53 44.0 24.40 - 65.07 0.579 
rDbpA 51.4 33.99 - 68.62 80.0 56.34 - 94.27 0.650 
pepBBK07 51.4 33.99 - 68.62 50.0 27.20 - 72.80 0.515 
rOspC-K 68.6 50.71 - 83.15 92.3 74.87 - 99.05 0.778 
rOspC-B 62.9 44.92 - 78.53 48.0 27.80 - 68.69 0.581 
rVlsE 40.0 23.87 - 57.89 84.0 63.92 - 95.46 0.714 
PepVF 94.3 80.84 - 99.30 73.1 44.33 - 82.79 0.934 















POC: Late Lyme 
  Sensitivity (%) CI (95%) Specificity (%) CI (95%) AUC 
rP100 70.0 34.75 - 93.33 70.0 45.72 - 88.11 0.745 
rP41 60.0 26.24 - 87.84 64.0 42.52 - 82.03 0.582 
rDbpA 60.0 26.24 - 87.84 95.0 75.13 - 99.87 0.723 
pepBBK07 70.0 34.75 - 93.33 70.0 45.72 - 88.11 0.703 
rOspC-K 40.0 12.16 - 73.76 96.2 80.36 - 99.90 0.529 
rOspC-B 90.0 55.50 - 99.75 64.0 42.52 - 82.03 0.758 
rVlsE 70.0 34.75 - 93.33 100.0 86.28 - 100.0 0.794 
PepVF 100.0 69.15 - 100.0 96.2 80.36 - 99.90 0.985 
Abbreviations: CI, confidence interval; AUC, area under the curve
POC: Early Lyme 
  Sensitivity (% CI (95%) Specificity (%) CI (95%) AUC 
rP100 68.0 46.50 - 85.05 70.0 45.72 - 88.11 0.680 
rP41 60.0 38.67 - 78.87 56.0 34.93 - 75.60 0.643 
rDbpA 56.0 34.93 - 75.60 80.0 56.34 - 94.27 0.621 
pepBBK07 56.0 34.93 - 75.60 65.0 40.78 - 84.61 0.560 
rOspC-K 84.0 63.92 - 95.46 92.3 74.87 - 99.05 0.877 
rOspC-B 76.0 54.87 - 90.64 56.0 34.93 - 75.60 0.717 
rVlsE 68.0 46.50 - 85.05 64.0 42.52 - 82.03 0.682 
PepVF 92.0 73.97 - 99.02 73.1 52.21 - 88.43 0.914 






2.3.4 Comparison of ELISA with the multiplexed microfluidic chip test (mChip-Ld) 
Next, we analyzed four potential multiplex panel designs: (1) rP100+ PepVF + rOspC-K; (2) 
rVlsE+ PepVF+ rOspC-K; (3) rVlsE+ rP41+ rOspC-K, and (4) rVlsE+ rDbpA+ rOspC-K on 
both ELISA and POC platforms compared to gold standard reference tests of clinical 
classification and culture tests (Fig. 8, Table 7). A simple multivariate model was used to 
combine the signals for each marker and develop a new cutoff in order to classify samples as 
positive or negative in these multiplexed tests. rP100+ PepVF + rOspC-K, had 94.3% sensitivity 
90% specificity on ELISA compared to 88.5% sensitivity, 90% specificity (AUC: 0.844) on the 
mChip-Ld system (Fig. 8A, Table 7). The remaining combinations of: (2) rVlsE+ PepVF+ 
rOspC-K, (3) rVlsE+ rP41+ rOspC-K and (4) rVlsE+ rDbpA+ rOspC-K all had 100% 
sensitivity, and >95% specificity on ELISA.  On the mChip-Ld system, combination (2) of  
rVlsE+ PepVF+ rOspC-K yielded the highest sensitivity of 94.3%. with 75% specificity (AUC: 
0.932) (Fig. 8B, Table 7).  The triplexed panel rP100+ PepVF + OspC-K (Fig. 6A) showed 
comparable performance on both the ELISA and POC plaforms when compared to clinical 
classification and culture tests. VlsE+ PepVF+ OspC-K (Fig. 8B) had higher sensitivity than 
p100+ PepVF + OspC-K on the POC platform, however with a tradeoff of lower specificity with 
the cutoff chosen here.  
 







Figure 8. Comparison of ELISA and an initial version of multiplexed microfluidic chip platform (mChip-
Ld). A vertical scatterplot showing signal-to-cutoff ratios of samples positive (Pos) or negative (Neg) for Lyme 
Disease, as determined by gold standard tests of clinical confirmation and culture tests, on ELISA and mChip 
platforms using a multiplexed combination of (A) rP100, PepVF and rOspC-K; (B) rVlsE, PepVF and rOspC-K; 


















Table 7. Comparison of ELISA and point-of-care (POC) multiplexed tests 
 
 
Abbreviations: CI, confidence interval; AUC, area under the curve 
 
  
ELISA: Early + Late Lyme 
 
Sensitivity (%) CI (95%) Specificity (%) CI (95%) AUC 
rP100+PepVF+rOspC-K 94.3 80.84 - 99.30 90.0 68.30 - 98.77 0.976 
rVlsE+PepVF+rOspC-K 100 90.00 - 100.0 95.0 75.13 - 99.87 0.994 
rVlsE+rP41+rOspC-K 100 90.00 - 100.0 95.0 75.13 - 99.87 0.997 
rVlsE+rDbpA+rOspC-K 100 90.00 - 100.0 100 83.16 - 100.0 1.000 
POC: Early + Late Lyme 
 
Sensitivity (%) CI (95%) Specificity (%) CI (95%) AUC 
rP100+PepVF+rOspC-K 88.5 69.74- 95.19 90.0 68.30 - 98.77 0.844 
rVlsE+PepVF+rOspC-K 94.3 80.84 - 99.30 75.0 50.90 - 91.34 0.932 
rVlsE+rP41+rOspC-K 71.4 53.70 - 85.36 75.0 50.90 - 91.34 0.807 
rVlsE+rDbpA+rOspC-K 82.9 66.35 - 93.44 80.0 56.34 - 94.27 0.844 






We compared the sensitivity of the current standard C6 ELISA to a multiplexed POC test 
consisting of p100+ PepVF + OspC-K  (Fig. 9) . The multiplexed POC test achieves comparable 
results to the C6 ELISA in identifying Lyme positive samples (88.5% mCHIP v 85.7% C6 




Figure 9. Comparison of C6 ELISA Lyme test with “PPO” triplexed mChip-Ld test. Vertical scatter plots 
showing samples previously validated to be positive for Lyme disease (Early and Late Stage) as tested on 
the C6 ELISA test (left) and multiplexed mChip device (right).  The multiplexed mChip test used a combined 
signal of three proteins (rP100, PepVF and rOspC-K), and produced results comparable to the single-




Here, we report the development of a microfluidics based rapid assay for the serodiagnosis of 
Lyme disease. The platform is designed for intended use in primary or urgent care settings in the 
U.S., with an assay that can be done by moderately trained personnel in 15 minutes. 
 






Previously we have demonstrated a dual HIV and syphilis immunoassay using low-cost 
hardware for lower resource settings (Use-Cases 3 & 4)[61, 64]. In designing a POC assay 
primarily for a doctors’s office or an urgent care setting in the U.S. (Use Case 1), some design 
criteria such as portability and cost are less constrained. Here, we leveraged the simple and low 
cost optics required for signal detection with a proprietary analyzer developed by OPKO 
Diagnostics, that can be packaged as a benchtop instrument or battery-operated hand held unit, 
with wireless, wired or printer output capabilities. Fluid handling, temperature control and signal 
detection modules are integrated and automated into a single device that is suitable for primary 
or urgent care settings. The detection mechanism, as previously described [61], consists of paired 
light-emitting diodes (LEDs) and photodetectors aligned directly with the microfluidic test zones 
(Fig. 5). The material cost of each disposable cassette is about $1.50[62]  [63]. 
 
Our prior work showed an application for our POC system in a Sub-Saharan setting where 
temperature and humidity can be significant factors; here, we anticipate primary usage in a Use 
Case 1 setting where refrigeration is available for shipping and storage, and where environmental 
conditions are typically controlled. Thus, assay reagents such as secondary antibodies were left 
in liquid form under refrigeration. Future steps include optimization of assay parameters (such as 
anti-coagulation reagents and washing conditions) to work with whole-blood samples, as 
performed previously[62, 63]. 
 
All the biomarkers tested have been shown to detect antibodies in blood from Lyme disease 
patients. Most antigens (rVlsE, rP93/100, rBmpA/P39, rFlaB/P41, rDbpA/P18, rDbpB/P18, 






rOspC/P23) are currently included in Western blot or line blot assays [73, 74]. We found that 
two types of OspC (type K and type B) might be ideal to identify early Lyme disease samples 
[75]. OspA and OspB were identified as potential good candidates to discriminate late Lyme 
[76]. BBK07 immunodominant peptides were defined as good serodiagnostic markers for Lyme 
disease  [77, 78]. In addition, the C6 peptide ELISA was widely adopted for diagnosis of Lyme 
disease [52, 79-81]. We modified a peptide based in the core sequence from C6 from B. 
burgdorferi B31 [60] and added a 13-aminoacid sequence from FlaB (pepVF).  In the studies 
reported here, ELISA screening (Fig. 6) showed six recombinant proteins, p100, p41, DbpA, 
OspC-K, OspC-B, VlsE and two peptides pepBBK07 and pepVF, were promising antigens for 
diagnosis of Lyme disease. rOspA and rOspB showed the poorest sensitivity and specificity 
performance compared to other antigens and were eliminated as antigens for point of care. 
 
The mChip system has comparable performance to ELISA with respect to sensitivity and 
specificity but is faster and can be implemented at the point of care. Further, we can separate 
antigens per zone of detection, which allows the physician to make a comprehensive diagnostic 
decision. Our ELISA results identified the eight antigen candidates for the microfluidics screen 
(Fig. 7). These studies led to the further elimination of two antigenic candidates, OspC-B and 
pepBBK07 due to high cross-reactivity with healthy samples. At this point we compared 4 
combinations of antigens in multiplexed microfluidics and ELISA formats, rP100-pepVF-
rOspCK, rVlsE-pepVF-rOspC-K, rVlsE-rP41-rOspCK and rVlsE-rDbpA-rOspC-K (Fig. 8). On 
ELISA our best combination was rVlsE-rDbpA-rOspC-K which detected accurately 35 LD 
positive samples and 20 negative healthy samples (100% sensitivity and specificity). On the 






microfluidics format, the best combination of antigens was the only one that did not contain 
rVlsE (rP100-pepVF-rOspC-K), which detected 31/35 positive LD samples and 18/20 negative 
healthy samples (88.57% sensitivity, 90% specificity, AUC of 0.844). Here, VlsE 
underperformed in the microfluidics format as it produced higher cross-reactivity with healthy 
samples. In these studies, we did not optimize the conjugation chemistry beyond physiosorption 
for most antigens, and also did not optimize concentration of coating protein and blocking 
conditions. Specificity in the microfluidics format would have to be optimized further before 
clinical use, though we note that all screening work performed here was done with an older, sera 
sample set. Validation of findings may have to be repeated with a newer, well characterized 
Lyme sera panel.  
 
With additional clinical data sets, a more detailed, powered analysis for multiplexing can be 
undertaken, to refine coefficients in this model [66, 82].  Further, we did not perform advanced 
assay development testing to identify positive samples from a blinded mixture of healthy and LD 
samples. Future optimization of this assay would include those studies. Another limitation of the 
POC assay, which can be generalized to all other serologic assays, is that it does not detect 
antibodies which may not be present in serum in the first two weeks post infection.  
 
We compared our best mChip-Ld candidate (P100-pepVF-OspC-K) to the C6 ELISA which is 
generally recognized as the best first tier assay for serodiagnosis of Lyme disease (Fig. 9) and we 
found that the sensitivity for overall diagnosis of Lyme is just as high for microfluidic test as the 
C6 ELISA test. More than one-third of the Lyme-positive samples, covering both Early and Late 






Stage Lyme, were classified as “Negative” by Western Blot, though classified as “Positive” on 
C6 ELISA. In addition, the OspC-K antigen in a microfluidic format shows promising results as 
detection of early-stage LD.  
 
One of the antigens used in our lead microfluidics assay, PepVF, is based on the 26-mer 
invariable region (IR(6)) of the variable surface antigen of B. burgdorferi (VlsE). This antigen is 
conserved among European pathogenic genospecies [83] and it was reported recently that B. 
mayonii infection was identified by C6 ELISA [50]. Thus, we speculate that a rapid detection 
assay based on PepVF, as described in this study, should identify B. bugdorferi sensu lato 
infections.  
 
Diagnostic testing for Lyme disease is traditionally achieved by determination of the serologic 
responses to B. burgdoferi sensu lato, with the exception of the very early localized phase of 
disease (EM<10 days), in which the diagnosis must be done clinically due to the recognized lack 
of antibody availabe for detection by serologic assays [84]. In this study, we show that we can 
detect culture confirmed clinically characterized LD using an assay suitable for use at the point 
of care. The versatile nature of the microfluidcs platform allows us to explore development of a 
single tiered assay for the future rapid diagnosis of Lyme disease that provides the physician 
with information on reaction to individual antigens. 
  








2.5 Background  
Like Lyme, Leptospirosis is a bacterial spirochete infection with largely non-specific clinical 
manifestation. Symptoms can range from those of general febrile illness (fever, chills, muscle 
aches) to severe kidney or liver failure, meningitis, and even death[85]. Leptospirosis occurs in 
urban environments of both industrialized and developing countries as well as rural regions 
around the world [86]. Human infection largely results from direct or indirect exposure to 
reservoir hosts and to contaminated water or soil with infected urine from carrier mammals[86]. 
Although incidence in the U.S. is low (~ 100-150 identified cases per year), the CDC estimates 
more than 1 million cases occur worldwide each year, including 59,000 deaths[85]. Urban 
epidemics are reported in cities in developing countries and will likely increase as the world’s 
slum population doubles to 2 billion by 2030 [87].  An unexpected outbreak was reported in New 
York City recently and climate change may account for its re-emerging status [88]. Incidence 
rates are currently considered to be underestimated due to lack of awareness of the disease and 
lack of accessible, rapid diagnostics[86].  
 
Recovery of leptospires from blood or cerebrospinal fluid (CSF) through culture remains the 
definitive diagnostic test, though the drawbacks of this method are discussed above. Molecular 
methods for direct detection using PCR are currently being explored, however serology remains 
the most frequently used diagnostic approach for leptospirosis [86]. The microscopic 
agglutination test (MAT), which detects agglutinating antibodies in serum, is the most widely 






used reference standard serological test for Leptospirosis[89]. This involves incubating patient 
serum with various Leptospirosis serovars (serological strains of bacteria) to determine the 
infecting serovar before testing various serum dilutions for antibody titer determination[89]. As 
MAT involves maintenance of live serovars and human interpretation, it is laborious, difficult to 
standardize and limited to specialized, reference laboratories. Alternate serologic tests like 
conventional ELISAs are also not suitable for near-patient or seroepidemiologic settings.  
 
Here we describe exploratory work towards a rapid, quantitative assay for Leptospirosis. We 
investigate the potential of several candidate antigens comprised of recombinant Leptospira 
proteins with a high degree of homology between the many pathogenic serovars. In an initial 
study, we show that successful translation from an ELISA format to a quantitative microfluidic 
format is possible, laying the groundwork for subsequent development efforts towards clinical 
usage.  
 
2.6 Methods  
2.6.1 Leptospirosis mouse serum panel 
Antigen-specific polyclonal serum (i.e. serum containing antibodies for one specific antigen) was 
generated in mice for initial reactivity testing experiments. Serum from mice infected with 107 
cells of L. interrogans serovar Copenhageni Fiocruz (n=12) as well as serum from non-infected 
control mice (n=6) were used for testing and evaluation of candidate biomarkers on both ELISA 
and mChip platforms.   
 






2.6.2 Candidate antigen biomarkers  
Five recombinant, purified  L. interrogans (serovar Copenhageni) proteins were chosen for 
preliminary analysis: rLigA7-13, rLigB1-6 , rLoa22, rTolC and rLipL32 (Table 8).  
 
Table 8. Recombinant biomarkers from L. interrogans serovar Copenhageni 
 
Immunoglobulin-like proteins rLigA7-13, rLigB1-6 
Outer membrane lipoproteins rLipL32, rLipL41, rLipL42, rLipL53, rLemA 
Virulence factors rLoa22, rColA 
Transporters rTolC, rPhnL 
Flagellar proteins rFliE, rFlgB, rFlaB, rFlgC, rFlgJ, rFlgH, rFlbC 
 
 
2.6.3 Point-of-care immunoassay  
Microfluidic cassettes were functionalized by direct adsorption of antigen candidates  (purified 
recombinant proteins of L. interrogans) at concentrations ranging from 5-50 μg mL−1 for initial 
optimization testing reactivity between each purified protein and its respective polyclonal serum. 
Multiplexed panels were functionalized with the following concentrations: 5 μg mL−1 rLigA, 20 
μg mL−1 rLigB, 5 μg mL−1 rLoa22, 20 μg mL−1 rLipL32 and 20 μg mL−1 TolC.  All other 
protocol and assay conditions are identical to those of the POC Lyme assay (2.2.5), with the 
exception of gold-conjugated secondary antibody consisting of goat anti-mouse IgG molecules.  
 
2.6.4 Statistical Analysis 
ROC analysis was performed as described previously (2.2.6) to report sensitivity and specificity 
values for each antigen. Gold-standard reference tests were culture confirmation. 
 
 







2.7 Results & Discussion 
 
We aim to develop an antibody capture assay (Fig. 10). for rapid, quantitative detection of 
Leptospirosis at the POC. By investigating the diagnostic potential of candidate antigens and 
evaluating performance on both ELISA and the mChip microfluidic platform, we aim to follow a 






Figure 10. Schematic of Leptospirosis sandwich immunoassay design. Serum samples that contain 
disease positive antibodies will bind to the surface of microfluidic cassettes functionalized with Leptospira 
capture antigens. A sequence of washes is followed by gold-labeled IgG antibodies, which bind to the primary 
antibodies immobilized on the surface. Subsequent automated reagent delivery of remaining washes and 
silver amplification reagents results in silver ion reduction of gold nanoparticles, as described previously [90]. 
 
The first step in trying to recapitulate an ELISA assay on our microfluidic platform requires 
choosing an appropriate capture concentration on the surface of the microfluidic cassettes. 
Preliminary ELISA testing indicated that each candidate antigen showed high reactivity when 
tested against its respective polyclonal serum. We proposed using the same matched antigens and 
polyclonal serum samples to help select capture concentrations based on reactivity. Thus, in 
microfluidic cassettes functionalized with rLigA antigens for example, polyclonal serum 
containing only LigA antibodies was used as the “sample”. Just as in ELISA, we observed 
generally high reactivity between all the candidate antigens and their respective polyclonal serum 






across all concentrations that were tested (Fig. 11). In choosing a preliminary capture antigen 
concentration, we aim to pick the lowest concentration that shows the best signal (high 
magnitude of signal and low variability).  Choosing a lower concentration allows us to maximize 
the most expensive components of an assay (the biological capture molecules) which could play 
a greater role in downstream scale-up efforts.  
 
 
Figure 11. Reactivity of candidate Leptospira antigens at various capture concentrations. Each 
candidate antigen of (A) rLigA, (B) rLigB, (C) rTolC, (D) rLipL32 or (E) rLoa22 was spotted on microfluidic 
cassettes at capture concentrations ranging from 5-50 μg-mL-1. Serum containing polyclonal antibodies 
specific to each antigen were tested on corresponding  cassettes to assess reactivity, shown in plotted bars. 
Data are averages ±1 SD (n=3). Asterisk (*) indicates statistical significance (p<0.05) using Student’s t-test. 
 






After choosing initial capture antigen concentrations for each candidate marker, we worked to 
develop preliminary multiplexed assay panels (Fig. 12). Given that each microfluidic cassette 
could hold three target detection zones (in addition to internal positive and negative control 
zones), we functionalized microfluidic cassettes with 2 designs: (1) rLoa22–rTolC-rLipL32 and 
(2) rLigA-rLigB-rLipL32 in Target Positions 1 to 3 respectively. A second, more unexplored 
factor in developing multiplexed assays on our platform is the role of zone order (Fig. 12) on 
resulting signals. For highly specific matched antigen-antibody combinations, zone order should 
have minimal impact on reactivity. In cases where cross-reactivity effects are stronger, 
optimization of zone order position could be required. Preliminary multiplexing optimization 
indicated that rLigB performed slightly better with a higher capture antigen concentration (20 μg 
mL−1 instead of 5 μg mL−1) when placed in Target Zone Position 2 (behind rLigA in Position 1). 
While there was no statistically significant difference between the two concentrations when 
tested against the LigB polyclonal serum, the 20 μg mL−1 concentration produced a slightly 





Figure 12. Schematic of multiplexed microfluidic channel design. In the current microfluidic cassette 
format, there are five zones available for functionalization; addition of internal positive and negative controls 
reduces the number of target zones to three. The direction of fluid flow across the channel is such that Target 
Zone Position 1 is the first to encounter the sample (or subsequent reagents), followed by Position 2 and then 
3. 








Figure 13. Reactivity of rLigB in Target Zone Position 2 on multiplexed cassettes. Zone order of 
multiplexed cassettes was negative control, rLigA in Target Position 1, rLigB at either 5 μg mL−1  or 20 μg 
mL−1  in Target Position 2, blank Target Position 3 and a positive control. LigB polyclonal serum was tested 
on both cassette designs and resulting signals are plotted. Data are averages ±1 SD (n=3). No significant 
differences using a Student’s t-test. 
 
The next step was to screen each candidate antigen on ELISA using a mouse serum panel 
consisting of 18 samples (12 infected and 6 controls. ROC analysis of the ELISA screening 
results showed that rLigA, rLigB, rLoa 22 and rLipL 32 all had 100% sensitivity and specificity 
compared to culture reference test (Fig. 14, Table 9). rTolC had the lowest performance with 
83.3% sensitivity and 66.7% specificity (AUC of  0.694) on ELISA (Table 9).  
 
Next, we did a preliminary assessment of performance using the same give antigens on the 
microfluidic platform. ROC analysis showed that rLigB, rLoa22 and rLipL32 performed the best 
out of the candidate antigens, with sensitivities > 90% and specificities of 100% (Fig.15, Table 
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Figure 14. ELISA screening of candidate antigens for Leptospirosis diagnosis. Signal to cutoff plots 
showing specificity and sensitivity of candidate antigens using IgG ELISA compared to reference testing with 
culture. 6 sera samples from healthy mice and 12 sera samples from mice infected with 107 cells of L. 
interrogans (serovar Copenhageni Fiocruz) were used to test specificity and sensitivity of candidate antigens 
of rLigA, rLigB, rLoa22, rLipL32 and rTolC. 
 
 
Table 9. Performance of ELISA screening using 5 antigens to diagnose Leptospirosis 
 
  Cutoff Sensitivity 95% CI Specificity 95% CI AUC 
LigA > 0.339 100 73.54% to 100% 100 54.07% to 100% 1 
LigB > 0.763 100 73.54% to 100% 100 54.07% to 100% 1 
Loa22 > 0.302 100 73.54% to 100% 100 54.07% to 100% 1 
LipL32 > 0.076 100 73.54% to 100% 100 54.07% to 100% 1 
TolC > 0.028 83.3 51.59% to 97.91% 66.7 22.28% to 95.67% 0.694 
  
 








Figure 15. Preliminary screening of recombinant Leptospira candidate antigens with mChip. Signal to 
cutoff plots showing specificity and sensitivity of candidate antigens using the mChip platform compared to 
reference testing with culture. 6 sera samples from healthy mice and 12 sera samples from mice infected 
with 107 cells of L. interrogans (serovar Copenhageni Fiocruz) were used to test specificity and sensitivity of 





Table 10. Performance of mChip screening using 5 antigens to diagnose Leptospirosis 
 
  Cutoff Sensitivity 95% CI Specificity 95% CI AUC 
LigA > 0.522 91.7 61.5% to 99.8% 83.3 35.9% to 99.6% 0.931 
LigB > 0.1324 100 73.5% to 100% 100 54.1% to 100% 1 
Loa22 > 0.0424 100 73.5% to 100% 100 54.1% to 100% 1 
LipL32 > 0.0873 91.7 61.5% to 99.8% 100 54.1% to 100% 0.958 
TolC > 0.0116 83.3 51.6% to 97.9% 66.7 22.3% to 95.7% 0.750 
 
  






rLoa22 was a better diagnostic candidate than rLigA when placed in Target Zone Position 1 on 
the microfluidic platform. We also observed that TolC was not a good marker with the mouse 
sera panel, which could potentially be the same for human sera panels as well. From the 
preliminary assessment of candidate antigens in multiplexed microfluidic panels, the next round 
of multiplexed testing could include rLoa22 in Position 1, rLigB in Position 2 and rLipL32 in 
Position 3.  
 
In this exploratory work, we have shown that a quantitative POC test is possible for 
discriminating between positive and negative Leptospirosis diseased sera samples. We also 
illustrate the steps that are needed in creating a new multiplexed assay on the mChip microfluidic 
platform. Next steps would entail potential addition of IgM antibodies for early infection 
detection, testing with human sera samples and validation with a larger sample size. Additional 
cross-reactivity studies may be necessary to determine if further optimization of zone order 
placement is necessary. The assay development work presented lays the groundwork for future 
development efforts towards a fully integrated POC system that can be implemented in clinical 
settings.  For Use-Case 3 implementation (e.g. primary care settings in developing countries), 
additional work towards low cost, usability for minimally trained personnel as well as 
considerations for limited ground electricity for equipment and refrigerated reagents should be 
considered. Understanding clinical workflow for Leptospirosis screening in local settings would 
also enhance design and development process particularity if higher clinical utility lies in Use 
Case 4 implementation (in the field).   
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Developing a smartphone-integrated HIV-
syphilis assay and demonstrating use in the 
field  
 
Antenatal Screening Tool for Healthcare Workers in the 
Field 
3.1 Background 
Previous work in our lab focused on miniaturizing of the complex ELISA into a simpler, 
microfluidic assay that could expand access to diagnostic testing. Significant efforts were also 
made in building custom hardware to be used with the microfluidic assay cassette platform.  
From a proof-of-concept device using low-cost optical components to a fully integrated form 
factor with fluidic control and data transmission modules, we demonstrated the ability to design 
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technology that could be used outside of a laboratory setting[61, 64]. Our goal for the next phase 
of POC device evolution, was to create diagnostic tools that could be used in the most remote 
regions of the world, particularly in lower-infrastructure settings of the developing world (Use 
Case 4). This work also represents the next stage of POC device development, by integrating 
assay chemistry, microfluidics and connected instrumentation towards a fully integrated system 
that can be deployed in the field (Fig. 4).  
 
3.1.1 Connected instrumentation  
The uptake of smart consumer electronic devices has moved forward with breathtaking speed.  
Their omnipresence has transformed how services are delivered for entire sectors of the 
economy, with several consequences for POC diagnostics, namely the use of smartphones as 
platform devices. Towards health and monitoring, smartphones are increasingly adapted for 
imaging, sensing, and diagnostics[91].  Miniaturized components used in consumer electronic 
devices can be adapted for use in POC diagnostic devices.  The camera lens in smartphones can 
be used for microscopy, cytometry, and optical readouts for different detection methods[1], low-
energy Bluetooth modules for data connectivity are becoming standardized and prevalent, and 
batteries are becoming longer lasting.  The use of these components for POC devices can be 
extended from prototyping to large-scale manufacturing by leveraging the established supply 
chains for smartphones and smart devices.  For design of POC tools for resource constrained use-
case settings, smartphones provide a platform that leverages powerful processing, 
communication tools and an extremely portable interface, which can replace peripheral 
equipment needed to run conventional diagnostic tests.  
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3.1.2 Prevention of mother-to-child transmission of sexually-transmitted infections (STIs) 
Developing countries experience a higher burden of death and disability due to infectious 
diseases compared to those in developed settings. The World Health Organization estimated 
around 170,000 infants are born with HIV every year, predominantly in sub-Saharan Africa[92]. 
Congenital syphilis accounts for 500,000 stillbirths every year (CDC, 2014). While there has 
been progress made towards reducing new infections, efforts are still needed in reducing 
congenital syphilis and new HIV infections among children.  
 
Most transmissions could be eliminated by routine diagnosis and simple treatment of infected 
mothers. High-burden countries thus require antenatal care testing to screen for both HIV and 
syphilis. By enabling early detection of STIs, both mothers and children can avoid significant 
adverse health outcomes. The Fast Track Targets towards the UN Sustainable Development 
Goals of ending the AIDS epidemic by 2030 include the “90-90-90” target: 90% of people living 
with HIV know their HIV status, 90% of people who know their HIV-positive status are getting 
treated and 90% of people receiving treatment have suppressed viral loads[93].  Our aim is to 
tackle the first component of expanding access to HIV diagnostic tools. 
 
Currently, lateral flow rapid diagnostic tests (RDTs) are amongst the most widely used class of 
diagnostic tools for screening, particularly in resource-constrained settings. This is mainly due to 
the use of paper, which has long been held as an inexpensive and resourceful material choice for 
a resource-limited, field use case (Use Case 4).  Typically, these RDTs rely on lateral flow or 
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immunofiltration technologies, require minimal cold-chain requirements for shipping/storage and 
forego instrumentation for human interpretation of the result (e.g. visual presence of bands)[41].   
The World Health Organization lists 28 lateral flow rapid tests as “prequalified” in vitro 
diagnostic products for HIV and malaria from companies such as SD Bioline, Chembio, Alere, 
Trinity Biotech, bioMerieux, OraSure, ABON Biopharm, ARKRAY Healthcare, Access Bio, 
Premier Medical etc[42]).  While some dual-HIV-syphilis RDTs have been developed[94-96], 
the major drawbacks of lateral flow platforms include subjective user interpretation, and limited 
assay complexity capabilities for multiplexing and multi-step reactions. We aim to leverage the 
power of connected instrumentation such as smartphones to build an improved HIV-syphilis test 
suitable for healthcare workers to use at the POC. 
 
3.1.3 Microfluidic, multiplexed STI test with a smartphone accessory 
Previously our group has demonstrated reproduction of ELISA-like performance and objective 
readout capabilities with a microfluidic dual HIV-syphilis assay platform[61, 64]. We propose to 
build on this work to create a more integrated, triplex HIV-syphilis assay on disposable, plastic 
cassettes, pre-loaded with all reagents for field-deployment in Sub-Saharan Africa (Fig. 17). We 
also illustrate design and fabrication of a portable diagnostic device that attaches to the audio 
jack of a smartphone, which integrates fluid handling, signal detection and quantification. 
Finally, we demonstrate usage by healthcare workers in Kigali, Rwanda to evaluate field-
performance as well as gather preliminary user feedback on acceptability of our device. The 
three main components of this project are: (1) assay development, (2) hardware design and (3) 
field trial design and testing.  
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3.2.1  Triplex HIV-syphilis assay 
Surface modification of injection molded, plastic cassettes was done through direct physisorption 
of antigens onto plastic microfluidic target detection zones, as described previously[97]. We used 
recombinant multi-epitope chimeric antigens (gp41, gp36, and O-IDR) for an HIV 1/2 (Biolink 
International) marker, a 17-kDa recombinant outer membrane protein TpN17 (Lee Labs) [97, 98] 
for a treponemal syphilis marker and synthetic cardiolipin prepared from plant source [99] 
provided by CDC for a non-treponemal syphilis marker. Internal positive control zones were 
functionalized with an anti-goat IgG antibody (Life Technologies) as described previously 
(Chapter 2). Negative control zones were treated with a blocking agent. 36 µL each of 2 µg-mL-1 
of HIV chimeric antigens, 15 µg-mL-1 of TpN17, and 10 µg-mL-1 of anti-goat IgG Ab in 
bicarbonate buffer solution (pH 9.6) were spotted on the detection zones using a robotic arm as 
an automated fluid dispenser (Fig. 21). Cardiolipin was covalently attached to the plastic surface 
using EDC-Sulfo-NHS reaction (which activates the carboxylate groups on cardiolipin for 
binding with amine-groups on poly-L-lysine coated plastic).  
3.2.2 Blocking/stabilizing agent selection  
To preserve the conformation and reactivity of the adsorbed antigens, we analyzed the 
performance of three blocking/stabilizing agents: casein (Thermo Scientific), SeaBlock (Thermo 
Scientific) and StabilCoat Immunoassay Stabilizer (Surmodics Inc.). Cassettes were 
functionalized with the various protein markers as described above. Fluid was dispensed by 
manual pipetting onto cassette surfaces. Each detection zone was spotted with 36 µl of blocking 
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agent and incubated for 1 hour at room temperature in a humid chamber. After incubation, the 
blocking agent solution was aspirated and plastic cassettes were placed in a vacuum desiccator 
for 20-30 minutes. The vacuum-sealed chamber containing the microfluidic cassettes was then 
placed in a 30°C oven for 4-6 hours of secondary drying. Cassettes were sealed with clear 
adhesive tape (OPKO Diagnostics) and stored at 4°C until use.  An HIV/Syphilis co-infected 
sera sample as well as a disease negative sera sample both diluted 75X in 1% BSA – 0.05% 
Tween-20 in PBS were tested on cassettes prepared with each blocking agent. 
3.2.3 Lyophilization of secondary antibodies 
Lyophilization of secondary antibodies was performed by OPKO Diagnostics (Woburn, MA). 
9.5 µL of gold-nanoparticle conjugated goat anti-human IgG (0.53 µg/mL) and goat anti-human 
IgM (0.27 µg/mL) antibodies were lyophilized into 2.5cm of plastic tubing. No detergent or anti-
coagulant excipients were included in the lyophilization buffer. Lyophilized antibody holders 
were stored at 4ºC until use. Prior to running an assay, lyophilized antibody holders were filled 
with 9µL of 3% BSA-0.2% Tween in PBS solution and incubated for 8-10 minutes at ambient 
conditions.  
3.2.4 Early dongle prototype 
3.2.4.a Hardware 
To investigate feasibility of scaling down the hardware footprint and power requirements, we 
built an early dongle prototype with two detection zones using the same low-cost LEDs and 
photodiode detectors as in previous protoypes ($0.50 and $6.00 per unit respectively) and power 
supplied by an iOS device (iPod Touch, 4th gen.) as shown in Fig. 16. The optical signal was 
converted to analog signal, and then converted to digital signal by the A/D converter of a 
CHAPTER 3.   DEVELOPING A SMARTPHONE-INTEGRATED HIV-SYPHILIS ASSAY 





separately attached microcontroller. A laptop computer was used to obtain light transmission 
values through the TI Code Composer Studio with proper settings of the JTAG (used to test 
interconnects on PCBs) as shown in Fig. 17. 
 
 
Figure 16. Schematic of early dongle prototype. (A) 2 zone detection system conserving previously 
developed hardware design of using low cost optical components. The light emitted from the LEDs transfers 
through the cassette zones that serve as filters, and then detected by the photodiodes. The optical signal is 
converted to analog signal, which is then converted to digital signal by the A/D converter of the 
microcontroller. (B) Control flow program for the dongle. 
 
3.2.4.b Running a test 
The PCBs had no casing, therefore manual adjustment was needed to correctly align the cassette 
with the dongle setup such that light emitted from the LEDS was transferred through the cassette 
zones and then detected by the photodiodes. Furthermore, no fluidic actuation module was 
integrated into this design; sample and reagent fluids were introduced through loading a PE tube 
to the inlet channel and drawn through the microfluidic cassette using syringe-actuated negative 
pressure (33kPa) at the outlet. Silver reduction of the gold nanoparticles was used, as in previous 
tests, for signal amplification. Readings were taken at the beginning and end of the 4 minute 
silver development sequence to calculate optical density (OD) values for each zone. Prism 
software was used to determine cutoffs and for ROC analysis. 
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Figure 17. Components of early dongle prototype setup. (A) The microfluidic cassette is sandwiched 
between the PCBs holding the LED and photodiode arrays. With no casing to guide insertion or hold cassette in 
place, lab tape was used to secure alignment of the components such that the two detection zones of the 
cassette were aligned with the optical components of the dongle. An iOS device (iPod Touch, 4th gen.) and 
microcontroller (not pictured) were attached to the dongle, with the latter connected to a laptop computer for 
data visualization. A 60cc syringe with a metal spacer was used to induce constant negative pressure of 33kPa 
for fluid actuation. (B) Close-up of the cassette sandwiched between LEDs and photodiodes while a reagent 
loaded PE tube and syringe are attached to the inlet and outlet respectively. Wired connections to the iOS 
device and microcontroller are shown.  
 
3.2.4.c Cassette functionalization 
In the early dongle prototype, only 2 detection zones could be functionalized for the test. Thus, 
we designed cassettes to have a positive reference zone and HIV sample zone using coating 
methods similar to those previously developed for the mChip. Attachment of Protein G for the 
positive reference zone was done through EDC-SulfoNHS chemistry, which activates the 
carboxyl groups on the protein for binding with the amine-groups on the poly-lysine coated 
plastic of the cassettes.  HIV plasma samples that were known to be positive (n=13) or negative 
(n=9) by rapid test and ELISA reference tests were selected for evaluation with the dongle 
prototype. Reagent tubes were loaded with a 100X sample dilution in 1%BSA-0.05%Tween-20 
in PBS and 100X dilution of gold labeled goat-anti-human IgG (capture antibody) in 3% BSA-
0.2% Tween-20 in PBS. 
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3.2.5 Smartphone Dongle “1.0” 
3.2.5.a Design 
The smartphone dongle features power-free fluid flow and objective signal read-out with 
powering and signal transmission solely via audio jack connection (Fig. 18). 
Power-free fluid flow. We designed a power-free mechanically-activated vacuum source, using a 
simple mechanics of rubber bulb and one-way valve. With this mechanism, the dongle generates 
a reliable, repeatable vacuum at the time of the assay, while keeping the consumables low cost 
and simple to manufacture.  
Audio jack powering and signal transmission. We use the audio jack for both power delivery to 
the device and signal transmission from the device, as has been shown by Kuo, et. al. [100]. We 
programmed a microcontroller that performed frequency-shift keying (FSK) by converting a 
decimal integer into binary and each bit was sent as a high-frequency (1632 Hz, or “1”) or low-
frequency (816 Hz, or “0”) signal, and transmitted the photodiode readings through the audio 
jack and back to the phone. 
User-friendly app interface. A custom smartphone application (app) was designed on an iPod 
Touch to assist in assay operation, power the device to take intensity readings, and demodulate 
the FSK signals sent by the device. The app provides step-by-step directions with pictures to 
assist the user through steps necessary to perform the assay. A results page provides objective 
readout of a positive or negative diagnosis for each of the three tests performed. The app also 
saves the raw data, diagnosis, time and date of testing, and patient ID number for review at a 
later time.  
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Custom printed circuit boards (PCBs) were designed in Altium and printed from PCB Universe. 
LEDs and photodiodes were precisely aligned with the cassette slot so testing zones align 
without manual effort. 1-mm pinholes made of 1-mm thick black Delrin (McMaster-Carr) above 
each photodiode. The dongle casing was designed in SolidWorks and printed in-house (Objet 24 
3D-Printer, Stratasys). Vacuum chamber was created with a one-way umbrella valve 
(Minivalve), a rubber bulb from a 140-mL syringe (Becton Dickinson), and a conical spring 
(Century Spring Corp) inside to aid re-expansion. Silicone rubber o-rings and sheets (McMaster-




Figure 18. Mechanism of the smartphone dongle. Schematic diagram of dongle highlighting a power-free 
vacuum generator, with the sub-figure showing vacuum activation. The audio jack connector on the dongle 
is used for audio-based powering and FSK data transmission to a smartphone. 
 
3.2.6 Running a test with the smartphone dongle 
To perform a test (Fig. 19), the user (e.g. a health care worker) collects a fingerprick whole 
blood sample using conventional methods. 1 µL of whole blood is mixed with 9 µL of 1% BSA - 
0.05% Tween-20 in PBS (10X dilution) and 2 µL of the mixed sample is pipetted into the inlet of 
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the disposable test cartridge. Step-by-step directions on the app guide the user to attach the 
antibody holder (pre-filled with 9 µL of 3% BSA – 0.05% Tween-PBS) to a microfluidic 
cassette, insert the cassette into the dongle, and press the rubber bulb fully to initiate a vacuum. 
The user is prompted to start “Phase 1” of the assay on the app, which consists of a 6 minute 
timer during which the sample and all wash buffers flow through the cassette. The user is then 
prompted to move a toggle to close a venting port on the reagent cassette in order to initiate 
silver development and signal measurement in “Phase 2” of the assay. OD readings were taken at 
the beginning and end of the 5 min silver development as described previously (Chapter 2). 
Afterwards, results for all markers were displayed on the screen, and raw absorbance values are 
recorded along with the study ID. 
 
3.2.7 Field trial design 
We wanted to evaluate the smartphone-integrated STI test performance and field-readiness by 
putting it in the hands of target end-users, in this case, local healthcare workers (HCWs) in 
Rwanda. We also wanted to get preliminary feedback from local patients, more than half of 
whom typically had to wait for results at the health centers without knowing how long it would 
take and over a third of whom typically had to wait for more than 2.5 hours to receive results 
from one clinic visit.  Three community level health centers were selected as study sites in 
Kigali, Rwanda: 1)  Kimironko  (Remera) HC,  serving  56,000  people,  2)  Biryogo  HC,  
serving  50,000 people, and 3) Gahanga HC, serving 28,000 people. This study was approved 
by the Columbia University IRB and Rwanda National  Ethics  Committee. All rules and 
regulations pertaining to human subject involvement and protection of confidentiality and 
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sensitive data were followed.  
 
3.2.7.a Healthcare workers (HCWs) 
Five HCWs across the three study sites were selected for study involvement based on willingness 
to participate. All five HCWs were lab technicians with no prior experience or training in 
ELISA, though all had experience with  HIV rapid tests using plasma/sera and fingerprick 
sampling. Training consisted of a 30-minute session with the study team. HCWs were given 
background information related to the study and hands-on training on how to use the dongle to 
perform a test using fingerprick whole-blood.  
  
3.2.7.b Patient recruitment and enrollment 
A target sample size of 100 subjects was chosen for this study. No power analysis was performed 
as the study aims focused on a preliminary assessment of field-readiness of the device and 
appropriateness for local clinical work flow. Patient recruitment focused on individuals already 
enrolled in “Prevention of Mother to Child Transmission” (PMTCT) or “Voluntary Counseling 
& Testing” (VCT) programs in the local health centers. Patients in these programs were already 
scheduled to receive HIV and syphilis testing from venipuncture blood draws during their clinic 
visit. HCWs used a recruitment script provided by the study team during PMTCT and VCT 
information sessions, and emphasized that participation was completely voluntary and did not 
affect any services received at the health center. Interested patients were referred to the study 
team (Rwanda study facilitor) for more information and to undergo an informed consent process 
with a third party translator fluent in the local Kinyarwanda language.  
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3.2.7.c Study visit procedure 
After patients received regular venipuncture blood draws as part of their regularly scheduled 
clinic visit, they were guided through a study consent process (Fig. 19). HCWs entered study 
participant ID numbers into the app before obtaining a fingerprick blood sample (< 20 uL) from 
the patient. Patients then completed a survey that consisted of a questionnaire regarding their 
medical history as well as their experience with the dongle assay. These questionnaires were 
administered by a third-party interviewer fluent in local Kinyarwanda as well as French and 
English. Responses  to  questionnaires  were  written  in  English  by  the  third-party  interviewer  
and  returned  to the study team for  analysis.  Participants  were  compensated  1000RWF  
(approximately $1.54  USD)  for  their  time. Disease statuses were blinded to the Columbia 
study team and HCWs who conducted the test. HCWs ran the test as outlined in 3.2.6, with the 
study team performing pre-filling of antibody holders and sample dilution steps (Fig. 19). 
Aliquots of corresponding venipuncture blood samples were tested on the dongle by the study 
team for comparison with tests run by healthcare workers using fingerprick blood samples.   
 
3.2.7.d Confirmatory testing of samples 
HIV RDTs (Colloidal Gold, Determine and Unigold) were completed at each site. HIV 
ELISA (Vironostika), syphilis TPHA (Spinreact), and RPR (Spinreact) as reference tests for 
HIV, treponemal syphilis and non-treponemal syphilis respectively were performed at the 
Rwandan National Reference Laboratory (NRL) using plasma (0.5mL) separated from 
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venipuncture blood.  At the end of the trial, the results were unblinded to the study team, 
and reference tests were compared to the tests obtained by the dongle.  
 
3.2.7.e Statistics 
Averages, standard deviations, linear fit, and two-sided Student’s t-tests (α = 0.05) were 
calculated with Microsoft Excel. Student’s t-test was chosen to compare two small sets of 
quantitative data when data in each sample set were related. Vertical scatter plots, sensitivity, 
specificity, 95% confidence intervals, ROC curves, and McNemar’s test were created in 
GraphPad Prism. 
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Figure 19. Process flow diagram for a study visit session in Kigali, Rwanda using the smartphone 
dongle STI test.  Sequence of steps for patient (shown in black), healthcare worker (shown in blue) and 
study team (shown in red), are depicted for a typical study visit session.  
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3.3 Results  
 
3.3.1 Triplex HIV-syphilis assay 
Several changes were made with respect to the previously developed HIV-syphilis assay from 
our group[61]: (1) addition of IgM antibodies for early detection of infection, (2) addition of 
cardiolipin as a non-treponemal syphilis marker, (3) prepackaging of all wash buffers in to a 
reagent cassette, (4) lyophilization of gold-nanoparticule conjugated secondary antibodies as 
well as blocking agent optimization for increased assay stability and (5) scale up of fabrication 




Figure 20. Two-layer microfluidic cassette and antibody holder for triplex HIV-syphilis immunoassay. 
(A) The reagent cassette (top layer) contains pre-loaded reagents (washes (yellow), silver nitrate (blue), and 
reducing agent (green)) and the assay test cassette (bottom layer) contains five detection zones. Reagents 
are numbered in the order they flow through the test cassette. (B) Sequence of reagent flow is shown from 
cassette inlet to the detection zones before exiting into the embedded waste-pad for containment of all 
sample and reagents. The power-free vacuum chamber connects to the cassette outlet, drawing fluids from 
the inlet towards the waste pad. (C) Schematic of immunoassay on the surface of target detection zones.  
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The addition of anti-human IgM antibodies as detection antibodies for early detection of 
infectious diseases was important for enhancing the sensitivity of the non-treponemal syphilis 
assay (Fig. 21). Antibodies produced against cardiolipin are used as a non-treponemal marker for 
syphilis and are commonly found in IgM antibodies. Cardiolipin is a lipoidal material released as 
a result of damage to the host cells because of the active infection and also from the cell surface 
of Treponema pallidium, the causative bacterial agent of syphilis [101]. It indicates active 
infection and is helpful in tracking the effectiveness of treatment, which is usually measured by 
an RPR, or rapid plasma reagin, test.  In the RPR test, a nontreponemal serological test for 
syphilis, a reactive agglutination indicates a positive result. A subsequent quantification of RPR 
titer can be done to establish a baseline titer value and should go down at least 4-fold with 
successful treatment (e.g. 1:32 to 1:8)[102]. Non-treponemal antibodies may not always be 
specifically directed against the Treponema pallidium however, as other conditions such as 
pregnancy, Lyme Disease, certain types of pneumonia, malaria and tuberculosis could cause 
false-positive results [103]. Clinical algorithms for syphilis detection vary in first line test choice 
but typically include both a treponemal antibody test, which is highly specific for syphilis, as 
well as a non-treponemal antibody test, to confirm active infections. 
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Figure 21. Addition of gold-labeled anti-human IgM for syphilis detection. Comparison of signal 
measurements obtained by additional of gold-labeled anti-hIgM to gold-labeled anti-hIgG and gold-labeled 
anti-hIgG alone as detection antibodies for negative, weak positive non-treponemal syphilis (RPR titer 1:2), 
and strong positive non-treponemal syphilis (RPR titer 1:32) plasma samples. Data are averages ±1 SD 
(n=4 for anti-hIgG and n=3 for anti-hIgG + anti-hIgM). 
 
3.3.2 Blocking agent selection   
In evaluating the blocking agents, the optimization goals for each detection zone were as 
follows: (1) minimize noise on the negative control zone; (2) minimize non-specific binding on 
target zones for tests with disease-negative samples; (3) maintain optimal conditions for antibody 
binding on target zones for tests with disease positive samples, and (4) maintain high positive 
control signals for all tests. StabilCoat satisfied these parameters better than Seablock or Casein 
blocking agents and was chosen for subsequent fabrication of the triplex HIV-syphilis 
microfluidic assay (Fig. 22).  
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Figure 22. Comparison of blocking agents. SeaBlock, casein, and StabilCoat® were tested as blocking 
agents, using optical density measurements of microfluidic detection zones after testing. (A) Disease 
negative sample and (B) HIV and Syphilis disease positive sample. Data are averages (n=2), with individual 
data shown as dots (•). 
 
3.3.3 Scale-up procedure for functionalization of microfluidic cassettes 
An automated liquid dispensing robot (OPKO Diagnostics) was used for scale-up manufacturing 
efforts for reproducible and high-throughput cassette preparation (Fig. 23). The robotic 
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dispensing arm was used to prepare microfluidic cassettes at Columbia University prior to 
shipping to study sites in Rwanda. 
 
Figure 23. Robot-assisted manufacturing for cassette preparation. Spotting solutions of capture 
proteins are prepared in batches of 5mL and then connected to plastic inlet tube feeds to the robotic 
dispensing arm. Trays of microfluidic cassettes (12 cassettes per tray) are placed under the robot arm and a 
pre-programed dispensing path deposits 36uL of fluid per zone. For negative control zones, no solution was 
fed into the corresponding plastic inlet tubing line. Each tray requires ~1 minute for completion of spotting 
 
3.3.4 Stability of microfluidic assay 
3.3.4.a Reconstitution of lyophilized secondary antibodies for field work 
To improve long term stability in shipping and storage of our device, we lyophilized gold-
conjugated secondary antibodies inside the antibody holder, along with a stabilizer (but no 
detergent or anticoagulant) and packed the holder in an individual moisture barrier bag prior 
shipping them to Rwanda. We showed that lyophilized gold-conjugated antibodies had 
comparable performance to those freshly diluted in buffer from a refrigerated stock solution (Fig. 
24). No significant differences were observed for IgG (as shown by the hIgG target zone and 
rabbit anti-goat IgG positive control zone signals) or IgM (as shown by the hIgM target zone) 
antibody yields.  
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Figure 24. Comparison of signal from gold-labeled anti-hIgG/anti-hIgM antibodies lyophilized in a 
plastic antibody holder and freshly prepared in solution. Detection zones were functionalized with 
human IgG, human IgM and rabbit anti-goat antibodies (positive ctrl). Data are averages ±1 SD (n=3). n.s. 
not significant, Student’s t-test. Comparison of signal from gold-labeled anti-hIgG/anti-hIgM antibodies 
lyophilized in a plastic antibody holder and freshly prepared in solution. 
3.3.4.b Prepackaging of reagents 
Two PBS-T and four water washes as well as Silver Reagents A and B (silver nitrate and 
hydroquinone respectively) were loaded into the reagent cassette (Fig. 20) manually by pipetting 
and sealed using an adhesive tape (OPKO Diagnostics). The two silver reagents are stable 
separately and thus stored separately on the reagent cassette; the venting port design allowed 
mixing of the silver reagents immediately prior to use, minimizing silver auto-catalysis. To 
prevent exposure of chemicals to the user, sample and reagents were contained in a membrane 
filter within the cassette, and the antibody holder was securely connected to the cassette. 
Industrial robotic techniques for loading reagents and applying adhesives can be employed for a 
high-throughput manufacturing. 
 
3.3.4.c Shelf life and transportation of assay cassettes 
To mimic real testing conditions, we prepared assay test cassettes ahead of time at Columbia 
University before transporting them to field testing sites in Rwanda. By using StabiliCoat, a 
blocking and stabilizing agent, during physisorption of capture proteins, we found the protein to 
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retain its original function over 3 weeks at 60°C (Fig. 25) (equivalent to roughly 28 weeks at 
25°C according to Arrhenius-like approximations [104]). Assay cassettes were transported from 
New York City to Kigali, Rwanda through regular check-in baggage packaging and procedures, 
with cassettes stored in sealed plastic bags with desiccant, and some ice packs to counteract large 
spikes in temperature. Further stability experiments should be carried out at room temperature 
with humidity-controlled packaging for long-term stability of prepared cassettes. Additional 
stress tests for transportation and handling are also required for full characterization of shelf life.  
 
 
Figure 25. Stability of functionalized protein on microfluidic cassette. Cassettes were prepared using 
StabilCoat Immunoassay Stabilizer (Surmodics). Microfluidic surfaces were stored for 21 days at 60⁰C, after 
which signals on HIV 1/2, treponemal syphilis, and cardiolipin zones were measured with stored plasma 
samples. Data are averages (n=2), with individual data shown as dots (•). n.s., not significant, two-tailed 
Student’s t-test. 
 
The silver amplification reagents remain the main component of our device that require cold-
chain storage. The remaining other wash buffers (water, PBS-Tween solutions) are stable at 
ambient conditions and lyophilized antibodies have been shown to be stable for over 6 months at 
room temperature [97, 105].  
 
3.3.5 Early smartphone dongle prototype 
We demonstrated that a portable iOS device was capable of powering the dongle for HIV 
antibody detection. The sensitivity and specificity of the early dongle instrument in classifying 
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HIV plasma samples was 100% and 100%, respectively using an OD cutoff of 0.500 (Fig. 26). 
This could only be considered as a preliminary study however, as samples were pre-selected for 
strongly positive/negative status. Integration of electrical and optical components as well as a 
fluidic actuation module was also not completed. Significant manual adjustment was needed to 
place the microfluidic cassettes in correct alignment with the dongle optical components, 
obviating the need for a form factor with simpler insertion and stabilization of cassettes for run-
to-run standardization and ease of use as a POC instrument. 
 
 
Figure 26. Diagnostic performance of early dongle prototype. (A)  The receiver-operating characteristic 
(ROC) curve showing sensitivity and specificity as a function of OD cutoff values. (B) A vertical scatter plot 
showing signal-to-cutoff values for the HIV disease positive and negative specimens using cutoff 
normalization of 0.500. 
 
3.3.6 Smartphone dongle for field-usage 
In developing a device that could be deployed for field-usage in resource-constrained settings, 
our aims were to design a robust, portable and low-cost instrument that could expand access to 
ELISA-quality diagnostic tests and allow for “plug and play” operation. The smartphone dongle 
measures 7.5cm x 7cm x 5cm, weighs 130g and uses the audio jack of a phone for power and 
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data transmission (Fig. 27). Conventional ELISA assays require a plate-reader and computer 
instrumentation that can cost > $15000 to perform a quantitative test with objective readout; in 
contrast, the dongle cost is approximately $34 for a semi-quantitative test with objective readout. 
A full bill of materials is outlined in Table 11. This was achieved through the power-free 
vacuum design and the FSK implementation of power and data transfer between the dongle and 
smartphone.  
 
The dongle measures the optical density (absorbance) of silver enhancement on each assay as 
described previously (Chapter 2). Power is only consumed during optical density readings (8.5 
mW) and information transfer back to the smartphone (1.5 mW). Over the course of the 15-
minute assay, the dongle has an average power consumption of only 1.6 mW as no power is 




Figure 27. Image of smartphone dongle with a microfluidic chip connected to an iPod Touch (4th 
Gen).   
 
The dongle has no internal battery and uses only the power delivered by an audio signal sent 
from the smartphone. In our field work, a 19-kHz audio signal was sent from an iPod Touch (4th 
generation) through the audio jack to the dongle, and converted into a stable DC 3.0V. The 
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power harvested from the audio jack is stable and sufficient for reliable optical density (OD) 
measurements. The custom app converts the photodiode signals to OD (or absorbance) units and 
can be reported as “positive” or “negative” when compared to pre-set cutoff thresholds for each 
assay marker.  
 
In a direct comparison of OD signal measurement of an HIV-positive sample on the smartphone 
dongle compared to a benchtop analyzer (OPKO Diagnostics, see Chapter 2), no significant 
differences were observed on both the R17 and HIV target zones (Fig. 28A). The negative 
control zone showed a slight difference (p = 0.03) between the two instruments, however the 
dongle also showed close linear correlation (R2 = 98.9%, Fig. 28B) between OD signals and 
RPR titers (1:128 titer) measurement.  
 
Figure 28. OD readings using smartphone dongle. (A) Optical density (OD) measurements on negative 
control, R17 (treponemal syphilis) and HIV target zones were recorded on both the dongle and a benchtop 
analyzer for an HIV-positive whole blood sample. Readings were done on the same cassette between both 
instruments. Data are averages ± 1 SD (n = 3). n.s., not significant, two-tailed Student’s t-test. (B) OD 
measurements on the non-treponemal target zone were recorded for serial dilution of an RPR positive 
(1:128) serum. Data are averages ±1 SD (n=3) and plotted with a linear regression fit and correlation.  
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Table 11. Bill of components for dongle 
 
Component Vendor Part no. Qty 




Audio connector Amazon n/a 1 1.000 1.00 
Transformer Coilcraft LPR6235 1 0.770 0.77 
MOSFET, N-Channel Mouser 522-ZXM61N03FTA 2 0.210 0.42 
MOSFET, P-Channel Mouser 522-ZXM61P03FTA 2 0.210 0.42 
Schottky diode Digikey DFLS120LDICT-ND 1 0.180 0.18 




Digikey 296-22900-ND 1 10.310 10.31 




R2CT-ND 5 1.300 6.50 
636-nm Red light-
emitting diode (LED) Digikey 67-2194-1-ND 5 0.190 0.95 
Photodiode Digikey 475-2659-1-ND 5 0.560 2.80 
Capacitor, 0.1 µF Digikey 1276-1443-1-ND 10 0.003 0.03 
Capacitor, 1 µF Digikey 1276-1010-1-ND 1 0.009 0.01 
Capacitor, 2.2 µF Digikey 1276-1183-1-ND 1 0.020 0.02 
Capacitor, 4.7 µF Digikey 1276-1056-1-ND 1 0.049 0.05 
Capacitor, 10 µF Digikey 1276-1451-1-ND 3 0.140 0.42 
Resistor, 27 Ω Digikey 311-27JRCT-ND 5 0.002 0.01 
Resistor, 1 kΩ Digikey 311-1.00KLRCT-ND 1 0.003 0.00 
Resistor, 10 kΩ Digikey 311-10KJRCT-ND 1 0.002 0.00 
Resistor, 100 kΩ Digikey 311-100KJRCT-ND 1 0.002 0.00 
Resistor, 300 kΩ Digikey P300KGCT-ND 5 0.004 0.02 
Resistor, 5.1 MΩ Digikey 541-5.10MHDKR-ND 1 0.017 0.02 
10 pin flat flexible 
cable (FFC) 
connectors 
Digikey HFN410CT-ND 3 0.840 2.52 
10 pin FFC Digikey WM14313-ND 1 2.020 2.02 
Printed circuit board 
(PCB) – Mainboard 
PCB 
Universe Custom 1 0.420 0.42 
PCB – Photodiode 
PCB 





Custom 1 3.000 3.00 
    TOTAL COST 34.23 
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3.3.7 Field trial 
Healthcare workers (HCWs) tested freshly obtained fingerprick blood samples from 96 patients 
in three clinics in Kigali, Rwanda (Tables 12-13). After a short 30-minute training, HCWs were 
able to run a fingerprick blood sample on the smartphone dongle STI test, using the smartphone 
app for guidance and visualization of results. In parallel, the study team performed the test on the 
smartphone dongle platform using corresponding venous blood from the same patients.  
 
Test results for detection of each marker were compared with the gold standards of lab-based 
HIV ELISA, TPHA, and RPR, and presented in terms of signal-to-cutoff of each target relative 
to its reference test displayed as vertical scatter plots and ROC curves. Cut-off values to 
determine if a sample was positive or negative for each marker were selected by using receiver- 
operating characteristic (ROC) curves. Although a final product will offer preset cut-off values, 
in this development work, we identified cut-off values retrospective to data collection that 
maximize sensitivity (and thus minimize false-negatives) because our test is targeted towards 
first-line screening applications. 
 
From fingerprick whole blood testing performed by local HCWs, HIV antibody detection had a 
sensitivity of 100% (95% CI: 59–100%) and specificity of 87% (95% CI: 78–93%). Treponemal 
syphilis antibody detection had a sensitivity of 92% (95% CI: 64–100%) with specificity of 92% 
(95% CI: 83–97%). Anti-cardiolipin antibody detection had a sensitivity of 100% (95% CI: 48–
100%) with specificity of 79% (95% CI: 69–87%). ROC curve analysis showed AUCs of 0.96 
for HIV, 0.90 for treponemal syphilis, and 0.92 for non-treponemal syphilis (Fig. 29). 
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Figure 29. Diagnostic performance of the dongle with clinical fingerprick whole blood samples run 
by minimally trained healthcare workers. Vertical scatter plots (left) showing signal-to-cutoff ratios of 
samples positive (Pos) or negative (Neg) for HIV, treponemal (TP) syphilis and non-treponemal syphilis 
(non-TP) as determined by gold standard tests of HIV ELISA, TPHA and RPR tests. Receiver-operating 
characteristic (ROC) curves illustrating Area-Under Curve (AUC) for each marker are shown on the right.  
 
From venipuncture whole blood testing performed by the study team, the dongle yielded a 
sensitivity and specificity of 100% (CI, 59.0 – 100), 91% (CI, 83.0 – 96.0) for HIV, 77% (CI, 
46.2– 95.0), 89% (CI, 80.4 – 95.0) for treponemal syphilis, and 80% (CI, 28.4 – 99.5), 82% (CI, 
73.0 – 89.6) for non-treponemal syphilis (Fig. 30). There is no statistical difference of dongle 
assay performance on fingerprick and venous whole blood with p-values of 0.45, 1.0, and 0.33 
for HIV, treponemal syphilis, and non-treponemal syphilis, respectively using McNemar’s test. 
 
 
Figure 30. Diagnostic performance of the dongle with venipuncture whole blood samples run by the 
study team. Vertical scatter plots (left) showing signal-to-cutoff ratios of samples positive (Pos) or negative 
(Neg) for HIV, treponemal (TP) syphilis and non-treponemal syphilis (non-TP) as determined by gold 
standard tests of HIV ELISA, TPHA and RPR tests. Receiver-operating characteristic (ROC) curves 
illustrating Area-Under Curve (AUC) for each marker are shown on the right.  
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3.3.8 User feedback 
A third party interviewer administered surveys to gather feedback from both users (HCWs) and 
patients involved in the study, in order to reduce biases from the study team. Qualitative 
feedback from surveys of HCWs involved in this study indicated that they appreciated the lack 
of user interpretation to read the test result or external power to operate. Most thought that 
the dongle would be most useful in low-volume testing sites such as mobile visits or 
neighborhood outreach sessions compared to the higher level health centers. When asked 
how long it typically takes to perform each test (from sample acquisition to issuing results), 
HCWs self-reported an average of 31 minutes to perform HIV rapid tests, 21 minutes for 
an RPR test (nontreponemal syphilis) and 16 minutes for the triplex HIV-syphilis test using 
the dongle. HCWs also noted that the dongle system could be used as a backup test during 
power outages, which occurred several times during the field trial itself. In concurrence 
with our own observations and design planning, HCWs felt that the dongle could be made 
more field ready with reduction of minor peripheral steps currently performed by the study 




Figure 31. Feedback from patients on their experience with the smartphone dongle testing platform 
during the field trial. 
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Table 12. Patient demographics in field trial (Kigali, Rwanda) 
 
Patients (n = 96) 
Average age (years) 31 (21-62) 
Gender  
 Male 40 
 Female (pregnant) 56 (23) 
Clinic  
 VCT (Voluntary counseling and testing) 52 
 PMTCT (Prevention of mother to child transmission) 38 










Table 13. Healthcare workers in field trial (Kigali, Rwanda) 
 
Healthcare workers (n = 5) 
Average age (years) 32 (26-47) 
Gender (n)  
Male  0 
Female 5 
Background  
 Average time working in clinical settings (years) 10.8 (7-24) 
 Laboratory technicians, (n) 5 
 Experience with RDT, (n) 5 
 Experience with fingerprick, (n) 5 




CHAPTER 3.   DEVELOPING A SMARTPHONE-INTEGRATED HIV-SYPHILIS ASSAY 





Patients were surveyed on their experience with the dongle, preferences for blood sampling 
methods and acceptability of the dongle as a recommended test method (Fig. 31). The vast 
majority of patients preferred fingerprick over venipuncture blood sampling, preferred a test 
method with a shorter turnaround time and would recommend the dongle to others. 97% of 
patients surveyed would recommend the dongle to others because of the fast turnaround time 
(57%), potential to offer results for multiple diseases (44%), and simplicity of procedure (29%). 
Fingerprick blood collection was preferred to conventional venipuncture by 95% of patients 
because it is less painful (98%), takes shorter time (60%), the HCW had trouble with the needle 
collection (55%), the patient is scared of a needle (43%), and a fingerprick takes less volume of 
blood (42%). 2% of patients however, stated a preference for venipuncture because they trusted 
the result more with venous blood.   
 
3.4 Discussion 
We demonstrated that healthcare workers could successfully run a multiplexed STI test on our 
smartphone-dongle platform with minimal training and high patient approval. This was also the 
first study in which our device was tested with fingerprick whole blood, which showed no 
significant difference to venous whole blood for HIV, treponemal and non-treponemal syphilis 
markers on our STI panel. This study allowed us to assess field-performance of the smartphone-
dongle STI test, which offers significant differences from testing in the controlled settings of an 
academic or clinical laboratory. In the field, sensitivities have been reported to be as low as 82% 
and specificities as low as 85% for the widely used HIV RDTs [106-108]; 64–96% sensitivity 
and 97–99% specificity for treponemal syphilis antibody tests (Determine, SD Bioline, 
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Syphicheck, VisiTect, and Chembio) [109-111]; and 85% sensitivity and 96% specificity for 
non-treponemal syphilis antibody test (Chembio) [111] on whole blood (fingerprick or 
venipuncture) performed by trained staff. The diagnostic performance of the smartphone dongle 
was comparable to that of other RDTs in the field. We were also able to gather feedback from 
target end-users and observe clinical workflow to see where integration of our device could be 
most useful or applicable.  
 
Testing in the field requires considerations markedly different from testing in controlled 
academic or clinical laboratories. We built on previous work in creating a dual HIV-syphilis 
assay with ELISA-like performance to develop an assay platform with considerations for scale-
up, stability, reagent pre-packaging and transport to field sites in mind for “plug and play” 
operation by target end users. By leveraging the portability, processing power and audio-jack 
powering and data transmission features of a smartphone, we also developed a low-cost device to 
expand diagnostic testing capabilities in resource and infrastructure constrained settings. While 
not demonstrated in this study, digitization of rapid test results and ability to upload or link to an 
electronic medical record (EMR) system further delivers on the value proposition of a 
smartphone as a platform device for diagnostic testing.  
 
Addition of a non-treponemal test and detection of IgM, performed alongside HIV, moves 
another step towards a complete POC multiplex antenatal-care panel. Performing three 
individual commercially-available tests can cost up to $8.50 USD [$0.80-5.00 for HIV RDT 
[57], $1.00-3.00 for treponemal RDT [49], and $0.50 for RPR [58]]. By comparison, material 
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and reagents cost per test for our triplex test is about $1.50 USD, leaving room for a competitive 
market pricing. In addition, compared to RDTs, the dongle offers automation of assay, objective 
readout of signal, and quantitation, although it requires more instrumentation than RDTs. RDTs 
present challenges for untrained users to execute precise liquid handling and metering, 
particularly in multi-step tests. To improve user interpretation of RDT band intensities, 
researchers have expanded detection methods and integrated the tests with electronic readers [22, 
23]. A series of advances have been made on smartphone readers for POC tests by the Ozcan 
group[112-114], which has led to the creation of a startup company[115]. Most of these 
technologies remain limited to academic demonstrations and even commercial devices have not 
yet penetrated widely for global health use cases.  
 
Remaining work to further translate our device for a resource and infrastructure limited setting 
(Use Case 4) would be to continue optimization with whole blood, reduce peripheral assay 
operation steps, continue to characterize and improve overall device and assay stability as well as 
further deliver on the value proposition of the smartphone integration (e.g. software development 
to connect to medical databases). Finally, a large-scale validation of the assay to determine 
clinical sensitivity and specificity would be needed to begin any kind of regulatory approval 
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During the first field trial, we demonstrated user testing of our device in the field with healthcare 
workers. This work generated a parallel interest from our in-country partner, the Rwandan 
Ministry of Health/Rwandan Biomedical Center, in assessing the potential to expand HIV 
diagnostic services even beyond the clinic.  
 
Self-testing has been proposed as the next step in HIV prevention strategy, particularly in the 
case of high risk groups around the world where uptake of traditional testing and counseling 
services remains low[116]. Barriers include lack of regular access to clinical testing sites or 
primary care, fear of stigmatization, discrimination and concerns of confidentiality of results. 
Alternate strategies such as community outreach HIV counseling and testing (HCT) programs 
through mobile clinics and door to door testing have improved testing uptake in many areas of 
Sub-Saharan Africa and Asia[116]. Self-testing could supplement outreach efforts, enabling 
consumers to find out their status in the privacy of their own homes. A recent meta-analysis of 
eleven HIV self-testing studies revealed high acceptability of HIV self-testing for risk groups 
in study populations that spanned resource-limited settings (Kenya and Malawi) as well as high 
income countries (United States, Spain and Singapore)[116]. Saliva based (OraQuick HIV 
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Test, Orasure Technologies) and blood based (Determine HIV 1/2 Test, Abbott Laboratories) 
rapid diagnostic tests (RDTs) were evaluated along with home collection services where clients 
collected samples for mail-in laboratory testing. Self-testing could be performed accurately by 
the majority of self-testers, who valued privacy and confidentiality of this option[116]. 
 
Several aspects of our platform lend themselves to a self-testing application, namely that 
minimally trained users can perform the steps needed to run the test and get objective readout 
results. Integration of a smartphone as a platform device adds further value for future options to 
manage, store and potentially even share testing data.  
 
Smartphones are becoming more accessible even in resource-limited settings. In Q1 2016, the 
total number of mobile subscriptions was around 7.4 billion, of which 2.6 billion were 
smartphone users[117]. By 2020, the projected increase in smartphone subscribers will reach 6.1 
billion users[118].  Emerging markets in Asia Pacific, the Middle East and Africa are predicted 
to be the biggest drivers of growth in mobile subscriptions[117, 118]. The powerful built-in 
sensors, processors and data transmission capabilities, including Global System for Mobile 
Communication (GSM), wireless fidelity (Wi-Fi), Bluetooth, and universal serial bus (USB) for 
long and short range communication make the smartphone an extremely powerful tool for 
healthcare applications, particularly for diagnostics[119]. 
 
To this end, we sought to explore the feasibility of a smartphone-integrated HIV diagnostic test 
for a home-testing in a resource-limited setting (Use Case 4, consumer use). From our previous 
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field trial, we identified several areas for improvement and implemented several changes to the 
assay and device. We designed a follow-up pilot field trial in Rwanda with aims to explore  1) 
assay performance in the hands of completely untrained users and 2)  user-friendliness of a 
smartphone-interfaced device and 3) preliminary feedback on user acceptability of diagnosis, 
data storage and potential for sharing sensitive information in a smartphone format.  
 
3.6 Methods 
3.6.1 Hardware (“Dongle 2.0”) Fabrication 
Custom-printed circuit boards were designed in Eagle CAD and printed from PCB Universe. 
Bluefruit LE Bluetooth Low Energy (BLE 4.0) nRF8001 Breakout Board (Adafruit) was 
connected to the microcontroller and powered by a CR2032 Lithium 3V coin battery (20.0mm). 
LEDs and photodiodes were precisely aligned with the cassette slot so that testing zones aligned 
without manual effort. One-mm pinholes made of 1-mm thick black Delrin (McMaster-Carr) 
were aligned above each photodiode to prevent stray light. The dongle casing was designed in 
SolidWorks and printed  in-house  (Objet  24  3D-Printer,  Stratasys).   Vacuum  chamber  was  
created  with  a  one- way umbrella valve (Minivalve), a rubber bulb from a 60-mL syringe 
(Becton Dickinson), and a conical spring (Century Spring Corp) inside to aid re-expansion. 
Silicone rubber o-rings and sheets (McMaster-Carr) were used to connect to outlet and seal the 
venting port. A bill of materials is provided (Table 14).  
 
3.6.2 Smartphone app for self-testing users in Rwanda  
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The app was written in iOS Swift using the XCode IDE for macOS. The app was manually 
downloaded by research staff to iPhone 5 device used by participants. Captured results were 
stored locally on the phone during the study, extracted through SQLite browser and exported as a 
CSV file for analysis. The app framework consisted of step-by-step instructions with pictures 
and text instructions that were translated from English to Kinyarwanda (local language in 
Rwanda) by a third-party translator on the study team.  
 
3.6.3 Assay optimization 
3.6.3.a Whole blood  
De-identified whole blood samples with known disease status were provided from the Columbia 
University Medical Center (CUMC), through study approval from Columbia University’s 
Institutional Review Board. Sample reference testing was conducted by CUMC staff, as per the 
IRB protocol, using plasma separated from whole blood on the Abbott ARCHITECT. Blinded 
samples with study numbers were then provided to the Columbia development team for assay 
optimization testing.  
 
Plastic cassettes were functionalized with HIV antigen spotting concentrations at the usual 
concentration of 2 µg/ml and an increased concentrations of 4-10 µg/ml. Signal performance was 
assessed after introduction of 2 µl of undiluted whole blood sample, per test.   Reagents were 
pre-loaded as described previously and OD measurements were taken using the benchtop 
analyzer. Signal performance was compared after testing with 18 clinical whole blood samples.  
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Table 14. Bill of components for “Dongle 2.0” 
 





Photodiode Digikey 475-2659-1-ND 5 0.514 2.57 
Operational Amplifier Digikey ADA4505-1ARJZ-R2CT-ND 5 
1.980 
9.90 
Capacitor, 0.1 uF Digikey 1276-1443-1-ND 5 0.003 0.02 
Resistor, 300 kΩ Digikey P300KGCT-ND 5 0.003 0.02 
Resistor, 100 kΩ Digikey 311-100KJRCT-ND 1 0.002 0.00 
Resistor, 35 Ω Digikey 1276-3914-1-ND 5 0.002 0.01 
Resistor, 10 kΩ Digikey 311-10KJRCT-ND 1 0.002 0.00 
636nm Red LED - 1100 mcd Digikey 754-1786-1-ND 5 0.182 0.91 
Thermistor 10 kΩ Digikey 490-2414-1-ND 1 0.043 0.04 
Capacitor, 1 uF Digikey 1276-1010-1-ND 2 0.009 0.02 
10 pin FFC connectors Digikey WM6790CT-ND 1 1.013 1.01 
10 pin FFC connectors Digikey HFJ110CT-ND 2 1.000 2.00 
10 pin flat flexible cable Digikey WM14313-ND 1 2.420 2.42 
Voltage Regulator Digikey 296-22681-1-ND 1 0.650 0.65 
Pins Digikey SAM1000-32-ND 0.3 4.913 1.54 
Pin Sockets Digikey SAM1104-32-ND 0.3 4.959 1.55 
Switch Digikey EG4934-ND 1 0.457 0.46 
CR2032 Battery Digikey N189-ND 1 0.184 0.18 
Battery Holder Digikey BU2032SM-HD-GCT-ND 1 0.755 0.76 
Bluefruit LE Breakout (Adafruit) Digikey 1528-1199-ND 1 15.960 15.96 
MSP430f1611 Microcontroller Digikey 296-17205-ND 1 10.310 10.31 
PCB - Photodiode Pentalogix Custom 1 0.420 0.42 
PCB - Mainboard 
PCB 
Universe 





Custom 1 3.000 3.00 
Rubber bulb - 60ml 
Allegro 
Medical 561516 1 1.000 1.00 
Silicone sheet McMaster 5787T11 1 0.002 0.00 
Switch Digikey CKN9838-ND 1 2.460 2.46 
Viton O-ring 007 (black) McMaster 8297T117 1 0.120 0.12 
Silicone O-rings 011 (orange) McMaster 9396K16 1 0.150 0.15 
One-way umbrella valve Minivalve UM100.014-151.01 1 0.830 0.83 
      
  
Total Cost 58.72 
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Addition of an FTA-ABS sorbent (SCIMEDX) was tested for potential effect in reducing non-
specific binding (and false positive rate) for the treponemal syphilis assay. Whole blood samples 
were diluted in a 1:1 ratio with the sorbent (2 µl whole blood mixed with 2 µl sorbent), and 2 µl 
of the resulting mixture was pipetted into the assay cassette inlet.  
 
3.6.3.b Lyophilized antibody reconstitution 
Lyophilization of secondary antibodies was performed by OPKO Diagnostics (Woburn, MA). 
9.5 µL of gold-nanoparticle conjugated goat anti-human IgG (0.53 µg/mL) and goat anti-human 
IgM (0.27 µg/mL) antibodies were lyophilized into 2.5cm of plastic tubing. No detergent or anti-
coagulant factors were included in the lyophilization buffer. Lyophilized antibody holders were 
stored at 4ºC until use. Microfluidic cassettes were prepared at Columbia University using 
physio-sorption procedures similar to previous studies. Human IgG and rabbit anti-goat IgG 
were used as capture proteins to test the yield of goat anti-human IgG and human IgM was used 
as a capture protein to test yield of goat anti-human IgM from the lyophilized antibody holders. 
It should be noted that rabbit anti-goat IgG was the internal positive control on all HIV-syphilis 
test cassettes used in previous field work (3.2.1).  
 
3.6.4 Pilot field study in Rwanda  
This pilot study was designed to get preliminary observations and feedback on the feasibility of 
a smartphone integrated diagnostic test for self-testing in developing countries. This study was 
approved by the Columbia University IRB and Rwanda National Ethics  Committee. All rules 
and regulations pertaining to human subject involvement and protection of confidentiality and 
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sensitive data were followed.  
 
3.6.4.a Participant recruitment and enrollment 
The study was conducted at Kimironko (Remera) Health Center in Kigali, Rwanda. Site 
selection was chosen based on target recruitment from the “Preventing Mother to Child 
Transmission: (PMTCT) clinic, “Voluntary Testing and Counseling” (VCT) clinic and CD4 
clinics for existing HIV-positive persons. Eligibility criteria included enrollment in one of these 
clinics (thus, already scheduled for HIV and syphilis testing), age 21-65, ability to read and 
willingness to perform a fingerprick based self-test. Recruitment was done by clinic staff at 
program specific clinic information sessions using a script developed by the study team. 
Participants interested in the study were directed to a third-party interviewer fluent in local 
Kinyarwanda as well as French and English to get more information and undergo the informed 
consent process. 
 
3.6.4.b Study visit procedures and evaluation methods 
After consent, third party interviewer administered a pre-use survey to participants to assess past 
medical history, risk factors and mobile phone usage. Next, participants underwent a skill 
demonstration with the device. For training, participants were first shown a short 1 minute 
instructional video (no audio instructions) on how to operate the device. Participants were then 
provided with a demo lancet, demo test cassette and the dongle and given the opportunity to go 
through the directions once with feedback from the study team. After the training, participants 
were provided with all the test kit components: alcohol swab, lancet, test cassette, dongle and a 
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smartphone (iPhone 5) with the app already loaded. Participants navigated the app to follow the 
step by step directions in order to perform the test on their own with no feedback or intervention 
from the study team (unless they were about to perform a step that was potentially harmful to 
themselves). Study team used a rubric of steps performed correctly and a timer to assess the 
participants’ skill demonstration. Participants were not given diagnostic results through the 
device and study visit; instead they received diagnostic results through their normal clinic visit. 
Afterwards, a third party interviewer administered a post-use interview to assess reactions to the 
test. Participants were compensated 1000 RWF ($1.33 USD at time of study) for involvement in 
the study.  
 
Post-use interviews were audio-recorded, transcribed and translated from Kinyarwanda to 
English by third party interviewers. Three different interviewers conducted the post-use sessions, 
and transcripts were checked for concordance by at least two individuals.   
 
3.6.4.c Confirmatory testing 
Venipuncture whole blood samples in EDTA anticoagulant tubes were collected from each 
participant as part of their normal clinic visit. After clinical testing was completed, an aliquot of 
whole blood was used by the study team to test on the device. Another aliquot (~ 500 uL) of 
plasma was used for HIV ELISA (Vironstika) and TPHA (Spinreact) reference testing at the 
Rwanda National Reference Laboratory. 
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3.7.1 “Dongle 2.0” Hardware 
Four main design elements were modified from our previous smartphone accessory: 1) Bluetooth 
module for data communication (Fig. 32), 2) Button cell battery for power, 3) Silver reagent 
actuation and 4) Smaller overall footprint (casing). Minor changes in fluidic actuation and 
venting port components were introduced as well.  
 
Figure 32. “Dongle 2.0” Schematic.  Schematic diagram of the device highlighting a button-cell battery 
powered Bluetooth module and power-free vacuum generator for fluidic actuation. Once a microfluidic 
cassette is inserted into the device, each test zone is sandwiched between paired LEDs and photodiodes. 
Silver development on the cassette results in a proportional decrease in the light sensed by the photodiode 
and can be quantified by optical density values. The Bluetooth module is connected to a microcontroller (not 
shown), which is programmed to wait for a signal from the smartphone, take light intensity readings of each 
zone and then send the information back to the smartphone. 
 
 
By switching to Bluetooth and adding a button battery for power, we could achieve faster data 
transfer and a more reliable connection compared to FSK through the audio jack of the phone. 
Bluetooth allowed for data transfer of five 16-bit integers in under 1 second compared to 90 
seconds with FSK. Additionally, we could reduce variability associated with different 
smartphone models (e.g. varying impendence from audio jacks that affect efficiency of power 
harvesting). We added a small button cell battery (CR2032, 3.0V) to power the Bluetooth  
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module, which uses 4.6mW (using the Bluetooth Low Energy Mode) compared to an average 
1.5mW used in the FSK audio jack module. While this is a slightly higher power usage, the 
button cell battery is estimated to last about 760 assays and can be replaced easily. When we 
designed the first dongle in 2014, the 3.5mm audio jack was a nearly universal feature amongst 
smartphone versions for both iOS and Android models. In 2016, a year after we switched to 
Bluetooth, Apple removed the audio jack in the iPhone 7 and all future iPhone models [120]. 
Google has since eliminated the audio jack in the recently released Pixel 2 and Pixel XL phone 
models released in 2017 [121].  
 
Using the button cell battery also decreased the CV in replicate optical measurements to 2.8% 
compared to 10.3% when using the smartphone powered dongle (Fig. 33). By increasing the 
LED intensity, we were able to further decrease CV of signals to 0.23%.  These changes allowed 




Figure 33. Optical measurement reproducibility. Coefficient of variation (CV %) is shown for photodiode 
readings from dongles with smartphone power, button cell battery power and with increased LED intensity 
(150mcd to 700mcd, where millicandela is a unit of luminous intensity). 
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The casing components were modified to enhance robustness and ease of use. The overall 
footprint of the “Dongle 2.0” device was almost half (58%) by volume than that of the previous 
version and untethered from a smartphone for increased portability (Fig. 34). For the vacuum 
chamber, we used a rubber bulb from a 60mL piston syringe, instead of the 140mL bulb in 
“Dongle 1.0”. Previously, the valve opening and associated rubber-o-rings could be jostled out of 
position with rough handling. The venting port for the one-way valve was moved to the 
underside of the vacuum bulb chamber, in order to increase device robustness.  
 
 
Figure 34. Dongle hardware versions. (A) “Dongle 1.0” was tested in a field trial by minimally trained 
healthcare workers in Rwanda (citation). Dongle 1.0 measures 7.5cm x 7cm x 5cm, weighs 130g and uses 
the audio jack of a smartphone for power and data communication through FSK implementation. A 140mL 
piston syringe bulb was used for the vacuum chamber. (B) “Dongle 2.0” was used in pilot study with 
untrained users in Rwanda as well as a self-testing study in New York City. Dongle 2.0 measures 5.5cm x 
7cm x 4cm, weighs 100g, uses a button cell battery (3V) for power and Bluetooth Low Energy module for 
data communication. A 60mL piston syringe bulb was used for the vacuum chamber. 
 
We also noted that actuation of silver reagents to connect with the microfluidic circuit in our 
previous design, required users to slide a toggle component that would cover or open a venting 
port on the reagent cassette. This would initiate the flow and mixing of silver reagents. From our 
previous field trial, we observed sliding the toggle back and forth for each run, caused the 
silicone rubber used to seal the port to get worn down easily, and required replacement every 
couple of days. We designed a manual switch adapted from electrical toggle switches as an 
alternative to reduce abrasion on the silicone rubber (Fig. 35). We removed the electrical contact 
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from the switch and placed a pin in its place with silicone rubber below. When the switch is 
pushed in the closed direction, a metal level pushes down the pin, sealing the venting port. This 






Figure 35. Schematic of dongle switch mechanism.  Side view of an electrical toggle switch that was 
modified such that electrical contacts were removed and a pin placed with silicone rubber below. When the 
switch is pushed in the closed direction, a metal level pushes down the pin, sealing the venting port of the 




3.7.2 Assay improvements to streamline user-operation 
In our previous field trial, the study team had to perform companion operation steps, namely in 
diluting the fingerprick whole blood (and subsequent pipetting back into the mChip cassette), 
and an incubation step for reconstitution of lyophilized antibodies (Chapter 3.1-3.4 and Fig. 19). 
These steps were necessary to achieve an acceptable signal-to-noise ratio on target zones, both 
for primary antigen-antibody binding as well as yielding adequate reconstitution of secondary 
antibodies for signal amplification and internal positive control measurements. To better adapt 
our product for minimally trained or untrained users, we wanted to reduce the number of 
peripheral steps needed to perform an assay, particularly those involving other laboratory 
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equipment such as pipetters. To do this, we wanted to be able to use neat (undiluted) whole 
blood and eliminate incubation steps using low-shelf life reagents.  
 
We streamlined the assay in two  major ways.  First, we removed the need for blood dilution.  By 
increasing the surface antigen coating concentration for the HIV detection zone to 10 µg/ml 
(from 2µg/ml used in the previous field trial, Chapter 3), we were able to improve the sensitivity 
and specificity of the HIV zone with neat whole blood (Fig. 36, Table 15). It should be noted 
that this optimization was done with venous whole blood samples (with EDTA anti-coagulant).  
 
We also removed the need to pre-fill the antibody holder with buffer to aid with resolubilization. 
In the previous field trial, the addition of the manual pre-filling step was compounded by using a 
buffer with limited stability to achieve adequate reconstitution of the secondary antibodies. BSA 
solutions are typically recommended to be stored under refrigeration and used in 1-2 weeks. PBS 
and PBS-Tween solutions on the other hand are widely used with long term storage at ambient 
conditions. In optimizing our reconstitution method, we demonstrated that (1) substitution of a 
temperature-stable buffer was possible and (2) an incubation period of the reconstitution buffer 
in the lyophilized holders could be eliminated to achieve comparable end target zone signals 
(Fig. 37).  
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Figure 36. HIV antibody detection optimization with neat whole blood.  18 venous whole blood samples 
comprising positive (n=15) and negative (n=3) HIV serostatus were tested on microfluidic cassettes with 
varying HIV antigen capture concentrations of (A) 2 µg/ml, (B) 4 µg/ml, (C) 6 µg/ml, and (D) 10 µg/ml. 
Vertical scatter plots (left) show signal-to-cutoff ratios of samples positive (Pos) or negative (Neg) for HIV as 
determined by gold standard tests of Abbott ARCHITECT HIV ELISA. Receiver-operating characteristic 
(ROC) curves (right) illustrate Area-Under-Curve (AUC).  
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Cutoff Sensitivity (95% CI) Specificity (95% CI) AUC 
2 µg/mL 0.1429 86.67 % (59.94-98.34) 33.33% (0.84-90.57) 0.822 
4 µg/mL 0.2816 93.33 % (68.05-99.83) 66.67% (9.43-99.16) 0.911 
6 µg/mL 0.3710 93.33 % (68.05-99.83) 66.67% (9.43-99.16) 0.889 
10 µg/mL 0.3167 100.0 % (78.20-100.0) 100.0% (29.24-100.0) 1.000 
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Figure 37. Target zone signals for a dual positive (HIV+/Syphilis+) sera sample using various reconstitution 
methods for lyophilized secondary antibodies. Field trial condition of using a 3% BSA-0.2% Tween in PBS 
solution incubated in the lyophilized holder for 10 minutes is shown in green bars. Two additional conditions showing 
0.05%Tween in PBS solution incubated for 10 minutes and 0 minutes (direct flow through) are shown in grey bars. 
(A) Negative control zone signals (B) HIV target zone signals, (C) Treponemal syphilis target zone signals and (D) 
Non-treponemal syphilis target zone signals. Optical Density (OD) measurements were normalized with internal 
positive control values. Data are averages ± 1 SD (n=3). Asterisk (*) indicates statistical significance (p<0.05) using 
Student’s t-test. 
Additionally, we wanted to be able to pre-package all reagents into the reagent cassette to create 
a true “plug and play” experience for minimally trained users in the field. Instead of having to 
find a way to integrate a relatively large 9 µl bolus into the lyophilized antibody holders, we 
worked to find a buffer sequence that could work within the constraints of our existing 
microfluidic circuit (Fig. 38). The reagent cassette was designed to hold a maximum of seven-
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2µl buffer plugs separated by air gaps (along with compartments for silver amplification 
reagents).  
 
Figure 38. Microfluidic reagent cassette. The reagent cassette allows loading of seven-2µL buffer plugs 
separated by air gaps and contains two compartments of 50 uL each, for silver amplification reagents A and 
B.  
  
We demonstrated that reconstitution buffer sequences using the large 9 µl bolus could be 
substituted with those using only sequences of 2 µl buffer plugs while still achieving comparable 
antibody yields (Fig. 39). Lyophilized gold secondary antibody resolubilization occurs within the 
first few buffer washes, with the later washes acting to remove non-specific binding. 
 
 
Figure 39. Selection of reconstitution sequence to eliminate pre-filling of lyophilized antibody 
holders. Detection zones were functionalized with human IgG, human IgM and rabbit anti-goat antibodies 
(positive ctrl). The previous field trial sequence is shown in green bars (9μL of 3% BSA-0.2% Tween in PBS 
solution, incubated in the lyophilized holder for 10 minutes, followed by six 2μL wash plugs). Sequences 1-3 
used of seven 2μL buffer plugs with no incubation time in the lyophilized holders. Sequence 1 consisted of 
five 2uL plugs of 0.05%Tween in PBS, followed by two 2uL plugs of water. Sequence 2 consisted of four 
2μL plugs of 0.05%Tween in PBS, followed by three 2μL plugs of water. Sequence 3 consisted of three 2μL 
plugs of 0.05%Tween in PBS, followed by four 2μL plugs of water. Data are averages ±1 SD (n=3). Asterisk 
(*) indicates statistical significance (p<0.05) using Student’s t-test after ANOVA. 
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3.7.3 Pilot field study 
3.7.3.a Participant background 
68 participants were recruited over the study period of 2 weeks (Fig. 40). Exclusions based on 
eligibility criteria reduced the study cohort to 55 and a summary of participant demographics and 
background is provided in Table 16. Approximately two-thirds of participants were female and 
about a third male. The majority of participants (69%) had a primary school education, with an 
additional 28% having completed secondary school and only one participant having completed 
college (undergraduate) education.  The majority (86%) lived in an urban area, which correlated 
with the study occurring in Kigali, the capital city of Rwanda. Median self reported travel time to 
the clinic was 60 minutes, with the upper end of the range reaching 180 minutes (3 hours). The 
median annual income was 60,000 RWF (~ $80 USD), with a range of 0 to 2,400,000 RWF (0 to 
$3200 USD).  
 
3.7.3.b Training and usability 
For the first set of participants (n= 15), there was no training process before the skill 
demonstration with the smartphone based diagnostic device. These participants were simply 
provided with fingerprick materials (alcohol swab, lancet, gauze, bandage), one disposable test 
cassette and sample collector, the dongle (“Dongle 2.0”) and a smartphone pre-loaded with the 
custom app. Participants were told to use the app to follow step by step instructions, which 
included pictures and text (translated in to Kinyarwanda). The study team provided minimal 
assistance however if participants got stuck or confused on a step for a long time, a study team 
member would explain the step and move on, while noting assistance on the rubric assessment.  
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What we observed was that on average, participants in this cohort performed 11.3 out of the 15 
required steps correctly (Table 18). Difficulties occurred with (1) certain instructions and 
buttons in the smartphone app, (2) sample collection, (3) connecting the sample holder (Part A) 
and test cassette (Part B), (4) fully inserting the test cassette into the device, and (5) pushing the 
bulb to initiate the vacuum. To address some of these issues during the trial itself, we modified 
text instructions in the app and added a short instructional video (~1:30 minutes) for the next trial 
set of participants (n= 6, data not shown). For the second set of participants (n= 34), we also 
added a training sessions for participants to handle the test kit pieces and familiarize themselves 
with the general test procedure (e.g. understanding the orientation to connect Part A and Part B).   
 
The training took an average of 11 minutes (range: 5-19 minutes) and average time for 
participants to complete a test was 20 minutes (range: 13-40 min), compared to the first set who 
took an average of 27 minutes (range: 21-40 min). The minimally trained participant cohort 
performed 13.7 out of 15 required steps correctly (Table 18), showing a statistically significantly 
improvement (p < .001) compared to the first set of participants.  While 12 participants 
performed all steps correctly, only 4 were able to generate a test with a valid positive control. 
The main reason for the last of valid assay runs seemed to be due to fingerprick blood sample 
clotting in the channel before flowing completely through, due to lag times in engaging the 
vacuum. Due to the low number of fully completed runs, we could not compare diagnostic 
performance in the hands of participants to that of the study team.  
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Figure 40. Pilot study field trial design 
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Table 16. Participant demographics in pilot study (Kigali, Rwanda) 
Gender, n (%) 
  Male 21 (38%) 
  Female 34 (62%) 
     
Age,  
  In years, median (range) 31 (22 - 54) 
     
Educational Level, n (%) 
  Primary School 40 (73%) 
  Secondary School 14 (25%) 
  Undergraduate 1 (2%) 
     
Annual income, median (range) 
  In USD $133 ($0 - 3200) 
     
From Rural or Urban area, n (%) 
  Rural 8 (15%) 
  Urban 47 (85%) 
     
Travel time to clinic, median (range) 




Table 17. Mobile phone usage of participants in pilot study (Kigali, Rwanda) 
Do you own a mobile phone? n (%) 
  Yes 48 (87%) 
  No   7 (13%) 
     
What type of phone do you own? n (%) 
  Basic 34 (71%) 
  Internet-enabled 11 (23%) 
  Smartphone   4 (8%) 
     
How do you use your mobile phone? n (%) 
  Texting 40 (83%) 
  Phone calls 47 (98%) 
  Taking photos 13 (27%) 
  Listening to music 16 (33%) 
  Watching videos 11 (23%) 
  Games   6 (13%) 
  Surfing the internet   6 (13%) 
  Email   6 (13%) 
  Banking   3 (6%) 
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Table 18. Steps performed correctly by participants in pilot study 
 
  First set Second set p-value 
1. Cleaned finger with alcohol wipe 15 (100%) 33 (97%) 0.5157 
2. Pulled lancet tip off 7 (47%) 31 (91%) <0.001 
3. Used same finger that was cleaned 15 (100%) 33 (97%) 0.5157 
4. Pricked finger with lancet 13 (87%) 34 (100%) 0.0251 
5. Squeezed finger 13 (87%) 31 (91%) 0.5823 
6. Collected blood into Part A 6 (40%) 31 (91%) <0.001 
7. Only filled to the line 9 (60%) 14 (41%) 0.3125 
8. Connected Part A to Part B 6 (40%) 31 (91%) <0.001 
9. Inserted chip into device 8 (53%) 33 (97%) <0.001 
10. Pressed bulb 14 (93%) 34 (100%) 0.1188 
11. Started Phase 1 (> 1 min) 15 (100%) 33 (97%) 0.5157 
12. Switch 14 (93%) 26 (76%) 0.1835 
13. Pressed bulb 15 (100%) 32 (94%) 0.3524 
14. Started Phase 2 (> .5 min) 14 (93%) 33 (97%) 0.5157 
15. Saw Results page 13 (87%) 34 (100%) 0.0251 
Total (average) 11.3 13.7 <0.001 
All 15 steps correct 0 (0%) 12 (33%) 0.0105 
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3.7.3.c Venipuncture blood testing by study team 
The study team performed parallel testing of venous blood collected from participants during 
their normal clinic visit. Neat (undiluted) whole blood as well as blood diluted in a 1:1 ratio with 
an FTA sorbent was tested on dual HIV-treponemal syphilis cassettes. In both cases, a 2 µl 
volume of sample (whether neat or diluted) was used. Results of this testing are shown in 
Figures 41 & 42. With undiluted venous blood, HIV antibody detection had a sensitivity of 81% 
(95% CI: 58–95%) and specificity of 50% (95% CI: 33–67%). Treponemal syphilis antibody 
detection had a sensitivity of 100% (95% CI: 16–100%) with specificity of 66% (95% CI: 52–
78%). With venous whole blood mixed with sorbent, HIV antibody detection had a sensitivity of 
90% (95% CI: 68–99%) and specificity of 71.4% (95% CI: 54–85%). Treponemal syphilis 
antibody detection had a sensitivity of 100% (95% CI: 16–100%) with specificity of 77.4% (95% 
CI: 64–88%). 
 
While previous optimization (using n= 18 samples) of HIV antibody detection showed 100% 
sensitivity and specificity with neat whole blood (Fig. 36), we observed lower sensitivity and 
specificity performance with samples (n=55) tested in this pilot study (Fig. 40). We did show 
that HIV antibody detection using whole blood was improved with a dilution, in this case a 2X 
dilution compared to the 10X dilution used in the previous field trial.  
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Figure 41. HIV diagnostic performance in pilot study. Venous whole blood was tested (A) neat, or 
undiluted, or (B) in a 1:1 ratio of blood mixed with an FTA-Abs sorbent (SciemedX). Vertical scatter plots 
(left) show signal-to-cutoff ratios of samples positive (Pos) or negative (Neg) for HIV as determined by gold 
standard tests of HIV ELISA (Vironstika). Receiver-operating characteristic (ROC) curves (right) illustrate 
Area-Under-Curve (AUC). 
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Figure 42. Treponemal syphilis diagnostic performance in pilot study. Venous whole blood was tested 
(A) neat, or undiluted, or (B) in a 1:1 ratio of blood mixed with an FTA-Abs sorbent (SciemedX). Vertical 
scatter plots (left) show signal-to-cutoff ratios of samples positive (Pos) or negative (Neg) for syphilis as 
determined by gold standard tests of TPHA (Spinreact). Receiver-operating characteristic (ROC) curves 
(right) illustrate Area-Under-Curve (AUC). 
 
With treponemal-syphilis detection, we also saw an improvement in specificity with the addition 
of the FTA-Abs sorbent. The sorbent is a standard extraction from a Reiter treponeme culture. 
Sorbent group treponemal antigens are capable of absorbing major non-specific treponemal 
antibodies to “group treponemal antigens” found in healthy individuals, but not to antibodies 
against virulent treponema in diseased individuals[122]. These results indicate that further 
optimization and large scale validation of neat whole blood assays for both HIV and syphilis are 
needed on our platform before clinical or consumer deployment. The alternative method would 
be to include a dilution step, in order to maintain diagnostic performance levels previously 
reported (3.3.7). 
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We demonstrated that with only a short 11 minute training, participants, majority of whom only 
had a primary school education and all of whom had no technical background in immunoassays 
or other laboratory techniques, were able to perform the steps required to use a smartphone based 
microfluidic diagnostic test. Between the two cohorts analyzed in this study, we saw significant 
improvement in 4 steps: (1) pulling the lancet tip off, (2) collecting blood into Part A (sample 
collector), (3) attaching Part A to Part B (test cassette), and (4) inserting the chip fully into the 
device. The addition of an instructional video and opportunity for a brief training period that 
caused these changes show that most steps for our device are easy to perform. While actual 
diagnostic results were not provided to participants, a dummy screen with an example of results 
was incorporated into the app to show that no interpretation of results was required.  
 
Additional improvements in usability can be mitigated through engineered solutions, such as 
incorporation of more audio-visual cues to indicate if a step was performed correctly. For 
example, steps like pressing the switch (Fig. 35), gave an audible click signaling the step had 
been completed. One of the most challenging steps  we observed was attachment of Part A to 
Part B, which required the tips of the capillary tubes in Part A to connect with inlet holes of Part 
B. As there was no cue to indicate when this had been completed, participants struggled to see if 
more force was required to make the proper connection between the two pieces, often resulting 
in bent capillary tips of Part A.  
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In Rwanda, the middle class is roughly classified as people earning 50.000-600,000 RWF per 
month[123], so participants in this pilot study represented a lower-income sample of the 
population. This was also reflected in the survey results pertaining to mobile phone usage (Table 
17). While the majority of participants (89%) owned a mobile phone, most were basic phones. 
23% owned internet-enabled phones and 8% owned smartphones. While the majority in this pilot 
study did not own their own smartphones, the scale of smartphone accessibility is still 
expanding, particularly in the developing world. Countrywide, mobile penetration rate in 
Rwanda as measured in 2014 was 68.1%, however internet penetration rate was only 25%[124]. 
Plans to implement 4G broadband service are underway through the support of the national 
government[124]. Another barrier to implementation of our device however, is the relatively 
high cost of the new device (“Dongle 2.0”) at ~$58 USD. While this represents current 
manufacturing costs that we could decrease if produced at scale, in current format it may not be 
affordable for lower-income consumers in resource-constrained settings.  
 
Additionally, the Rwandan Ministry of Health (MOH) collaborated on this study based on an 
interest in deploying self-testing services and products for HIV diagnosis. On December 1st 2017 
(as part of World AIDS Day commemoration), the Rwandan MOH approved the launch of the 
OraQuick self-testing kit to provide self-testing opportunities as a supplement to existing testing 
services in health facilities or mobile VCT programs[125, 126]. Even in the developing world, 
there is a demand for consumer-facing products that expand access to diagnostics. Understanding 
the requirements and constraints for product design enables us to better drive innovation and 
engineering efforts to help achieve this. 

















Assessing the potential of a smartphone 





Increasingly, there will be interactions of microfluidic diagnostics and untrained users. The 
microfluidic field has been moving towards more field demonstrations of devices[27, 63, 127]. 
With more untrained and minimally trained users having access to such devices, it is important 
to understand how they use devices, what the device failure points are and what the most 
relevant design features are to spur user adoption and meaningful usage.  
 
Human centered engineering encompasses tailoring technology to human needs and interests and 
is increasingly being recognized as part of the larger engineering process[128]. Human centered 
engineering design principles involve framing the user at the center of the process and designing 






around them rather than asking human beings to adapt to technological, process, tradition or 
other constraints. This engineering process is based on an understanding of users, tasks and 
environments, refined by user-centered evaluation and addresses holistic user-experience[129]. 
The process puts the user in the center of the design process by integrating the user into each 
aspect of the process. The user-centered engineering design process is roughly divided into four 
steps: (1) understand and specify the user context, (2) specify the user requirements, (3) design 
and produce solutions to meet the user requirements, and (4) evaluate the solution against the 
requirements[130]. The process encourages iteration until a product or service meets the 
requirements of the user and does not necessarily require starting at Step 1(Fig. 43). For  POC 
developers, the clinical need and potential POC approach have often already been examined and 





Figure 43. User centered engineering design process based on ISO 9241-210:2010. Taken from [[130] 
 






By employing engineering approaches from interdisciplinary fields, we can better investigate the 
interaction of people with technology and technical development. We can use this towards 
biomedical applications in developing interventions and designing new tools to support or 
prompt positive changes in people’s behavior, thinking or awareness. Biodesign and designing 
persuasive health technologies has been emphasized more in engineering for impact over the last 
decade as reflected in research and engineering centers across the country (e.g. Biodesign 
initiative and Persuasive Technologies Laboratory at Stanford University, Harvard Biodesign 
Laboratory at Harvard University, Department of Human Centered Design & Engineering at 
University of Washington etc). It emphasizes the iterative design and evaluation strategy, with 
additional exploration into strategic implementation.  
 
 
Figure 44. Biodesign innovation process. Taken from [128] 
The FDA has also outlined the importance of usability engineering or human factors engineering 
in an updated guidance document (non binding recommendations) in 2016, stating that medical 
device developers “should conduct appropriate human factors study, analyses, and tests in the 
early stages of design process”[131]. Human factors engineering can be seen as a type of systems 
engineering discipline where analysis of a device entails examining the system boundaries at that 
device[131]. Users and interactions cause those boundaries to be moved out, so one can now 






consider all the interactions within those boundaries. The key elements that affect device use are 
use-environment (use case setting), the user and characteristics of the users as well as the device 
interface (hardware/software). All of those elements can interact and research aims can focus on 
understanding the mechanisms behind that interactions- in sum a basic systems model[131]. 
Human factor studies  and the application of human factors engineering principles to device 
development have been receiving increased attention from the scientific community, standard-
setting bodies, and regulators both in the United States and European Union (EU)[132]. This 
focus is directed towards mitigating risk in misuse and enhancing effectiveness of use, 
particularly for consumer (non-health professional) applications.  
 
Usability testing was first widely used in the field of web design to uncover errors and areas of 
improvement. This was done by observing users who were asked to solve given tasks on the site. 
To better understand why users’ interactions with web sites might succeed or fail, people began 
to recognize  limitations of only examining task related problems. Attention to the holistic user 
experience began to take shape in human-computer interaction field, which is where Peter 
Morville, an information architect, came up with the UX Honeycomb model [133] [134]. This 
was generated from his experience working at an internet training firm in the mid 1990s, 
teaching clients to use what was, at the time, state of the art internet tools such as Gopher, 
Archie, FTP and WAIS[135]. Information architecture became a tool for web design to try to 
anticipate users’ major information needs, using both top-down and bottom architecture schemes 
(organization systems, navigation systems, search systems, labeling systems etc )[136]. Since 
then, human-computer interaction has grown in importance as a discipline, and encompasses web 






and mobile applications[137]. User experience (UX) design, is now commonly used in modern 
digital technology and design industries to study interactions between users and products. The 
UX Honeycomb model outlines an expandable evaluation model where separate facets of UX 
(useful, usable, desirable, valuable, findable, accessible, and credible from the user’s 
perspective) are considered in order to measure success[134]. Though it makes no claims on 
process, the combination of these elements in product design is thought to deliver maximum 
value to the user and can be explored in various permutations to iterate on product design. We 
can apply principles of UX and human centered design towards biomedical applications, 
particularly with POC microfluidic device engineering, to build products that are better 
positioned for successful adoption by end-users (whether they are clinicians or 
patients/consumers).   
 
HIV self-testing is one of the first areas where we will see an increased interaction between 
microfluidic devices and untrained users. In the United States, while the overall rate of HIV 
incidence is declining, the population of gay, bisexual and other men who have sex with men 
(MSM) is disproportionately affected[138]. The Centers for Disease Control and Prevention 
(CDC) reported that in 2015, MSM accounted for 82% (26,376) of new HIV diagnoses among 
all males aged 13 or older and 67% of total new diagnoses in the U.S.[138]. The CDC has also 
reported a 65% increase in syphilis rates in the U.S. between 2011-2015. MSM in particular 
accounted for two-thirds of all reported syphilis cases[139]. Syphilis and other sexually 
transmitted infections (STIs) increase the risk of acquisition and transmission of HIV[140]. As 
a result, the CDC has recommended strengthening STI prevention measures, including yearly 






testing for syphilis, gonorrhea and chlamydia, for sexually active MSM and more frequent 
testing (every 3-6 months) for MSM with multiple or anonymous sex partners. Self-testing 
products for STI testing could address unmet needs for these target populations, not just in 
increasing access and frequency of testing but using these products with sexual partners for 
early diagnosis and potentially even prevention of infection.  Currently, the only FDA 
approved diagnostic product for over-the-counter use by consumers in the U.S., is the 
OraQuick In-home HIV Test (Orasure Technologies). The OraQuick test is an oral-fluid, 
lateral flow test for detecting presence of HIV antibodies (HIV-1 and HIV-2), that allows users 
to self-administer the test at home, obtain results in 20 minutes and interpret results following 
written instructions[141]. 
 
Intellectual framework for structured assessments can be useful for understanding interactions 
between new microfluidic devices and users. Other fields, such as economics, psychology and 
behavioral science have rigorous frameworks to study user motivations and behavior. The 
Behavioral Economics model studies how people make decisions about their behaviors, and 
aims to identify conditions under which individuals are likely to make systematic decision-
making errors or ‘biases’[142]. The Behavioral Economics model can be used to explain why 
motivation does not always translate into healthy behaviors and explore if additional incentives 
may be necessary to achieve healthy outcomes. The Fogg Behavioral Model (FBM) is another 
framework used to study behavior change[143]. It asserts that three factors of (1) necessary 
motivation, (2) sufficient ability, and (3) effective triggers influence whether a user performs a 
target behavior[143]. In the context of HIV prevention behaviors, this could be applied to 
analyze and design “persuasive technologies” such as self-testing diagnostic platforms as an 






intervention tool. The Fisher and Fisher Information-Motivation-Behavioral Skills (IMB) 
model was first proposed to understand, predict and promote adherence to highly active 
antiretroviral therapy among HIV positive individuals[144]. HIV prevention information, 
motivation and behavioral skills are seen as the fundamental determinants of HIV preventative 
behavior[145]. Specifically, in cases where “individuals are well informed, motivated to act, 
possess the behavioral skills required to act effectively, [and thus] likely to initiate and 
maintain patterns of HIV-prevention behavior”, the IMB framework is useful for studying or 
developing a particular intervention tool[144].  
 
Traditional translational research for therapeutics involves taking knowledge from basic science 
research and applying it to human clinical trials and eventually patient care. It typically involves 
a course of multiple observational studies, phases of clinical trials and implementation of 
evidence based practice. Patient behavior plays a large role in health outcomes and thus an 
integration of behavioral science into biomedical research has potential to advance and accelerate 
translational research.   
 
Figure 45. Example of research progression through translational stages. Taken from [146] 






Using Hommel et al’s proposed translational research model[146], we undertook what can be 
called a “Phase T1” trial where the primary objective was to establish feasibility and 
acceptability of treatment protocol, which in this case was a potential prevention intervention 
protocol (smartphone integrated microfluidic self-testing device) using a small sample size of 
patients/users. Incorporating user testing allows us to identify user requirements and evaluate our 
design solutions in an iterative development process to enhance user-device interaction. Future 
studies can then undertake controlled and blinded RCTs involved larger patient samples to 
evaluate effectiveness of the testing device in engagement towards increased testing as well as 
towards long term health outcomes.  
 
In this study, we build on our previous work in creating a smartphone-interfaced multiplexed, 
microfluidic STI test[63] and integrate the IMB theoretical model and elements of UX design 
to propose a new framework for microfluidic device evaluation that moves beyond traditional 
characterization of diagnostic performance. We worked with a sample of MSM population in 
New York City who qualified as a “high risk” cohort for HIV/STI infection based on self-
reported sexual behaviors to perform for the first time, a structured assessment of completely 




4.2.1 Self-testing study in New York City (“SMARTtest” study) 






We conducted the trial in New York City, USA with approval from the New York State 
Psychiatric Institute and Columbia University’s Institutional Review Board. 40 participants who 
met eligibility criteria were recruited for the study. All study procedures were performed in 
compliance with the relevant laws and guidelines of the Institutional Review Board and 
statements of informed consent were obtained for all participants involved in the study.  
 
4.2.1.a Participant recruitment and enrollment 
Eligibility criteria included: man or transgender woman who engages in unprotected receptive 
anal intercourse (URAI); 18 years of age or older; fluent in English or Spanish; HIV-negative by 
self-report prior to enrollment; not in a monogamous relationship at the time of enrollment; 
reports having intercourse at least three times per month, on average; reports never or seldom 
using condoms (no condom use in last 10 occasions for those with 4 or less partners or in less 
than 80 % of occasions for those with more than 4 partners in the past year); reports at least three 
episodes of URAI with serodiscordant or unknown status partner in prior 3 months, aware that 
URAI may lead to HIV transmission and owns a smartphone. 
 
Recruitment and screening took place in person and online using bilingual (English/Spanish) 
announcements about the study that were distributed at health clinics and gay community events 
(gay parades, health fairs), posted in authorized areas of gay establishments, reproduced  in print 
media and the Internet, and mailed to participants in prior studies who gave consent to be re-
contacted. Study candidates called the research office and responded to a brief eligibility 
screening questionnaire. Those who qualified were invited to the in-person study visit (Visit 1).  






4.2.1.b Study procedure and assessments 
Study procedure and assessments consisted of participants completing a consent process, A) Part 
1 of a quantitative computer-assisted self interview (CASI), B) skill demonstration using the 
SMARTtest (mock self test in front of the interviewer, no results shown to participant), C) Part 2 
of the CASI and D) a qualitative in-depth interview. Optional FDA approved rapid tests for HIV 
(OraQuick or INSTI HIV tests) and syphilis (Syphilis HealthCheck), were offered to participants 
interested in receiving rapid test results and performed by trained research staff. Post-test 
counseling procedures included information about test limitations concerning window periods of 
infection, the need for confirmatory testing as well as referrals to facilities for further evaluation 
and treatment. Participants received $50 in compensation after the study visit.  
 
A. CASI, Part 1: Participants were asked to fill in Part 1 of the Web-based questionnaire 
using a computer located at the research offices at the HIV Center. The structured 
questionnaire was computerized and self-administered. Participants were identified in the 
questionnaire only by an assigned numeric study ID and no identifiers (e.g., name, 
address, date of birth, social security number) were collected using the questionnaire 
itself. CiW-500 software program (Sawtooth Software, Inc.) was used to program the 
questionnaire. Participants received a brief training on how to use the system and 
responded to questions and response scales shown on the computer screen. Participants 
were informed that they could refuse to answer any question and could ask for assistance 
at any point in the interview. The programmed questionnaire and resulting data resided 
on the study center’s internal servers with firewall protection. In Part 1, participants 






answered questions related to demographics, smartphone usage, sexual behavior in 
relation to their HIV and syphilis knowledge, motivation to remain uninfected, substance 
use and concerns that may affect motivation.  
 
B. Skill demonstration: Participants were asked to use the SMARTtest in a mock testing in 
which they would not receive the test results. The SMARTtest kit consisted of a 
disposable blood collector (“Part A”), disposable microfluidic assay cassette (“Part B”), 
Dongle 2.0 hardware, and fingerprick materials (alcohol swab, lancet, gauze and 
bandage). An iPhone 5 device (Apple Inc.) with the accompanying SMARTtest app was 
also provided for the study visit. Participants were video-recorded, with the camera 
focused only on their hands, in order to assess how well they were able to use the device. 
If they wished, participants were provided with a mask to obscure their face. Participants 
sat a table with test kit materials placed in front of them and were asked to use the 
smartphone app to follow instructions provided therein. Participants were asked to 
abstain from asking questions to the interviewer until testing was completed. This was 
done to make sure that participants could follow instructions and could read the results 
accurately. Once participants indicated they had completed the procedures and the blank 
test result screen was shown, the camera was turned off. The participant was reminded 
that if he or she wished to have an HIV or syphilis test, rapid tests could be conducted at 
the end of the study visit or that study staff could provide a list of places where testing 
may be obtained. A structured rubric containing a checklist of required steps and open 






fields for comments on errors made was used to evaluate the skill demonstration based on 
in-person observations and video recordings.  
 
C. CASI Part 2: Participants were asked to complete Part 2 of the Web based questionnaire, 
which consisted of questions about the SMARTtest device, intention to use it and 
perceived effectiveness and/or difficulty of discussing usage of the device with partners.  
 
D. In-depth interview: Participants underwent an audio-recorded, qualitative interview 
conducted by a trained study member either in English or Spanish. An in-depth interview 
guide was developed to structure interviews. The in-depth interview guide focused on a) 
SMARTtest use with sexual partners; b) sexual decision making based on test results; c) 
potential content for accompanying smartphone app; d) privacy concerns; and e) 
conclusions and recommendations.  
 
 
4.2.1.c Microfluidic test cassettes 
Disposable, plastic microfluidic cassettes were functionalized at Columbia University using 
disease-specific proteins, as described previously[63]. Lyophilization of gold-nanoparticle 
conjugated secondary antibodies (anti-human IgG and IgM antibodies) was performed by OPKO 
Diagnostics (Woburn, MA). Lyophilized antibodies were held in capillary tubing within the 
sample collector. The protruding capillary tip of the sample collector was marked for collecting 
fingerprick whole blood collection using an orange sticker to indicate directionality and a black 
fill line for metering 2uL of blood. An additional sticker labeling the sample collector as “Part 






A” was attached. Wash buffers (three 2-µl PBS–0.05% Tween 20 and four 2-µl water washes) as 
well as 60 µl each of silver nitrate (silver A) and silver reducing agent (silver B) were pre-loaded 
to the reagent cassette by manual pipetting and sealed using an adhesive tape (OPKO 
Diagnostics). Plastic guidance pieces (OPKO Diagnostics) were soldered onto functionalized, 
reagent-filled microfluidic cassettes and labeled with “Part B” stickers as well as matching 
orange stickers to Part A to indicate directionality of attachment. Microfluidic cassettes and 
sample collectors (also containing lyophilized antibodies) were stored at 4ºC until an hour before 
use.  
4.2.1.d SMARTtest application 
The SMARTtest app was written in iOS Swift using the XCode IDE for macOS. The app was 
manually downloaded by research staff to iPhone 5 device used by participants. Captured results 
were stored locally on the phone during the study. The app framework consisted of an 
instructional video followed by step-by-step instructions with pictures and text instructions.  
 
4.2.1.e Data analysis 
For qualitative data management and analysis, audio recordings of in-depth interviews were 
transcribed, reviewed for accuracy and imported into NVivo software for data management and 
analysis. Coding categories were generated from interview questions and themes identified in 
participant narratives. Initial set of codes was generated by two research staff, compared, then 
synthesized to compiled shared coding categories and sub-categories with definitions, inclusion 
and exclusion criteria and examples. Coders discussed discrepancies until they achieved 80% 
intercoder convergence. Analysis of coded material will be aimed at progressive identification of 






regularities in the data under study and to its organization under a conceptual label. Analysis will 
include categorization, abstraction, comparison, integration, iteration and refutation.  
 
For quantitative data management and analysis, CASI (Part 1 and 2) and rubric data (skill 
demonstration) were compiled for analysis and generation of descriptive statistics using Excel or 
SPSS software.  
 
4.3 Results  
4.3.1 UX-IMB framework for evaluation  
Using the qualitative and quantitative data analysis we undertook in this study, we propose a 
framework for evaluation of microfluidic tools towards HIV/STI home testing that integrates 
behavioral science and UX design (Fig. 46).  We used the IMB model as the core theoretical 
frame[141, 147, 148], which asserts that specific informational, motivational, and skill factors 
are the fundamental determinants of behavior, in this case HIV preventative behavior, and will 
vary as a function of culture, class, economics, environment, and life circumstances. This 
model has been extensively validated with diverse populations in over 15 years of research and 
thus useful for design, implementation and evaluation of preventative interventions[145]. 
Ultimately, we seek to study the value of a microfluidic POC device for a self-testing use-case 
setting. To do this, we integrated UX concepts from the Honeycomb Model such as usability, 
credibility and acceptability of new POC devices for HIV/STI home-testing and consumer use, 
which influence user knowledge, motivation and behavioral skills towards engaging with a 
prevention method (i.e. microfluidic POC device). For microfluidic developers, this can 






provide a useful framework to assess and analyze mechanisms of user-device interaction, even 
in prototyping stages.  
 
 
Figure 46. Proposed UX-IMB framework for evaluation of microfluidic devices for HIV home-testing 
 
4.3.2 Description of participant sample 
40 participants were enrolled in this study (Fig. 47). Recruitment focused on gay and bisexual 
men, as well as transgender women, though no transgender women ended up enrolling in the 
study. Eligibility criteria primarily focused on those who qualified as high risk for HIV/STI 
transmission (including those on Pre-exposure prophylaxis, or PrEP). Full qualitative data was 
recorded for 39 participants. Participant demographics are listed in Table 19, showing diverse 
backgrounds and range of socio-economic status and education levels in our study cohort. 
Approximately three quarters (74.4%) of participants identified as gay with the remaining 
quarter (25.6%) identifying as bisexual or other (no participants identified as heterosexual). The 






median income was $30,000, which is somewhat lower than the median income of all New York 
City households ($93,162) as reported by the U.S. Census Bureau for 2016[149]. It should be 
noted that income varies significantly across the city boroughs ranging from median income of 
$37,525 for the Bronx to $77,559 for Manhattan. The median age of participants in this study 
was 33.5, which is close to the median age of 36.2 for all New York City residents[149]. About a 
quarter of participants (25.6%) identified as Hispanic/Latino, which roughly mirrors that of New 
York City (29.2%). 87% of participants reported owning a smartphone and using apps for a 
variety of purposes (Table 20). Primary phone usage activities besides phone calls were texting, 
email, photography, followed by streaming music and videos and surfing the internet or social 
media. There were also approximately equal number of iPhone and Android users (Table 20). 
 
Though at high risk for HIV/STI transmission based on self-reported sexual behavior (i.e. mainly 
from limited or no condom use), most participants expressed high interest in avoiding HIV 
infection. 80% of participants reported high motivation (ratings of 8-10 on a 1-10 scale of 
motivation) to remain HIV-uninfected. About two-thirds of participants (67.5%) also stated high 
willingness (ratings of 8-10 on a 1-10 scale of intended action) to enact actions to avoid HIV. 
This correlates with findings from previous studies that have shown that gay and bisexual men at 
high risk of HIV transmission are still motivated to remain HIV-uninfected[141]. Our study 
enrollment criteria included those on PrEP  (pre-exposure prophylaxis[150]) if they met 
remaining criteria to be high risk for syphilis or other STI transmission.  We found there was no 
statistically significant difference in expressed motivations to remain HIV-uninfected between 
PrEP users and non PrEP users in our study cohort.  































Table 19. Participant demographics in self-testing study (New York City, U.S.) 
 
 
  Age, mean (range) 38.7 (20- 73) 
Income, in thousands (USD)   
Mean 37,501  
SD 41,405  
Range 0 to 220,000 
Race / Ethnicity, n (%) 
  
African-American 19 (48.7)  
White 14 (35.9)  
More than one / Other  6 (15.4) 
Hispanic/Latino, n (%) 10 (25.6)  
Education, n (%)   
Partial/Completed High School 9 (22.5)  
Partial/Completed College 
21 (55) 
Graduate School  9 (22.5) 
Sexual Identity, n (%)   
Gay  29 (74.4) 
Bisexual / Other 
10 (25.6) 















Table 20. Phone usage by participants (New York City) 
 
  
Do you own a smartphone? 
  Yes, n (%) 38 (87%) 
  No/Not sure, n (%) 1 (2.5%) 
  Prefer not to say, n (%) 1 (2.5%) 
      
What type of phone do you have? 
  iPhone, n (%) 21 (52.5%) 
  Android, n (%) 19 (47.5%) 
      
Do you use smartphone applications (apps)? 
  Yes, n (%) 38 (87%) 
  No/Not sure, n (%) 2 (5%) 
     
How do you use your mobile phone? 
  Texting, n (%) 40 (100%) 
  Phone calls, n (%) 40 (100%) 
  Taking photos, n (%) 38 (95%) 
  Listening to music, n (%) 37 (92.5%) 
  Watching videos, n (%) 36 (90%) 
  Games, n (%) 23 (57.5%) 
  Surfing the internet (including social media), n (%) 36 (90%) 
  Email, n (%) 38 (95%) 
  Banking, n (%) 25 (62.5%) 
  Other, n (%) 4 (10%) 






Figure 48. Image of the SMARTtest kit. An image of the SMARTtest kit containing the device (“Dongle 
2.0”) with a microfluidic cassette, fingerprick materials of an alcohol swab, lancet, gauze and a bandage, and 
an iPhone with the SMARTtest app.  
4.3.3 Value of device for self-testing 
Assessment and demonstration of a microfluidic diagnostic device’s value for a particular use-
case  enables development of new tools that are poised for meaningful adoption by target end 
users. In order to assess potential value of the new device, in this case for a self-testing use-case, 
we undertook quantitative and qualitative questionnaires and interviews to expand on we sought 
to understand how users, specifically gay and bisexual men at high risk of HIV/STI transmission, 
felt about the microfluidic SMARTtest for a self- or home-testing application. We explored 
device usability, credibility, and acceptability in our assessment using the UX-IMB framework 
(Fig. 46). We note that these are expandable themes for inquiry that can be customized for a 
target use-case or trial phase. 
 
4.3.4 Ability of untrained users to perform a diagnostic test with the device  
During the skill demonstration, participants were given the “SMARTtest” kit consisting of 
fingerprick materials, disposable microfluidic assay components (sample collector and assay 






cassette), the SMARTtest device (“Dongle 2.0”) and a smartphone (iPhone) pre-loaded with the 
app (Fig. 48). We designed the app for a consumer-facing use case by first guiding users to 
watch an instructional video and then follow step-by-step directions to run the microfluidic test 
on their own (Fig. 49). Users could navigate back and forth between pages describing each step, 
observe a progress bar as they went through the testing process as well as watch (or skip) the 
instructional video as many times as they wished. To mimic the home or self-testing experience 
with an over-the counter (OTC) test, no training or explanations were provided by the study 
team.  
 
The sequence of steps to run the test consisted of preparing materials for the test (unwrapping 
gauze, removing the lancet cap etc), obtaining a fingerprick blood sample, collecting a 2-µL 
metered amount of blood in the sample collector (“Part A”), attaching the sample collector to the 
microfluidic cassette (“Part B”), inserting the cassette into the SMARTtest device, pushing down 
on the rubber bulb (negative pressure chamber) to initiate fluid flow, waiting 5 minutes for Phase 
1 of the test to run (duration of time for sample and initial set of reagents to flow through), 
pressing the manual switch and pushing down on the rubber bulb again for silver reagent 
actuation, and waiting another 5 minutes for Phase 2 of the test to run (flow time for silver 
amplification reagents and signal reading). Full details on assay sequence and biochemical 
reactions on the microfluidic chip surface are outlined in our prior work[63]. A final screen 
showing HIV and syphilis results concluded the test. For purposes of the study visit, only blank 
results were shown to participants during the skill demonstration. The rubric used for usability 






evaluation broke down this process as 16 steps; it should be noted that about half of these are 
related to fingerprick blood sampling and collection.  
 
 
Figure 49. SMARTtest iOS app user interface.  General steps of operation are shown: (1) entering log-in 
information (ID number); (2) a landing screen giving users the option to watch an instructional video and 
then follow step by step directions; (3) instructional video providing an overview of the test procedures; and 
(4) step-by-step directions with images. 
The majority of steps were easy for participants to perform, with an average 86% of steps 
performed correctly and average total time of 15.7 minutes to complete the test (Table 21). This 
included a built in 10 minutes of timers and the instructional video, therefore the average total 
time to complete all manual steps of the test was around 4.6 minutes (Table 21). We made some 
slight modifications to the instructional video between the first and second set of participants 
(n=20 in each), however observed no statistically significant differences between the two sets of 
participants in performing each step of the test correctly or overall number of steps performed 
correctly (88% of steps performed correctly in first set and 90% in the second set) (Table 21).  
90% of participants felt “pretty confident” or “very confident” in their ability to perform the test 
correctly when asked for self-evaluation of performance (using a Likert-type scale of 1-5, with 1 
being not confident and 5 being very confident). While there was some variability in collecting 
blood, all participants were able to successfully perform a fingerprick on themselves using the 
recommended directions in the app. The vast majority of participants (75%) chose to perform the 






fingerprick on their left forefinger, matching the finger shown in the instructional video, though 
no explicit directions were given on choice of hand or finger to sample from.    









Table 21. Number of steps performed correctly by participants in self-testing study  
 





1. Opened gauze packet n/a 20 (100%) - - 
2. Cleaned finger with alcohol wipe 20 (100%) 20 (100%) - 100% 
3. Pulled lancet tip off 20 (100%) 20 (100%) - 100% 
4. Pricked cleaned finger with lancet 20 (100%) 20 (100%) - 100% 
5. Squeezed finger 20 (100%) 20 (100%) - 100% 
6. Collected blood into Part A 15 (75%) 19 (95%) 0.077 85% 
7. Only filled to the line 15 (75%) 15 (75%) - 75% 
8. Wrapped finger in gauze n/a 20 (100%) - - 
9. Connected Part A to Part B 20 (100%) 20 (100%) - 100% 
10. Inserted chip into device until black lines matched 13 (65%) 11 (55%) 0.516 60% 
11. Pressed bulb 17 (85%) 15 (75%) 0.429 80% 
12. Pressed continue to start Phase 1 timer (< 1 min) 18 (90%) * 19 (95%) * 0.549 93% 
13. Pressed switch 14 (70%) 17 (85%) 0.254 79% 
14. Pressed bulb 15 (75%) 18 (90%) 0.211 85% 
15. Pressed continue to start Phase 2 timer 15 (75%) 14 (70%) 0.726 73% 
16. Saw Results page 11  (55%) 19 (95%) - 100% 
Total steps performed correctly (average) 13.2 (88%) 14.4 (90%) 0.513 13.8 
Number of participants who got all steps correct 6 (30%) 4 (20%) 0.465 10 (25%) 
Total time of test in minutes, average (range)  16 (11.8-34) 15.3 (13.4-17.4) 0.535 15.7 (11.8-34) 
Instructional Video (min) 1.05 1.73 - 1.39 
Built in timers (min) 10 10 - 10 
Time to complete manual steps, average (range) 5.5 (2.0 - 23) 3.6 (1.7 - 5.6) 0.086 4.6 (1.7 - 23) 
  






Microfluidic cassette components were modified to enhance visual recognition and handling 
through stickers and labeling (“Part A” and “Part B”). We also observed that in the previous 
pilot study, users had to insert the tips of the capillary tube component of the sample collector 
into matching inlet holes of the microfluidic cassette by eye, causing some difficulty in 
knowing how much force to apply in pushing the pieces together and in some cases, bending 
the capillary tube tips out of shape (Fig. 50). An additional plastic guidance piece was added to 
functionalized microfluidic cassettes to guide attachment of the sample collector (Part A) to the 
microfluidic cassette (Part B) through a simple sliding and locking motion (Fig. 50). Once 
attached, Part A and B are locked irreversibly, containing blood within the closed microfluidic 
circuit and embedded waste pad.  All participants in this study were thus able to attach the two 
components together.  
 
 
Figure 50. Microfluidic components of self-test kit.  Images showing modifications to Part A, the sample 
collector, Part B, the combined assay and reagent test cassette as well as attachment for pilot study (top 
row) and naïve-user testing (bottom row). 
 






From the usability evaluation rubric, the most challenging step to perform was inserting the 
microfluidic cassette into the SMARTtest device, with only 60% of participants able to do this 
correctly (Table 21). The main source of error was not inserting the cassette fully into the 
device, which affected alignment of the vacuum to the cassette outlet. The next most challenging 
step was collecting the specified 2-uL volume of fingerprick blood in the sample collector (“Part 
A”), with participants mostly overfilling past the indicated line on the sample collector or in a 
few instances, not collecting sufficient blood. The other main source of error was participants 
who did not use the step-by-step instructions and attempted to perform the test while the 
instructional video was playing. This resulted in missing steps such as pressing the switch or app 
buttons that started the built-in timers, or performing them in an incorrect order, particularly for 
the second phase of the assay. In self-evaluation interviews, most participants indicated that the 
hardest steps to perform were inserting the microfluidic cassette into the SMARTtest device and 
collecting the fingerprick blood in “Part A”, correlating to the usability analysis by the study 
team. Interestingly, the next most common step flagged as challenging by participants, was 
pushing the vacuum bulb, either due to the physical resistance of the bulb itself or feeling unsure 
about whether this was performed correctly or not.  
 
4.3.4.a Usability analysis 
10 participants performed all the steps correctly, however none were able to complete the assay 
with a valid positive control. When observing the full set of participants, we noted that 70% of 
the microfluidic tests used showed no blood sample reaching the waste pad of the microfluidic 
test cassette, indicating the sample had stalled in a prior portion of the channel. We also noted 






that 90% of participants took more than one minute between fingerprick blood collection and 
starting the assay (i.e. engaging the vacuum for fluid flow). While the one minute time period 
between sample loading and starting the assay was used a rough operational step in prior studies, 





Figure 51. UX-IMB Usability: effect of lag time on fingerprick whole blood flow time through 
microfluidic channel. Condition 1 consisted of lag time measured in minutes between pricking the finger 
and subsequent collection and immediate introduction to the channel. Condition 2 consisted of collected the 
fingerpricked blood sample into the capillary tube of the sample collector, followed by lag time at indicated 
time points before introduction into microfluidic channel. Time for blood to flow through channel was 
measured in seconds from inlet to waste pad (end of channel). 
 
We performed a preliminary exploration of lag time between fingerprick blood collection and 
flow through the microfluidic channel (Fig. 51). We examined two conditions that represent 
user-scenarios with the fingerpricking process: a lag time between pricking of the finger and 
collection into the capillary tube of the sample collector (Part A) and lag time between sample 
collection in the capillary tube and introduction to the microfluidic channel (connection with Part 
B and engaging the vacuum bulb). For fingerprick blood left on the finger, we found we could 
wait up to 2 minutes to collect and introduce into the channel and still have flow through with no 






sample stalling. In the condition of lag time after sample collection, we found we could wait up 
to 2.5 minutes before the blood would stall in the microfluidic channel. In both cases, we 
engaged the vacuum prior to sample addition. 
 
We also wanted to assess if there was any difference in occurrence of sample stalling or flow 
times through the cassette based on method of sample introduction via a standard manual pipette 
or capillary tube attachment to the microfluidic cassette inlet (Fig. 52).  In most of our 
optimization work, we had used a manual pipette for whole blood handling and dispensing into 
the cassette. With EDTA or heparinized venipuncture blood, we saw little difference between 
using a pipette or the capillary tube of the sample collector but had not assessed potential 
difference with fingerprick whole blood with no anti-coagulants. We saw no statistically 
difference in time for a 2µL fingerprick blood sample to flow through using either method (Fig. 
52) 
 
Figure 52. UX-IMB Usability: whole blood sample flow times with different methods of sample 
introduction to microfluidic chip.  A 2μL sample of disease negative whole blood was introduced using 
two methods (1) collecting in a standard pipette and dispensing into the inlet of the microfluidic chip, and (2) 
collecting in the capillary tube of the sample collector (Part A) and attaching to the microfluidic cassette inlet. 
Vacuum was engaged prior to sample introduction into the cassette in both methods. A pre-wash of 2μL 
plug of 0.05% Tween-PBS was flowed through the channel immediately before sample introduction. Data 
are averages ±1 SD (n=4). Asterisk (*) indicates statistical significance (p<0.05) using Student’s t-test. 
 






Another assay protocol step that differentiated this usability study setup from prior work 
(Chapter 3) was that channel priming with a 0.05%Tween-PBS wash did not occur just prior to 
whole blood sample introduction (i.e. a few seconds before blood was introduced to the channel). 
Microfluidic cassettes were functionalized and prepared for participant use the morning of a 
study visit session. To more closely mimic user-experience in the intended setting, no additional 
channel priming was performed after participants received the test kits, which could be up to 6-8 
hours after our initial priming step.  In Figure 52, the channel priming was performed just prior 
to sample introduction. We performed another ancillary experiment examining positive control 
zone signals using microfluidic cassettes that had been primed at various time points prior to 
sample introduction of disease negative whole blood (Fig. 53).  We saw a statistically significant 
decrease in positive control signals after 2.5 hours.  
 
 
Figure 53. UX-IMB Usability: comparison of positive control signals after channel priming. A 2μL plug 
of 0.05% Tween-PBS was flowed through the channel. At time points shown after channel priming, a 2μL 
sample of disease negative whole blood was introduced, followed by the usual reagent sequence for 
reconstitution of lyophilized gold-labeled anti-hIgG/anti-hIgM antibodies antibodies (three washes of 0.05% 
Tween-PBS, and four washes of water) and silver amplification. Data are averages ±1 SD (n=3). Asterisk (*) 
indicates statistical significance (p<0.05) using Student’s t-test. A comparison of signals at time point 0 and 2 
hours after channel priming  yielded minimal significance (p = 0.058). 
 






What is not reflected in this data is the number of times the vacuum was re-engaged to clear 
stalled sample or washes (which occurred more frequently in later time points). This suggests 
that sample stalling and channel priming are somewhat correlated.   
 
Finally, we wanted to assess how changes in the casing and negative pressure chamber in the 
current Dongle 2.0 design had an impact on user-activated flow. The main changes in the 
vacuum bulb from previous trials (Chapter 3) were: (1) rubber bulb from a 60mL syringe 
compared to the 140mL size in Dongle 1.0, and (2) minor adjustments in the height of the 3D 
printed vacuum chamber casing (Fig. 54) surrounding the bulb compared to Dongle 2.0 used in 
the pilot Rwanda study (which had to be made due to supply chain adjustments to obtain the 
source 60mL syringe needles). Previously the height of the vacuum bulb chamber was 1cm (total 
bulb height 2.5cm) and in the current design, the height of the chamber was 0.38cm (with total 
bulb height 1.5cm).  
 
 
Figure 54. UX-IMB Usability: integrated dongle casing for Dongle 2.0 used in SMARTtest study.  3D printed 
casing was produced in house, with minor adjustments in vacuum chamber height compared to previous designs. 
 
We performed a follow-up experiment to assess variation in user-activated flow using Dongle 
2.0 in this study (Fig. 55). Thus, we recruited three additional naïve-users (not included in 






SMARTtest Phase 1 cohort), to assess flow times using a standard reagent sequence of washes. 
We saw a statistically significant difference between flow times for two out of the three users, 
suggesting variable amounts of pressure applied to the bulb. The 60mL bulb provided higher 
resistance than the bulb in Dongle 1.0, as was reflected in user-feedback from SMARTtest 
participants in steps they found challenging. This suggests the slightly smaller footprint enabled 





Figure 55. UX-IMB Usability: user activated negative pressure-driven flow. Average time to flow a total 
sequence of 4 washes: two-2uL washes of 0.05% Tween-PBS and two 2-uL washes of DI water, are shown. 
All three users were naive users (not enrolled in study, but unfamiliar with device). Data are averages ±1 SD 
(n=3). Asterisk (*) indicates significance, using one way ANOVA followed by pair-wise t-test (P = 0.0248).  
 
 
We identified critical steps where both device and user-device interaction could be improved: (1) 
Sample collection and introduction of sample to microfluidic channel, (2) Inserting the cassette 
fully into the device, and (3) Engaging the bulb of the negative pressure chamber fully for 






consistent fluidic actuation. Additional sources of error were mainly due to users using the 
instructional video instead of step-by-step directions in the app for guidance.  
 
This indicates that various approaches to mitigate the main sources of error are needed, which 
could include: (1) enhanced user-guidance such as additional prompts in the app (e.g. specifying 
to wait until the instructional video was over to begin the test or recommended time frames to 
complete critical steps) or adding more audio-visual cues on the device to indicate if a step was 
performed correctly (e.g. cassette fully inserted into device, vacuum bulb pushed sufficiently); 
(2) assay refinement to increase tolerance for the variation in timing of steps performed by users, 
such as  incorporation of anti-coagulant or on-chip dilution to counteract lag time between 
sample collection and assay start time,  or (3) engineering design changes such as modifying the 
slot for insertion of the microfluidic cassette into the SMARTtest device (Fig. 54), adding more 
powerful  negative pressure vacuum system to drive fluid flow, automated microfluidic channel 
priming step (e.g. running a pre-wash buffer) to mitigate flow issues and modified actuation 
mechanism of the negative pressure chamber (e.g. larger bulb, changing to squeezing mechanism 
instead of push to engage etc). Performing usability analysis with target end-users allows us to 
better characterize friction points and iterate on design choices to increase tolerance for user 
error or variance in timing of steps.  
 
4.3.5 Device Credibility 
We surveyed participants on belief in results generated from the device. Most participants (over 
70%) felt “confident” or “very confident” in results received through the SMARTtest when 
asked to verbally rate on a 1-5 scale. From qualitative data analysis, we learned that many 






participants expressed this confidence stemmed from the perception that blood as a sample input 
would be more accurate than an oral saliva swab. Many also expressed greater confidence in 
receiving disease negative results, based on their own perceived risk/behaviors, stating that 
positive results would cause them to pursue confirmation with a second test or at a clinic. Those 
who expressed less confidence in results generated by the SMARTtest device stated this 
stemmed mainly from feeling unsure about performing steps of the test correctly (e.g. if the 
fingerprick blood collection was acceptable) due to the lack of feedback from the device or app. 
Many also expressed that confidence in results would increase if the SMARTtest had regulatory 
approval (e.g. FDA approval) or if they were provided information on test accuracy, diagnostic 
performance statistics and in some cases, how the device worked (i.e. mechanism of action, data 
transmission from device to smartphone).  
 
4.3.6 Acceptability of device for self-testing  
4.3.6.a Willingness to use device  
We explored desirability of the device though questions about participants’ willingness to use 
and/or buy the test if it was available. 95% of participants in our study expressed that they would 
be likely or definitely likely to use the SMARTtest on themselves, if cost was not an issue (Fig. 
55A). 85% also expressed high likeliness to use with sexual partners.  Pearson Chi-Square 
analysis showed no significant correlation between those who had previously used the Oraquick 
HIV self-test and willingness to use the SMARTtest for self or partner testing, suggesting that 
even those who had not been primed with exposure to other STI home-testing products were 
equally likely to use the SMARTtest.  







Participants overwhelmingly expressed that it would be very easy (86.4%) or easy (15.4%) to 
keep the SMARTtest in their homes (Fig. 56B). 74% felt it would be easy to carry it when going 
out, with the remaining quarter of participants stating they felt it would be fairly hard or very 
hard to carry SMARTtest when going out (Fig. 56B).  
 
Most participants (56.4%) stated a willingness to pay up to $25 USD for one SMARTtest kit, 
which would include the resuable SMARTtest device (“Dongle 2.0”), 2 sets of disposable, 
microfluidic HIV/syphilis test cassettes and fingerprick materials (lancet, gauze, alcohol swab, 
bandage) (Fig. 56C).  Three participants stated they would not purchase the kit and no 
participant expressed willingness to pay over $100 USD, however overall preference aligned 
with cheaper price points. There was a more bimodal distribution in price points that participants 
were willing to pay for each disposable HIV/syphilis test cassette, around the $3 USD range 
(~20% willing to pay less than $3 and 31% willing to pay $3-$6) and the $12 USD range (21%) 
(Fig. 56C). There was no significant correlation between self-reported annual income and 
willingness to pay more for a SMARTtest kit (Pearson correlation coefficient = -0.05, p=.780), 
or for disposable microfluidic cassettes (Pearson correlation coefficient = -0.14, p = 0.44). 
 
4.3.6.b Perceived usefulness for home-testing 
4.3.6.b.1 Circumstances 
When asked about potential usage of the SMARTtest, most participants discussed privacy of a 
home as the primary setting for where they might use it. Participants liked the option of doing 






test at home with follow-up options at a clinic or connecting with a doctor, particularly with 
potential positive test results. While they considered it physically easy to carry with them in the 
quantitative survey responses, many participants expressed they were less inclined to take 
SMARTtest on the go, unless it was pre-discussed with potential sexual partners. Some also felt 
that the SMARTtest was too bulky, though some felt this could be mitigated with a discrete 
carry-bag or travel kit with less packaging.  
 
4.3.6.b.2 Motivators 
When asked about potential prompts or motivating factors to use a device like the SMARTtest, 
the top two motivating factors expressed by participants were (1) perceived risky sexual behavior 
or encounters, including the use of drugs or alcohol that might affect judgement and (2) 
preventative or proactive testing to know or confirm one’s status. The ability to get syphilis test 
results in addition to HIV, was seen as a significant value-add, especially as syphilis information 
(transmission, symptoms, window period of infection etc) was perceived to be less disseminated 
or known compared to HIV information. Other prompts that participants discussed towards 
potential usage of the device was convenience and affordability of getting the SMARTtest, 
seeing visible symptoms (e.g. syphilis chancres), or using the test to encourage partners towards 
testing as well.  
 
4.3.6.b.3 Frequency 
Participants were asked how frequently they might use the SMARTtest and responses varied 
between those familiar with the 3 month HIV infection window period and those who discussed 






more frequent usage (e.g. once or twice a month). Many of those who stated they would test once 
every 3-6 months however, expressed they might use it more frequently based on perceived 
exposure events such as new partners or sexual behavior. Participants who were on PrEP 
mentioned that they already underwent a recommended quarterly HIV testing regimen under 
their current medication plan, and may not increase frequency of testing at home. Syphilis results 
however, were of interest and seen as a prompt to increase testing frequency for many 
participants.  
  









Figure 56. UX-IMB Acceptability: self-use of SMARTtest.  (A) Participants’ responses on likeliness to use 
the SMARTtest for self-use and with sexual partners if cost were not an issue. (B) Participants’ ratings on how 
easy or hard it would be to keep the SMARTtest at home or carry on the go. (C) Price (in USD) that 
participants were willing to pay for a full SMARTtest kit (device and 2 sets of disposable microfluidic test 
cassettes and fingerprick supplies) as well as for disposable microfluidic test cassettes alone.  







4.3.6.c Partner testing 
Both self-testing and partner-testing are seen as key features of harm reduction approach with 
HIV transmission[141]. We explored acceptability and perceived effectiveness of the 
SMARTtest for use with partners (Fig. 57). Most participants (>74%) expressed high likeliness 
to use test kits with a range of sexual partner types including one-night stands and spouse-
equivalent type of partners (defined here as those with whom participants shared an emotional 
connection with or who were repeat partners) (Fig. 57A). 92.3% of participants indicated a 
higher likelihood to test spouse-equivalent type of partners, compared to 74.4% who would use it 
with one-night stands and 87.2% who would use with all other types of partners (Fig. 57A).   
 
When asked about perceived use with potential partners, over 70% of participants felt that it 
would fairly easy or very easy to raise the idea of using SMARTtest with a partner, and to ask 
partners to be tested with it (Fig. 57B). All participants stated they would find it easy (fairly easy 
or very easy) to show a partner how to use SMARTtest (Fig. 57B), with about 69% of 
participants feeling comfortable performing the fingerprick HIV test themselves on a partner 
(Fig. 57C). When asked how they imagined typical partners would feel about having a 
fingerprick HIV test performed on them, participants’ responses were more split with slightly 
less than half (41%) envisioning partners feeling uncomfortable and the remaining half stating 
they imagined partners feeling comfortable with it. As a result, there was an approximately equal 
number of participants who would choose to test partners themselves or have the partner test 
himself with the fingerprick based SMARTtest (Fig. 57C). Another source of concern was usage 
of test with partners under the influence of alcohol or drugs. Participants expressed it would be 






slightly easier to use the test while they were under the influence (62%) compared to partners 
being under the influence (51%), though both cases revealed alcohol/drug use being a potential 
barrier to using the test (Fig. 57D).  
 
85% of participants also expressed they would find it easy or very easy to avoid intercourse (both 
RAI and AI) with partners who refuse to test, suggesting potential impact on sexual behavioral 
choices could be made through a self-test product. 85% participants also expressed high 
confidence in their ability to judge whether partners could become violent over using it and over 
87% of participants stated they would find it easy or very easy to avoid violent situations that 
might arise out of using a test.  
 







Figure 57. UX-IMB Acceptability: using SMARTtest with partners. (A) Participants’ likeliness to use SMARTtest 
with different types of sexual partners, ranging from one-night stands spouse-equivalents (defined as those 
participants felt an emotional connection with) and all other partner types, if cost were not an issue. (B) Participants’ 
responses on approaching partner-testing with the SMARTtest including how hard or easy it would be to raise the 
idea of the test, asking a partner to be tested and showing a partner how to use it. (C)  Comfort and ease of using 
SMARTtest with partners including how comfortable participants would feel performing a fingerprick on partners and 
preference on who would perform the test. (D) Perceived influence of drugs or alcohol on ease of using SMARTtest 
with partners when participants were under the influence or when partners were under the influence. 






4.3.7 Overall perception of device (advantages & disadvantages) 
The top two advantages participants perceived about the SMARTtest was the ability to get 
instant results (i.e. not have to wait to go to a clinic or make an appointment for testing) and the 
smartphone integration. Instant results were seen as an advantage for greater flexibility in timing 
and location of testing as well as using with partners. Participants discussed various perceived 
advantages of smartphone integration including the ubiquity of smartphone usage and opinion 
that people enjoyed new technology and apps, the ability to store and track test results and 
perceived future functionalities such as sharing results with partners (including social 
media/online dating profiles) or with providers for followup. Other advantages that many 
participants discussed was that the SMARTtest felt simple to use, was portable and provided 
both HIV and syphilis results. Most participants liked the video and step by step instructions in 
the app, and felt the in-app guidance made the testing process easier to follow along.  
 
Several participants compared the SMARTtest to their experiences with the OraQuick and 
expressed perceived advantages included greater portability compared to the commercial 
OraQuick testing kits, the ability to get dual test results, smartphone integration and faster time 
to result (10 minutes of waiting time in the SMARTtest versus 20 minutes with the OraQuick). A 
few participants also expressed that the SMARTtest was easier to use than the OraQuick and that 
it felt more accurate due to the removal of interpretation of visual lines for the result, use of 
blood over saliva as a sample input and reduced possibility of contamination (e.g. with saliva 
sample vial in the OraQuick).  
 






When discussing perceived disadvantages of the SMARTtest, more participants expressed 
concerns with potential usage with partners than using it on their own, such as how partners 
might react, and what to do if a partner tested positive (e.g. providing counseling). One 
participant mentioned that having a self-testing product like this could add to “politicization” of 
people’s decisions to test or not test, and subsequent stigma or social pressure based on these 
decisions. In terms of self-usage, some participants mentioned factors such as the use of blood 
and questions about test accuracy. Participants also expressed that while the device felt portable, 
making it even more compact would enable and encourage carrying it on the go. Some also 
discussed cosmetic refinements that correlated with translation of prototypes to commercial 
products (e.g. visually pleasing colors, sleeker form factor, making cassette insertion easier etc).  
 
We explored concerns about a blood based self-test further. As with general concerns about the 
SMARTtest, there was a dichotomy between usage on self versus with partners. Most 
participants stated that they themselves had little to no concerns about a fingerprick blood based 
test, however could imagine others who might be concerned. Blood sampling was seen as a 
bigger “ask” from partners than an oral swab. Some participants expressed that they felt more 
apprehensive about handling their own blood, however the majority of participants also 
expressed the perception that a blood based test inspired more confidence and accuracy than an 
oral saliva method for HIV/STI test results.  A few participants discussed that dealing with the 
fingerprick and bandage application after testing, might be disruptive to subsequent sexual 
activities, but the majority of participants did not see it as a significant barrier.  
 






4.3.8 Re-visiting UX-IMB Framework 
We used both analytical approaches to review and assess user interactions with the device (task 
analysis) as well as empirical approach deriving data from users’ experiences (qualitative 
interviews and quantitative surveys). We examined three major components of the UX-IMB 
framework (Fig. 46) in this study: credibility, acceptability and usability of our microfluidic 
device, where each component can be mapped onto the three major constructs of the IMB model 
(information, motivation and behavioral skills) (Fig. 58). This model posits that performing a 
health promotion behavior is a function of the extent to which someone is well informed about 
the behavior, motivated to perform the behavior, and has the requisite skills to execute the 
behavior and confidence in their ability to do so across various situations[151]. This was an 
initial feasibility trial, so user-behavior (usage of device for self-testing and sexual behavior 
decisions) was not directly measured, however using this framework allows us to understand 
theoretical device value for the intended use-case, here for HIV home-testing for a target 




Figure 58. Linkage of SMARTtest study measurements to key parameters of IMB framework.  






Usability analysis allowed us to evaluate a completely naive user’s skill in using the device. 
Many of the critical errors lie at the intersection of user and device interaction. We were able to 
evaluate the device on some key design parameters of: (a) simple and intuitive use, (b) tolerance 
for user-error, (c) physical effort needed, (d) perceptible information, and (e) flexibility in use for 
diverse users and settings. Our results showed that the SMARTtest was relatively simple and 
intuitive to use by users with varying levels of education and income (in this study cohort), 
however had a low tolerance for error and high physical effort needed for critical operation steps 
(e.g. cassette insertion and vacuum bulb engagement). Perceptible information was high in the 
sense that participants found the video and step-by-step directions in the app useful in conducting 
a microfluidic assay, however was counterbalanced by the commonly expressed feeling that the 
device did not provide sufficient informative feedback on steps that were performed. Participants 
generally felt the device was portable enough to carry outside of the home (particularly by those 
who compared it to current commercial OraQuick kits), though multiple components (e.g. 
microfluidic cassettes and fingerprick supplies in addition to the dongle device itself) was seen to 
require a more compact form factor for transport.  
 
Device credibility analysis showed us that in this cohort, a blood based test was perceived as 
more accurate for HIV and syphilis test results. The smartphone form factor can enhance 
information delivery, which could address remaining gaps in user knowledge and information on 
test information (e.g. diagnostic accuracy) that would enhance device credibility as well as 
provide additional resources on disease and testing information (e.g. window period of 
infection). Most participants indicated that follow-up testing or confirmation of positive results 






(more so than negative results) in regular clinical settings was desired, supporting the need to 
integrate linkage to care elements in the device platform.  
 
Device acceptability accesses user-motivation for engagement with the device for self-testing. 
This was measured through coding category themes that were derived from qualitative 
interviews: willingness to use the device, perceived usefulness for home-testing and potential use 
with partners. Key features of the SMARTtest device that participants identified as motivators 
for using was multiplexed results (syphilis and HIV), and opportunities to use the smartphone 
platform for results sharing and linkage to care.  
 
4.4 Discussion 
To maximize impact on patient care, the pace of translational research must be accelerated; 
integration of behavioral science into biomedical research has the potential to do this due to the 
large role of patient behavior in health outcomes[146]. We can use these frameworks to better 
understand the mechanisms of interactions between users and POC devices, that extend beyond 
physical interaction with the user-interface (hardware and software) and explore potential uptake 
and effectiveness of use based on user characteristics, environment  Our work aims to provide a 
user-centered framework for testing and evaluation of microfluidic devices, especially those 
targeted towards home- or self-testing (Fig. 46). Such a framework can enable microfluidic POC 
developers to integrate user-based evaluations earlier in the development process to refine design 
features as well as build products that motivate generation of consumer-driven health data and 
improve health outcomes.  







This is the first structured assessment, to our knowledge,  of completely naïve users using a 
continuous flow, microfluidic POC test. We demonstrated feasibility of adapting microfluidic 
POC devices for consumer use with generally high acceptability from target end users. We 
used interdisciplinary analytical approaches to assess user interactions with the device and 
derive data from users’ experiences from qualitative interviews and quantitative surveys. We 
examined three major components of the UX-IMB framework in this study: credibility, 
acceptability and usability of our microfluidic device, where each component can be mapped 
onto the three major constructs of the IMB model. From this, we were able to  characterize 
friction points for naïve users in device handling and identify critical user-device interaction 
mechanisms. We also expanded understanding of mechanisms that drive device usage and 
effectiveness of use.  
 
This was an initial feasibility trial, so user-behavior (usage of device for self-testing and sexual 
behavior decisions) was not directly measured, however using this framework for evaluation 
allows us to understand theoretical device value for the intended use-case, and future studies 
can assess implementation to evaluate device uptake for self-testing and health/behavior 
outcomes. 
 
Our previous work demonstrated the use of the smartphone dongle as tool for clinicians or 
healthcare workers to use in resource constrained health settings[63]. Here, we made some 
changes to the device and accompanying smartphone app to study the potential of the platform 






for a consumer-facing application. The modifications to the app included integration of a short 
instructional video, and step by step directions with photos and text for naïve users. Three main 
hardware design elements were modified from our previous smartphone dongle device[63]: 1) 
Bluetooth module  for data communication, 2) Button cell battery for power,  and 3) Smaller 
overall footprint (casing) (detailed in Chapter 3.7).  
 
One challenge of adapting the device for consumer use was providing instructions to perform a 
fingerprick blood draw for users who may have never handled lancets before. From observing 
the in-person skill demonstration of the first set of participants (n=20), we observed that 
additional guidance was needed even after blood was collected, as many participants were 
unsure about when to use provided gauze and bandages or how to handle the device if their 
finger was still bleeding. We modified the instructional video and in-app directions for the 
second set of participants (n=20) to provide explicit recommendations and cues on using gauze 
and bandages, which mitigated much of the friction points of handling the device and 
smartphone after the fingerprick process. This however, also increased lag time between 
fingerprick blood collection and pushing down on the vacuum bulb to begin flow of the blood 
sample through the microfluidic channel, often resulting in clogged channels. One modification 
could be to adjust the assay order of operation to insert Part B into the device, engage the 
vacuum first and then proceed to fingerprick blood collection and attachment of Part A to Part 
B to counteract user-introduced lag time.  
 






We had marked a black fill line on Part A (sample collector/lyophilized antibody holder) to 
provide visual indication of sample metering of 2 L. While this provided visual guidance, 
participants found sample collection into a capillary tube one of the more challenging steps of 
the test. To mitigate this in the future, we could redesign the capillary tube of the sample 
collector to have a maximum specified fill volume or provide additional guidance on collecting 
blood with a capillary tube (e.g. directionality of holding the sample collector, recommended 
time frame between generating a droplet of blood and collecting it etc). We also marked lines 
on the assay cassette and the dongle device to provide a visual cue to know when insertion of 
the device was completed, however the tight seal between the device and cassette (which was 
needed to ensure proper alignment between the vacuum port of the device and cassette outlet), 
resulted in higher resistance in pushing the cassette fully inside. Similarly, variation in force 
applied to the vacuum bulb resulted in both inconsistent (in some cases, insufficient) fluidic 
actuation and higher physical effort needed by participants. As a result, many participants in 
this study found these steps challenging. Binary steps with audio-visual cues (e.g. hearing a 
clicking sound) such as attaching the two microfluidic components together or pressing the 
switch were easier for participants to perform.  
 
None of the participants in this study could generate a diagnostic result, however we have 
previously demonstrated an evaluation of diagnostic performance in the hands of minimally 
trained users compared to trained users, showing no statistically significant difference in 
sensitivity or specificity results of the assay. In this study, we observed that completely naïve 
participants of varying educational levels could all, for the most part, navigate the use of a 






microfluidic POC test using a smartphone app. We characterized friction points for naïve users 
in device handling and test instructions, which can inform future engineering and assay 
development efforts. Credibility of results produced through the SMARTtest was moderately 
high and perceived to increase if provided with test accuracy statistics (requiring a large-scale 
characterization of diagnostic performance with clinical samples), or more feedback if steps in 
running the assay were performed correctly. Moreover, we were able to better understand 
target end-user needs such as designing a POC test that could be easily used with sexual 
partners and provide options for linkage to care. We found that acceptability of a device like 
the SMARTtest for home testing was generally high, in that participants saw value in a product 
that was relatively easy to use, portable, provided both HIV and syphilis test results, and 
utilized the smartphone as a platform device.  
 
In this feasibility study, we did not explore device accessibility to users at length, as several 
stages of development are needed before the SMARTtest is commercially available.  Our 
usability study did reveal that there was a low training burden through the in-app video and step 
by step directions and familiarity of a smartphone interface. The SMARTtest re-usable device 
costs approximately $60 USD under current in-house manufacturing protocols (Table 14). 
This is higher than the $25 price point many of the participants in this study stated they would 
be willing to pay for a full test kit, which includes the disposable fingerprick supplies and 
microfluidic cassette components. One OraQuick home-testing kit retails for ~$40-45 USD (in 
New York City) and consists of a single use lateral flow device, one test tube filled with 1-ml 
of liquid reagent, testing directions attached to a plastic box, pre- and post-test booklets, 






disposal bag and pencil. A timer for measuring 20-40 minutes is also required but not provided 
in the kit. Our system is more compact, integrates instructions and provides a platform for 
storing, saving or sharing results if desired, counseling, referral and linkage to care options 
(features of the app that will be explored in future studies). Smartphone integration was seen by 
participants in this study as one of the biggest advantages to our rapid test platform; in the 
context of accessibility, the ubiquity of the smartphones offered a familiar format and thus low 
training burden through the accompanying app. Additional value proposition of app features 
suggest smartphone integration may play a large role in adoption of new devices and tests. 
 
Some studies have shown participant preference for oral sampling over fingerprick blood[152] 
however other studies have shown that acceptability of blood-based testing increases if other 
STIs can be detected[153]. In our study, many participants expressed that while fingerprick 
blood sampling might be a greater ask with partners, they would be comfortable performing it 
on themselves.  Many also shared the perception that blood-based testing was seen as more 
accurate than oral saliva-based testing, suggesting acceptability of fingerprick blood based 
tests.  
 
A number of new companies are seizing on the business opportunity of at home STI testing, as 
evidenced by a number of new online and app based products[154]. Products vary from mail-in 
testing, telemedicine consultations and follow-ups, to enabling in-person visits at partner 
laboratories. Prices vary from $45 for an at home-test (Biem), $79-$350 for mail in testing 
(myLAB Box), $219-$349 for STI panel testing (STDCheck.com)[154]. Some aspiring 






startups such as Safe are attempting to integrate physician networks, traditional diagnostic 
testing companies and electronic health records into one app to facilitate testing at partner sites 
and storage of STI results[155]. These companies are capitalizing on the draw of upfront 
pricing, app-based linkage to care options and data storage to attract millennials and early 
adopters of “healthcare 2.0”. While the business models of many of these early stage 
companies are still unproven, the amount of venture capital funding[155] for them is one 
indication of the high interest in consumer-facing health care products and services in the 
United States.  
 
The growing availability and development of consumer-facing devices suggests that the 
potential for consumer led health has never been greater[156]. The attainment however, of 
desired clinical sensitivity and specificity is insufficient to motivate consumer use of health 
devices and hence gathering of large scale data. Thus far, deployment of consumer-led health 
devices has been ad hoc without structured assessment of user experience, which can lead back 
to appropriate design and technical parameters. We have created an integrated, user-based 
framework of behavioral and design evaluation which can be applied to microfluidic device 
development process. This in turn, will accelerate translation of new technologies in creating 
POC tools that are poised for more impact and widespread adoption by target end-users in 






















Microfluidic technology has long held the potential for miniaturizing high-performance 
diagnostic tools and expanding access to healthcare; our work shows several advances in 
realizing that potential through translational engineering. In this dissertation, we examined the 
development pipeline from proof-of-concept assay development in a microfluidic POC platform, 
to field testing prototypes and exploring user experience, for intended end-use settings that range 
from U.S. based primary care clinics, rural health centers in low-resource settings as well as self-
testing environments in both.  
 
We showed that translation of integrated microfluidic diagnostic devices from the bench to 
clinical use is analogous to climbing a development ladder, starting from the many parameters in 
assay development. Our Lyme Disease and Leptospirosis assay development work illustrated 
some of the considerations for the first stages of developing miniaturized ELISA-based 




immunoassay in a microfluidic format. We started with choosing appropriate capture antigens, 
optimizing the capture antigen concentration for antibody capture, multiplexing multiple markers 
on one microfluidic chip, and obtaining baseline clinical characterization of diagnostic 
performance using “cleaner” sample inputs such as diluted serum/plasma.  
 
The second stage of assay development moves beyond the initial proof-of-concept parameters in 
translating an established diagnostic technique into a miniaturized format. We illustrated these 
efforts with our work in developing an integrated triplex HIV-syphilis assay. This stage of 
development involves considerations for scale-up, stability/storage and adaptation of the assay to 
handle additional, unprocessed sample inputs such as venous and capillary whole blood. The 
latter remains one of the most challenging aspects of POC assay development as whole blood 
contains many components that present challenges to achieving high analytical reproducibility, 
sensitivity and specificity as well as uniform flow conditions in a microfluidic device. These 
components include immunoglobulins, lipoprotein particles, serum albumin and various other 
proteins, in addition to blood clotting factors, electrolytes, blood plasma proteins and nutrients 
(e.g. glucose, amino acids, fatty acids) that may be dissolved or bound to plasma proteins. We 
explored some strategies to handle whole blood as a sample input in a microfluidic device 
including dilution, increasing surface capture marker concentrations and exploring various 
blocking agents to reduce non-specific binding of analytes. Though we saw promising results 
with some of these strategies towards diagnostic performance, on-chip plasma separation or on-
chip dilution of whole blood could be better strategies to streamline and/or automate the number 
of manual steps needed to run the test by a target end-user while still achieving clinically 
relevant performance statistics. 





Integration with hardware and software to run the assay, acquire data and interpret results is the 
next rung of the microfluidic POC device development ladder. We leveraged silver enhancement 
for signal amplification, allowing us to use simpler and lower cost optical components for 
detection. This gave us more flexibility with companion hardware devices needed to run our 
microfluidic POC assays, from a benchtop instrument suitable for a physician’s office or urgent 
care setting in the U.S., to a handheld dongle for field usage or self-testing. In designing a 
product for the former setting, we envisioned greater access to refrigeration, electricity and less 
importance of portability and ability to withstand rough handling. For the latter setting, these 
parameters were flipped, and our hardware design criteria focused on developing an extremely 
portable and rugged form factor that required no other peripheral equipment, leveraging the 
ubiquity of smartphones as the source for device powering, data processing and communication.  
 
This led us to re-examine previous frameworks such as the ASSURED acronym [157], which 
has been widely used as criteria for building POC tools for global health applications or low 
resource settings. While initially useful for researchers, its introduction in the early 2000s came 
before the age of smartphones and widespread data connectivity. The letter “E”, standing for 
“Equipment-free”, did not take into account the recent explosive rise of consumer electronics and 
availability of hardware components with increasing capabilities at falling prices. By revisiting 
our revised 2x2 matrix model of defining four distinct POC use-cases, we can now summarize 
how each of these settings imposes specific constraints on device design based on the relative 
importance of translational engineering parameters (Fig. 59). 
 










Use Case 1.  Clinic level with moderate budget 
Use Case 1 encompasses settings with access to a moderate budget and some level of clinical 
infrastructure such as hospital emergency rooms, operating rooms, or intensive care units. Here, 
there are personnel and resources such as electricity and refrigeration which support operation of 
POC devices, as well as a moderate budget which can accommodate accessory equipment 
necessary to help run the test.  (At Columbia University Medical Center, the number of different 




platforms used for POC testing grew from 7 in 1995 to 29 in 2015, and the number of patient 
tests grew from about 500,000 in 1995 to more than 2,000,000 tests as performed by 4000 users 
in 2014[158].)  In these settings, a POC diagnostic device can be used at the patient’s bedside 
and return rapid results to help direct treatment.  Moderate throughput in testing of samples is 
sometimes desirable as a feature of the POC device. 
 
Use Case 2.  In the field with moderate budget 
Use Case 2, as in the previous use case, allows for a relatively flexible and moderate budget for 
the POC device, but it is set apart by differences in infrastructure available to run the test.  In this 
use case, there are often no trained users and no accessory laboratory equipment, such that a self-
contained, portable device is vital, with the ability to withstand rough handling and provide rapid 
analysis.  POC devices in this use case are intended for the field, and can contain sophisticated 
POC technologies to accomplish their analytical functions.  For example, POC devices used at 
home, what we commonly refer to as consumer electronics or consumer devices, may cost a 
significantly greater amount to the insurer or patient (compared to other field settings such as 
global health), but need to be operable by untrained users and are self-contained in terms of 
reagents and disposal.  This use case also encompasses many devices currently on the market and 
sold in pharmacies in the U.S., Europe, and other developed settings. 
 
Use Case 3.  Clinic level with constrained budget 
Use Case 3 presents settings with access to laboratory facilities and trained personnel, but where 
the resources and budget are more constrained than Use Case 1.  Examples include primary care 
clinics in developing countries, and nonprofit and non-governmental organization health centers.  




For researchers intending to develop POC devices for this use case, significant design 
considerations must be given to cost; in return, full integration (e.g. sample preparation steps), 
portability, and sample throughout may not be as critical.  In addition, while the goal remains to 
still provide diagnostic information within a single clinical visit to prompt a treatment decision, 
the turnaround time for results could be extended from minutes to hours.  
 
Use Case 4.  In the field with constrained budget 
Use Case 4 settings represent the greatest set of constraints for POC diagnostics. These have 
tight budget constraints, as exemplified by field settings such as lower-level clinics and health 
posts, mobile health and community health outreach, and self-testing settings.  A number of 
design choices, in cost, portability, and automation, must be made to ensure the POC device is 
usable in such settings. It should be noted that, with modifications and further iterations, devices 
listed in other use cases could also be appropriate for this use case. 
 
Table 22 illustrates specific design choices that can thus be made depending on the intended use-
case setting. For example, an early design choice in our work towards developing an HIV-
syphilis diagnostic device for low resource settings (e.g. Use Case 4), was the use of 
thermoplastics as a microfluidic cassette material choice[61]. This enabled easier scale-up and 
large scale fabrication (thus a relatively low-cost platform), while retaining features and channels 




Table 22. Range of POC device design considerations for Use Cases 1-4. 
 




 Use Case 1 
Moderate Budget, 
Clinic 
Use Case 2 
Moderate Budget, 
Field 
Use Case 3 
Constrained Budget, 
Clinic 








































































cheap machines only) 
Colorimetric 
Electrochemical 
Colorimetric (by eye, 
smartphone, or hand-
held device – must be 
cheap) 
Disposal Not needed Self-contained Not needed Self-contained 
Sample type / 
acquisition 
CSF, amniotic fluid, whole 
blood, urine, saliva, plasma, 
sera, swabs, tears 
Whole blood, urine, 
saliva, swabs, tears 
 
Whole blood, plasma, 
serum, urine, saliva, 
swabs, tears 
Whole blood, urine, 









While some design considerations such as long term stability and storage at ambient conditions 
or whole blood processing require additional development for our device to be used in actual 
clinical practice, our field studies in Rwanda showed the smartphone dongle based HIV-syphilis 
assay could achieve comparable performance to other rapid tests run under field conditions. 
Moreover, minimally trained healthcare workers who received only 30 minutes of training with 
the device, performed the test themselves on patients coming into local clinics. Assessing the 
performance of a test under real-world conditions, which can be markedly different than those of 
a laboratory, is critical in the POC design and development process.  
 
As POC diagnostic devices are becoming increasingly integrated, and tested with clinical 
specimens, we have presented our developments in the field through the lens of different use-
case scenarios, which impose different design constraints on all aspects of the POC diagnostics 
device, from material choice to signal detection (Table 22).  Unlike previous classifications of 
use-case scenarios, we propose a framework which decouples the infrastructure available to run 
the test, from the budget allocated to purchase the POC device.  This decoupling presents use 
cases which pose distinct constraints for researchers (Fig. 59), including different design 
constraints for use in a clinic or in the field which would depend on the budget available.  This 
framework presents the constraints across a more diverse set of POC settings than just global 
health.   
 
While access to peripheral equipment and trained personnel to use centrifuges and pipetters may 
not be a barrier to all POC settings, user-experience and consequently work flow, behavior and 
ultimately adoption of a new device are affected by such design choices. Our work in testing 




prototype devices in the hands of healthcare workers illustrated that in addition to portability and 
fast turnaround time that all POC tools offer, a device that relied on no other peripheral 
equipment or ground electricity and was relatively simple to operate was seen as more likely to 
integrate quickly and effectively with existing clinical work flow patterns for mobile health 
outreach efforts, our target use-case setting.  Potential opportunities to automate and digitize 
testing data, particularly outside of large urban centers, was also seen as valuable to public health 
administrators in Rwanda. We learned that new POC devices must present value to the end user 
over existing methods, whether in incorporation of sample processing, streamlining the number 
of manual steps to produce a diagnostic result or integration with data systems and health 
records.  
 
Self-monitoring via fitness trackers and smartphone apps reveal a growing demand by patients 
and consumers for managing and seizing control of their own health. While the increasing 
availability of diagnostic information to non-healthcare professionals presents questions on how 
diagnostic information should be handled and shared, the successful deployment of at-home 
glucose monitoring and home pregnancy tests[159] shows that self-testing (or home-testing) can 
supplement traditional clinical visits in meaningful ways. Whether by promoting preventative 
behaviors, drawing in first time users or triggering linkage to care, self-testing provides one 
avenue of increasing engagement between patients and providers.   
 
We assessed potential value of our smartphone-interfaced, microfluidic device for a self-testing 
application in our user-based evaluations with both patients in Rwandan clinics as well as MSM 
consumers in the U.S. In both cohorts we observed an interest and willingness to receive 




potentially sensitive health information outside of traditional clinical avenues. The smartphone 
was a key element in reducing the training burden needed for a completely naïve user to perform 
a diagnostic assay and also one of the features most likely to engage users in adoption through 
the potential for tracking and managing health data, as well as opportunities for linkage to care. 
In our self-testing evaluation with MSM consumers, we were also able to assess usability, 
accessibility, acceptability, and perceived effectiveness for home-testing in the U.S. This 
included use with sexual partners, which is seen as a key element of HIV harm reduction in this 
population.  
 
Naïve user testing also allowed us to characterize friction points in the overall testing process 
that can inform future design iterations of our POC tools. Steps to address these can range from 
increased user guidance on fingerprick blood sampling or feedback on steps performed, assay 
changes to increase tolerance for variable timing in users performing blood-based assays, as well 
as hardware design changes to enable more binary manual steps and automate troubleshooting 
(e.g. microfluidic flow issues). We also accessed mechanisms that affect user-device interaction 
through expanded human factor engineering analysis with frameworks from behavioral science 
models. Future implementation studies can be performed with participants taking devices home 
over a period of time for evaluation. Such studies can provide more longitudinal data on device 
performance, stability and usability as well as preliminary information on testing frequency, 
motivation for use and preferences with health data management.  
 
 





Broader technological and non-technological components in the POC ecosystem (Fig. 1) will 
also shape the path of new microfluidic tools for real-world use. This includes components like 
regulatory guidance, legislation and reimbursement, which affect patient health information 
protection, boundaries of direct to consumer diagnostic services and whether POC products will 
be reimbursed by public and private insurers or aimed for consumers and patients paying out of 
pocket for POC health products and services.  
 
Data Analytics 
Smartphones and accompanying fitness trackers have also enabled the collection of multimodal 
data.  In the near future, devices equipped with “Internet of Things” technologies will stream 
other types of health data from diverse sources.  For POC diagnostic devices, the value of health 
biomarkers could be augmented by interpreting the information alongside these ever expanding 
data sets. Health information collected from consumers (from Internet, mobile phones and social 
media platforms) are increasingly being entered into a central database for analysis.  For a 
patient’s health, information being collected into the ResearchKit (a database from Apple)[160] 
could link users to studies on Parkinson's disease, diabetes, asthma, breast cancer and heart 
disease[161].  Towards public health and epidemiology[162], search engine queries and page 
views to websites could be used to infer behaviors associated with medical conditions (such as 
cardiovascular disease, sexually transmitted infectious, pregnancy and mental health 
conditions[163], or outbreaks of communicable diseases[164]).  However, care must be taken to 
avoid over interpretation, by using multiple data sources and analysis methods and cross-




validation with public health data[164], and by addressing vulnerabilities in algorithms for 
overfitting[165].  Future analysis of large sets of health and medical data will be augmented by 
artificial intelligence (for example by leveraging IBM Watson Health’s cloud-based healthcare 
analytic platform[166]).  Already, interesting concepts are being proposed for how POC systems 
can be integrated with machine learning, such as the generation of a predictive model capable of 
assessing risks for heart attack and heart failure patients[167].  An intriguing (but less tested) 
approach for analyzing large sets of data is crowdsourcing [168].  
 
Clinical workflow 
As healthcare delivery becomes increasingly decentralized, healthcare professionals and patients 
are adapting their workflows to fit in the use of POC diagnostic devices.  For pathologists and 
clinicians, adoption of POC testing continues to grow[169].  Effective implementation of POC 
testing eliminates transport, processing, and aliquoting processes that take place in core 
laboratories, thereby creating a more streamlined and faster workflow[170] and enabling more 
face-to-face interactions between providers and patients to understand test results and plan 
treatment options[170].  Nevertheless, because more CLIA-waived tests means expansion of 
POC tests in diverse  settings[171], it is often difficult to ensure proper oversight and quality 
assurance[170] over minimally trained or untrained users.  Some hospitals and clinics appoint 
point-of-care coordinators or management teams to ensure consistent procedures, regulatory 
compliance, correct documentation of results, and end-user assistance[170, 172]. It is important 
for developers of POC devices to take advantage of advances in wireless connectivity and 
electronic health records to achieve ease of use and quality assurance.  
 




Integration into healthcare system 
Patients and consumers are increasingly adapting POC tests.  Examples include genetic testing 
services (such as 23andme)[171].  They are also expanding their use of on-demand home visits 
by doctors [173], which are being offered by a number of startup companies (including Heal, 
Pager, Doctors Making Housecalls).  Many of these visits entail the use of a large range of 
connected smart devices for POC or remote diagnosis[173], in the context of primary and urgent 
care as well as wellness assessments and annual physical exams.  Examples include POC 
assessments of sexually transmitted infections, and measurement of diabetes and cholesterol 
levels[174].  The use of such POC tests will only increase, spurred by the growth of more CLIA-
waived POC diagnostic tests, increased self-monitoring via fitness trackers and smartphone apps, 
and the growth of on-demand clinical services and telemedicine. How consumer driven usage of 
POC devices will intersect within the larger continuum of healthcare and delivery of clinical 
services remains an open question. For developers, it will be important to understand how new 
interventions will affect target populations, how linkage to care can be addressed and whether 
health outcomes can be measurably improved.    
 
It is also important to note that not all clinical diagnostics may be appropriate for POC application if 
they place excess burden on health workers or patients or do not provide actionable clinical 
benefits[175]. Additionally, recent events with consumer data breaches and unauthorized sharing of 
data[176, 177], illustrate the attention that must be given to safeguarding the collection and 
management of sensitive health information (e.g. HIV/STI or genetic testing data). 
 




Nevertheless, the rapid progress of non-traditional components in the new POC ecosystem – 
such as consumer electronics, connectivity, and data analytics -- has infused POC diagnostics 
with new energy, perspectives, and risk capital.  While this thesis has focused on  POC 
immunoassays, other classes of diagnostic assays are also poised for deep clinical and consumer 
impact such as molecular or cellular testing applications.  An application of human centered 
engineering design towards POC development, through a holistic integration of target-user and 
use case setting involves integration of interdisciplinary fields from biochemistry, materials 
science, electrical engineering and mechanical engineering to medicine and behavioral science. 
In the short term, both technological and non-technological challenges may persist before a large 
set of new POC devices will be introduced to the market.  In the long term, the field is on track 
to deliver POC diagnostic devices across all appropriate decentralized settings as the remaining 
technological hurdles are addressable, and the social benefits too rich for governments, 
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